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ABSTRACT 
The cancer stem cell (CSC) concept is still very controversial; therefore 
identification and isolation of this specific population remain challenging. A 
variety of putative markers have been described and measurement of high 
aldehyde dehydrogenase (ALDH) activity has been defined as a characteristic 
of stem cells (SCs). In this study, a library of novel small molecules (1,4-di-
substituted acetalanthraquinones, AAQs), containing an acetal group as 
protected aldehyde functionality, was designed with the aim of probing affinity 
for ALDH metabolism and demonstrating their potential as molecular 
fluorescent probes to identify CSCs. The AAQs were shown to be subjective to 
acidic hydrolysis using 2M HCl at 37ºC; however compounds containing 
secondary or tertiary amine functionalities in their sidechain were only partly 
hydrolysed at 70 ºC. Metabolism studies were conducted using cytosolic 
fractions from rat liver enriched in ALDHs, yeast ALDH and human recombinant 
ALDH1A1. Some evidence was demonstrated which linked ALDH metabolism 
with aldehyde functionalities of hydrolysed AAQs (HAAQs). The AAQs were 
shown to emit far-red fluorescence (600-750 nm). A close relationship between 
structure modifications and alteration of cellular localisation, with gained 
specificity for selected sub-cellular compartments were achieved when 
assessed in A549 and U-2 OS cell lines. Thermal DNA denaturation and 
chemosensitivity assays were used to obtain information about DNA binding 
properties and cytotoxicity of AAQs and HAAQ congeners. All compounds were 
shown to be weak-to-moderately binding to DNA, and symmetrical 1,4-di-
substituted compounds were shown to be non-toxic (IC50 = 100 µM) with non-
symmetrical analogues generating IC50 values in the 1-100 µM range. No 
fundamental variation in the biological activity was observed when comparing 
AAQs with HAAQs in the A549 (+ALDH) and MCF7 (-ALDH) cell lines. A pilot 
investigation revealed that aberrant gene methylation was cell-type dependent 
for three ALDH isoforms (1A1, 2, 3A1). Decitabine treatment led to enhanced 
protein expression for ALDH1A1 (A549), ALDH2 (MCF7) and ALDH3A1 (A549). 
In contrast, the protein level was reduced for ALDH1A1 in HT29 cells after 
decitabine treatment.  ALDH1A1, ALDH2 and ALDH3A1 were highly expressed 
in prostate cell lines, with expression linked to promoter methylation. In contrast, 
low levels of DNA methylation were found in primary prostate cancer cells and 
benign prostatic hyperplasia. Interestingly, ALDH1A1, considered a SC marker, 
was found to be expressed at low levels in CD133+/ α2β1
hi stem cell fraction and 
upregulated in CD133-/ α2β1
lo differentiated prostate cancer cells. In summary, 
the results in this thesis demonstrate the complexity and tumour type specificity 
of ALDH expression. This creates challenges for the development of selective 
probes for CSC isolation, such as the AAQs discussed in this thesis. Although 
inconclusive results were obtained in regard to AAQs and their potential in 
targeting ALDHs, selected AAQs were shown to reveal interesting biological 
features highlighting them as potential non-invasive cytometric probes for 
tracking molecular interactions in live cells. 
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I.1 Cells of origin in cancer 
The understanding of the normal cellular hierarchy within a given tissue is an 
important prerequisite to identifying the cellular origin of cancers. Organ 
development proceeds in a hierarchical manner from stem cells to committed 
progenitor cells, which in turn yield differentiated cells that constitute the bulk of 
the tissue or organ (Figure 1). The most primitive cells, stem cells (SCs), have 
been defined as cells that have the ability to perpetuate themselves through 
self-renewal and to generate mature cells of a particular tissue through 
differentiation. SCs have been favoured candidates for targets of transformation 
because of their capacity for self-renewal and their longevity, which would allow 
the sequential accumulation of genetic or epigenetic mutations required for 
carcinogenesis (Visvader, 2011). Any cell in the hierarchy with proliferative 
capacity could serve as a cell of origin in cancer, if it acquires mutations that 
reactivate self-renewal capacity and prevent differentiation to a post-mitotic 
state (Lin, 2002).  
Over the last decade, a distinction has been made between SCs and cancer 
stem cells (CSCs). One of the proposed differences is their degree of 
dependence on the SC niche, a specialised microenvironment in which SCs 
reside. The SC niche in adult somatic tissues plays an essential role in 
maintaining a balance between proliferation-inhibiting and proliferation-
promoting signals (Li and Neaves, 2006). CSCs may arise from an intrinsic 
mutation, leading to self-sufficient cell proliferation, and/or may also involve 
deregulation or alteration of the niche by dominant proliferation-promoting 
signals (Lin, 2002).  
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Figure 1.1 Mutations in SCs and/or progenitor cells. A combination of events that might give 
rise to CSCs (Bjerkvig et al., 2005). 
 
The theory of the CSC has generated as much excitement and optimism as any 
area of cancer research, as it provides opportunities for therapeutic targeting 
and ways to understand tumour progression and maintenance. Biologically, 
these cells are distinct from the other cells that form the bulk of a tumour in that 
they can self-perpetuate and produce progenitor cells in the same way of 
classical SCs (Matsui et al., 2004). Therefore, CSCs are thought to be 
responsible of tumourigenesis and possibly also play a key role in metastatic 
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disease. However, while several studies (Bjerkvig et al., 2005) have 
demonstrated the ability of CSCs to initiate and maintain a primary tumour, the 
functional contribution of CSCs to metastatic behaviour remains poorly 
understood (Visvader and Lindeman, 2008). CSCs may generate tumours 
through the SC processes of self-renewal and differentiation into multiple cell 
types. Such cells are proposed to persist in tumours as a distinct population, 
which cause relapse and metastasis by giving rise to new tumours (Maenhaut 
et al., 2010). For example, CSCs may contribute to tumourigenic and 
chemoresistant sub-fractions in a variety of malignancies, including brain 
tumours, leukaemias, and breast carcinomas (Croker AK, 2009; Reya et al., 
2001) leading to a search for targets for the specific elimination of CSCs 
(Maenhaut et al., 2010) or the mechanisms by which CSCs evade cytotoxic 
therapies (Visvader, 2011).  
A better understanding of the CSC biology could aid in elucidating whether 
these cells can grow tumours on their own and what other properties they might 
have to contribute to clinical outcomes. Importantly for the focus of this thesis, 
these might include roles in drug resistance or metastasis. 
 
I.2 Identification of stem cell markers 
The quest to understand the functioning of normal and cancer SCs have led to 
an intensified search for a more practical way of defining these populations. 
“Stemness” markers or genes are badly sought after. The term “stemness” 
refers to all these common markers as well as the critical biological functions in 
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terms of the self-renewal potential and the ability to differentiate to various 
downstream mature progenitors (Bjerkvig et al., 2005). 
Attempts to identify such common stemness markers have relied on taking 
molecular and biological markers of well-defined SC populations, such as 
embryonic SCs, hematopoietic SCs, and mesenchymal SCs and applying those 
markers to different tissues (Moreb et al., 2008). SC markers are given short-
hand names based on the molecules that bind to the surface receptors. In many 
cases, a combination of multiple markers is used to identify a particular SC 
subtype. Therefore, researchers often identify SCs in shorthand by a 
combination of marker names reflecting the presence (+) or absence (-) of them 
(see Table 1.1).  
In breast cancer, stem-like cells have, for example, been isolated from primary 
tumours based on a CD44+CD24- phenotype (Al-Hajj et al., 2003). Subsequent 
experimental studies have also isolated CD44+CD24- breast cancer cells and 
demonstrated increased in vitro expression of SC markers and enhanced 
capacity for mammosphere formation, invasion, and resistance to radiation 
(Croker AK, 2009). Furthermore, clinical studies indicate that CD44+CD24- 
tumour-initiating cells (TIC) express an invasive gene signature and may be 
associated with distant metastases (Hennessy et al., 2009). Additional putative 
CSC phenotypes have also been identified in other solid cancers, including 
CD133+ (brain, colon, pancreatic cancer) (Lee et al., 2005) (Oshima et al., 
2007) and CD44+CD133+ (prostate cancer) (Richardson et al., 2004). However, 
because of the heterogeneous nature of solid tumours, the reliability of using 
cell surface markers as the sole way to isolate CSCs remains controversial 
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(Clarke and Fuller, 2006). Furthermore, human SC sources (including tumours) 
may contain alternate stem/progenitor cell lineages not efficiently isolated using 
variably expressed cell surface markers (Holmes C, 2007). 
The reason of this dispute is probably caused by the identification of CSCs from 
studying “normal systems” (Matsui et al., 2004). In brain tumours, for example, 
early research focused on the cell-surface protein CD133, which had been 
identified as a marker for normal neural SCs. In addition to brain cancer, CD133 
has been used to identify potential CSCs in colon cancer, whereas CD44 has 
been used to identify breast cancer SCs. Aldehyde dehydrogenase (ALDH), in 
combination with other markers, has been used to identify CSCs in breast, 
prostate, and pancreatic cancer (Moreb, 2008) (see Table 1.1).  
Fundamental for isolation of the tumour-specific CSC population is to further 
explore the expression of a distinctive repertoire of surface markers alone and 
in combination with selected functional enzymes. However, it should be noted 
that the markers proposed are different for the different type of cancer tissue 
and different from those of the somatic SCs (Maenhaut et al., 2010). Their 
potential biological role is little considered and it is often assumed that they 
mark the same cells. 
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Tumour type Cell surface marker(s) Reference 
Breast CD44+CD24(-/low)Lineage- ESA+ (Al-Hajj et al., 2003) 
CNS CD133+ (Singh et al., 2003) 
Colon CD133+ (O'Brien et al., 2007) 
Head and neck CD44+Lineage- (Prince et al., 2007) 
Melanoma ABCB5+ CD271+ (Boiko et al., 2010; 
Schatton et al., 2008) 
Liver CD90+CD45- (CD44+) (Yang et al., 2008) 
Ovarian CD44+CD117+ (Zhang et al., 2008) 
Prostate CD133+/alpha 2 beta 1 
integrin/ CD44+ 
(Maitland and Collins, 
2008) 
Pancreas CD44+CD24+ ESA+, CD133+ (Li et al., 2007) 
Lung CD133+ (Eramo et al., 2008) 
 
_______________________________________________________________ 
Table 1.1 Cell surface phenotype of CSCs identified in selected solid tumours. CD: cluster 
of differentiation, ESA: epithelial-specific antigen. Table adapted from Visvader et al. (Visvader 
and Lindeman, 2008). 
 
I.3 The cancer stem cells plasticity and therapeutic challenges 
Multidrug resistance proteins, also known as ABC (ATP-binding cassette) 
transporters, are transmembrane proteins that utilise the energy of adenosine 
triphosphate (ATP) to transport a wide variety of substrates across extra- and 
intracellular membranes, including metabolic products, lipids and sterols, and 
drugs (Sparreboom et al., 2003). Enhanced drug efflux mediated by ABC 
transporters is one of several mechanisms of multi-drug resistance potentially 
linked with the chemoresponse failure of human cancers. Recently, a role of 
ABC transporters as phenotypic markers of SCs has been uncovered (Alison, 
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2003; Bunting, 2002).  As an example, the novel ABCB5 drug transporter 
(Huang et al., 2004) is a chemoresistance mediator in human malignant 
melanoma (Schatton et al., 2008) and has been recognised as a CSC marker 
(Boiko et al., 2010). ABCB5+ tumour cells, detected in human melanoma 
patients, show a primitive molecular phenotype and in vivo genetic lineage 
tracking can demonstrate a specific capacity of ABCB5+ sub-populations for 
self-renewal and differentiation (Schatton et al., 2008).  
 
_______________________________________________________________ 
Figure 1.2 ATP-dependent mechanism of drug transport. These membrane proteins 
function as pumps that extrude toxins and drugs out of the cell via ATP hydrolysis. TMD: 
transmembrane domain; ICD: intracellular domain; NBD: nucleotide binding domain. Figure 
adapted from Dong et al. (Dong et al., 2005). 
 
Both breast cancer resistance protein (BCRP1) and ABCB1 (also known as P-
glycoprotein or MDR1, multidrug resistance protein-1) are expressed in SCs, 
and enforced expression of either confers a typical phenotype in a variety of 
transduced cells (Zhou et al., 2002).  
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Some DNA interactive drugs are preferably subject to ATP-dependent efflux by 
BCRP1, a 655 aminoacids polypeptide designated as ABCG2 
(MXR/BCRP/ABCP1) (Doyle and Ross, 2003). ABCG2 also shows an intriguing 
linkage with the CSC phenotype (Visvader and Lindeman, 2008), given that 
enhanced ABCG2 transporter expression contributes to the definition of pluri-
potential "side population" of cells (Goodell, 2002; Goodell et al., 2005). In many 
mammals, including humans, an adult SC subset termed the "side population" 
(SP) has been identified (Challen and Little, 2006). SP cells can rapidly exclude 
the DNA minor groove-binding dye Hoechst 33342 to produce a characteristic 
profile based on fluorescence-activated flow cytometric analysis (Hirschmann-
Jax et al., 2005; Storms et al., 2000). Moreover, it is likely that the physiological 
function of ABCG2 expression in hematopoietic SCs is to provide protection 
from cytotoxic xenobiotics, such as mitoxantrone or topotecan (Zhou et al., 
2002).  
The ABCG2 half-transporter is sensitive to inhibitors (i.e. fumitremorgin C, 
FTC), which may lead to resistance reversal (Rabindran et al., 2000). However, 
ABCG2 is yet to have a fully defined role in drug resistance in human cancers 
due to complex substrate specificity patterns, co-expression of other ATP-
binding cassette transporters (as ABCB1/MDR-1), effects of mutation on the 
spectrum of molecules transported and uncertainty over the impact of only 
moderate increases in transporter function (Doyle and Ross, 2003; Rabindran 
et al., 2000). 
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I.4 Epigenetic regulation of gene expression in cancer 
I.4.1 Introduction 
Genetics alone cannot explain human variation and disease. The increasingly 
popular term epigenetics embodies a partial explanation of both phenomena. It 
was first introduced by C.H. Waddington (Haldane and Waddington, 1931; 
Waddington, 1939) to describe “the causal interactions between genes and their 
product, which brings the phenotype into being”. More recently, epigenetics has 
been used to define heritable changes in gene expression which are not due to 
any alteration in DNA sequence (Esteller, 2009). While the genetic code in an 
individual is the same in every cell, the epigenetic code can be cell-specific and 
may change over time with aging, disease or environmental stimuli (e.g., 
nutrition, life style, toxin exposure). Type of epigenetic modifications includes: 
methylation, acetylation, phosphorylation, ubiquitination, ADP-ribosylation.  
On a molecular level, covalent modifications of cytosine bases and histones, 
and changes in the positioning of nucleosomes, are commonly regarded as 
driving epigenetic mechanisms. They are fundamental to the regulation of many 
cellular processes, including gene and microRNA expression, DNA-protein 
interactions, suppression of transposable element mobility, cellular 
differentiation, embryogenesis, X-chromosome inactivation and genomic 
imprinting (Portela and Esteller, 2010). To date, the cytosine methylation of 
DNA is the most widely studied epigenetic modification in humans (Jones and 
Takai, 2001). 
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An explosion of data indicating the importance of epigenetic processes, 
especially those resulting in the silencing of key regulatory genes, has led to the 
realisation that genetics and epigenetics cooperate at all stages of cancer 
development (Robertson and Wolffe, 2000). Recent advances include the 
understanding that (i) silencing is part of global epigenomic alterations in 
cancer, (ii) alteration of pathways are relevant to SC growth and differentiation 
and (iii) there is a need for the approval of drugs that target these defects in 
cancer patients (Jones and Baylin, 2007).  
 
I.4.2 DNA methylation: health and disease 
DNA methylation occurs almost exclusively in the context of CpG dinucleotides. 
The CpG dinucleotides tend to cluster in regions called CpG islands, where "p" 
simply indicates that C and G are connected by a phosphodiester bond. 
According with the definition of Gardiner-Garden (Gardiner-Garden and 
Frommer, 1987), CpG islands are regions of more than 200 bases with a G+C 
content of at least 50% and a ratio of observed to statistically expected CpG 
frequencies of at least 0.6. CpG dinucleotides are usually quite rare in 
mammalian genomes (~1%). About 60% of human gene promoters are 
associated with CpG islands and are usually unmethylated in normal cells, 
although some of them (~6%) become methylated in a tissue-specific manner 
during early development or in differentiated tissues (Esteller, 2009). DNA 
methylation plays a key role in genomic imprinting, where hypermethylation at 
one of the two parental alleles leads to monoallelic expression (Kacem and Feil, 
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2009). The pattern of DNA methylation changes substantially when cells 
become cancerous (see Figure 1.3), as a result of two major events.  
Firstly, cancer cells show genome-wide hypomethylation, which has been 
associated with chromosomal instabilities as well as activation of normally 
silenced repetitive DNA elements (Teodoridis et al., 2004). Secondarily, discrete 
portions at the promoter region of tumour-suppressor genes (TSGs) undergo 
intense hypermethylation (Esteller, 2009).   
A
B
 
_______________________________________________________________ 
Figure 1.3 DNA methylation patterns. A representation of a region of DNA in non-cancerous 
(A) and cancerous (B) tissues shows the differences in DNA methylation in the two phenotypes. 
In non-cancerous tissue, genome wide hypermethylation of CpGs (green circles) and an 
actively transcribed tumour suppressor gene (TSG) is associated with a hypomethylated CGI 
(green lines). In cancerous tissue, the opposite is seen with genome wide hypomethylation (red 
lines) leading to genomic instability, and CGI hypermethylation (red circles) contributing to 
transcriptional silencing of a TSG. 
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Loss of DNA cytosine methylation (hypomethylation) results in genome 
instability, whereas focal hypermethylation of gene promoters causes heritable 
changes and therefore inactivation of TSGs. A combined effect of these two 
events contributes to cancer causation in humans, as alteration of homeostasis 
of epigenetic mechanisms (Baylin S. B. , 2006). 
 
I.4.3 Gene silencing and cancer 
The initial reports of hypermethylation of the CpG islands in the promoter region 
of the retinoblastoma (Rb) TSG were followed by the findings that 
hypermethylation of the CpG island was a mechanism of inactivation of the 
tumour-suppressor genes VHL (associated with von Hippel-Lindau disease), the 
cell-cycle inhibitor p16INK4a (Esteller and Herman, 2002), the mismatch DNA 
repair gene hMLH1 (Herman and Baylin, 2003) and BRCA1 (breast-cancer 
susceptibility gene) (Esteller, 2008). Therefore, the list of cancer-related genes 
affected by this disruption is growing steadily.  
 It has been estimated that in tumours there are on average 600 CpG islands 
aberrantly methylated compared to normal tissue (Costello et al., 2000), 
although this can vary widely between tumour types and within different 
histological fractions (Teodoridis et al., 2004). Moreover, methylation does not 
occur randomly, as there are CpG islands that are methylated in multiple 
tumour types, while other CpG islands are methylated only in specific cancer 
types (Costello et al., 2000). For example, BRCA1 hypermethylation is specific 
in breast and ovarian tumours but does not occur in other cancers (Strathdee 
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and Brown, 2002), whereas hMLH1 methylation-mediated silencing is typical of 
colorectal, gastric and endometrial cancer but it is unmethylated in other solid 
tumours (Davidson et al., 2001).  
Silencing via hypermethylation of the CpG-island promoter can affect genes 
involved in the cell cycle, DNA repair, the metabolism of carcinogens, cell-to-cell 
interaction, apoptosis, and angiogenesis, all of which are involved in the 
development of cancer (Esteller, 2008; Teodoridis et al., 2004). 
Hypermethylation occurs at different stages in the development of cancer in 
different cellular networks, and it interacts with genetic lesions. In other words, 
the normal epigenetic modulation of these genes allows them to prevent stem 
or precursor cells from becoming immortalised and acquiring infinite cell 
renewal capacity during periods of chronic stresses and renewal pressures on 
cell systems. The inappropriate silencing of these genes blocks their activation 
and allows for abnormal survival and clonal expansion and prevents 
differentiation (Jones and Baylin, 2007). 
 
I.4.4 Reactivating silenced genes: the epigenetic therapy 
The heritable activation of cancer-related genes by altered DNA methylation 
and chromatin modification has led to the realisation that silenced chromatin 
may represent a viable therapeutic target. Reversal of aberrant DNA 
methylation, using agent with hypomethylating activity, results not only in 
reactivation of epigenetically silenced genes including TSGs, but also in 
anticancer activity.  
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Several small molecule inhibitors of DNA methylation that are derivatives of 2’-
deoxycytidine are known (Goffin and Eisenhauer, 2002), e.g. 5-aza-2’-
deoxycytidine (DAC, decitabine, Dacogen) or 5-azacytidine (5-azaC, Vidaza). 
DAC was approved in 2006 by the American Food and Drug Administration 
(FDA) for the treatment of myelodysplasic syndromes (Baylin S. B. , 2006; 
Esteller, 2008; Jones and Baylin, 2007), as anticancer activity was 
demonstrated in several clinical trials in hematopoietic malignancies (Esteller, 
2009; Jones and Taylor, 1980; Yang et al., 2006).  
These small molecules, known as cytosine analogues, are incorporated into 
DNA in place of the natural nucleoside during DNA replication (see Figure 1.4).  
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Figure 1.4 DNMT enzymatic reaction and mechanism of DNMT inhibition of DAC. This 
consists of the covalent addition of a methyl group from the methyl donor S-adenosyl 
methionine (SAM) catalysed by DNMTs.. Adapted from (Gowher and Jeltsch, 2004). 
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Once incorporated into the DNA, these molecules trap the DNA 
methyltransferases (DNMTs) and target them for degradation (Baylin S. B. , 
2006), thus inhibiting the restoration of the original methylation pattern in 
daughter cells. However, the pathway of DNA demethylation by DAC turned out 
to be more complicated as demonstrated by the findings that the drug has a 
dual mechanism of action: an immediate cytotoxic effect is followed by induction 
of hypomethylation of the DNA (see Figure 1.5). The relative strength of both 
types of responses depends on the dose of the drug (Santi et al., 1983). 
Covalent attachment of the various DNMTs to DNA might well be responsible 
for the cytotoxicity of these agents, particularly at high doses (Michalowsky and 
Jones, 1987). 
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Figure 1.5 Dose-dependent activity of decitabine. Incorporation of high doses and low doses 
of decitabine lead to different cellular response due to activation of different biological pathways 
(Oki et al., 2007). 
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I.4.5 Histone modifications 
Histones are key players in epigenetics. The core histones H2A, H2B, H3 and 
H4 group into two H2.A-H2.B dimers and one H3-H4 tetramer to form the 
nucleosome (De Ruijter et al., 2003). During activation of gene transcription, 
this compact, inaccessible DNA is made available to DNA binding proteins via 
modification of the nucleosome (Esteller, 2008). This architecture of chromatin 
is strongly influenced by post-translational modifications of the histones. To 
date, the acetylation of core histones is probably the best understood type of 
modification (Egger et al., 2004). Histone acetylation relaxes the normally tight 
supercoiling of chromatin, enhancing accessibility of DNA-binding 
transcriptional regulatory proteins to promoter regions. Conversely, HDAC3 
maintains chromatin in a transcriptionally silent state. Loss of acetylation is 
mediated by HDACs, which have been found to be overexpressed or mutated in 
different tumour types (Zhu et al., 2004). Genes that can cause cell 
differentiation are normally downregulated by HDAC activity (Alcarraz-Vizan et 
al., 2009). HDAC inhibitors can induce differentiation, growth arrest and/or 
apoptosis in transformed cells in culture and in tumours. The driving hypothesis 
is that accumulation of acetylated proteins, particularly histones, results in the 
induction of genes and the upregulation of others that have become 
epigenetically silenced. In particular, the gene encoding p21 (Esteller, 2007), 
which is a cell-cycle kinase inhibitor, is commonly upregulated in tumour cells 
treated with these agents in the absence of p53 (Egger et al., 2004). 
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I.4.6 Dual therapy: DNA methyltransferase inhibitors and histone 
deacetylase inhibitors 
The links between histone modification and DNA methylation have encouraged 
investigators to think about dual therapies combining DNA methyltransferase 
(DNMT) inhibitors with histone deacetylase (HDAC) inhibitors (Egger et al., 
2004). 
 
 
_______________________________________________________________ 
Figure 1.6 Interplay between RNA, histone modification and DNA methylation in heritable 
silencing. Histone modification can attract DNA methyltransferases to initiate cytosine 
methylation, which in turn can reinforce histone modification patterns conducive to silencing 
(Egger et al., 2004). 
 
In 1999, Cameron et al. (Cameron et al., 1999) explored in detail the synergy of 
DNA demethylating agents and HDAC inhibitors. Indeed, the simultaneous 
inhibition of both processes would be the most efficacious approach to 
reactivating key genes for therapeutic purposes (Baylin S. B., 2006). The 
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synergy between these two families of compounds (see Figure 1.6) might allow 
the reduction of individual doses, which could minimise the toxic effect and 
optimise the gene reactivating response (Esteller, 2009). Some clinical studies 
concerning the combination of demethylating agents and HDAC inhibitors in the 
treatment of patients with haematological cancers led to complete or partial 
response (Gowher and Jeltsch, 2004).  
Currently there is considerable interest in the potential of activating silenced 
genes with epigenetic drugs which can sensitise cells towards the treatment 
with traditional chemotherapy (Egger et al., 2004). However, reactivation of 
genes may also results in activation of drug metabolising enzymes and other 
chemoprotecting protein such as ABC transporter family. This could, for 
example, impacts choice of combination treatment for clinical purposes. 
 
 
I.5 Aldehyde dehydrogenase family 
I.5.1 Definition and implications 
Aldehydes are generated from a wide variety of endogenous and exogenous 
precursors during numerous physiological processes, including the 
biotransformation of endogenous compounds such as amino acids, 
neurotransmitters, carbohydrates, and lipids. While some aldehydes play vital 
roles in normal physiological processes, including vision, embryonic 
development, and neurotransmission, many are cytotoxic and carcinogenic 
(Marchitti et al., 2008). Drugs such as cyclophosphamide  and ifosfamide are 
metabolised to aldehyde intermediates, which are substrates for ALDHs 
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(Bunting and Townsend, 1996). As such, ALDH protect the organism from 
potentially harmful xenobiotics that contain aldehyde functional groups or 
xenobiotics that give rise to aldehydes (Moreb, 2008; Moreb et al., 2008).  
Aldehydes are detoxified primarily through reductive and oxidative phase I 
enzyme-catalysed reactions, including the non-P450 aldehyde reduction 
enzymes as alcohol dehydrogenase (ADH), aldo-keto reductase (AKR), short-
chain dehydrogenase/reductase (SDR), and the aldehyde oxidation enzymes as 
xanthine oxidase (XO), aldehyde oxidase (AOX) and aldehyde dehydrogenase 
(ALDH) (Marchitti et al., 2008). 
Aldehyde dehydrogenases (ALDHs) are a group of NAD(P)+ dependent 
enzymes involved in oxidising a wide variety of aldehydes into their 
corresponding carboxylic acids (Ucar et al., 2009). At present, 19 putatively 
functional human ALDH genes (Marchitti et al., 2008) with distinct chromosomal 
locations have been identified (see Table 1.2). Furthermore, many allelic 
variants within the ALDH gene family have been identified, resulting in 
pharmacogenetic heterogeneity between individuals, which in most cases, 
results in distinct phenotypes (Moreb et al., 2008). Broadly, ALDH isoenzymes 
can be categorised as critical for normal development and/or physiological 
homeostasis. ALDH proteins are found in all subcellular regions including 
cytosol, mitochondria and endoplasmic reticulum with several found in more 
than one compartment. ALDH isoenzymes found in organelles other than 
cytosol possess leader or signal sequences that allow their translocation to 
specific subcellular regions (Braun et al., 1987).  
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ALDH Constitutive tissue distribution Subcellular location 
(predominant) 
1A1 liver, kidney, erythrocytes, skeletal muscle, lung, breast, lens, stomach 
mucosa, brain, pancreas, testis, ovary, more 
Cytosol 
1A2 testis, small amount in liver, kidney, more Cytosol 
1A3 kidney, skeletal muscle, lung, breast, testis, ovary, stomach mucosa, 
salivary glands 
Cytosol 
1B1 liver, kidney, heart, erythrocytes, skeletal muscle, lung, brain, prostate, 
testis, placenta 
Mitochondria 
1L1 liver, kidney, skeletal muscle Cytosol 
1L2 pancreas, heart, and brain. Mitochondria 
2 liver, kidney, heart, skeletal muscle, lung, lens, stomach mucosa, brain, 
pancreas, prostate, spleen, more 
Mitochondria 
3A1 stomach mucosa, cornea, breast, lung, lens, esophagus, salivary glands, 
skin, more 
Cytosol, partially in nucleus  
3A2 liver, kidney, heart, skeletal muscle, lung, brain, pancreas, placenta, more Endoplasmic reticulum 
3B1 kidney, lung, pancreas, placenta Endoplasmic reticulum 
3B2 parotid glands Endoplasmic reticulum 
4A1 liver, kidney, heart, skeletal muscle, brain, placenta, lung, pancreas, 
spleen, more 
Mitochondria 
5A1 liver, kidney, heart, skeletal muscle, brain Mitochondria 
6A1 liver, kidney, heart, skeletal muscle Mitochondria 
7A1 foetal liver, heart, skeletal muscle, more Cytosol 
8A1 liver, kidney, brain, breast, testis, more Cytosol 
9A1 liver, kidney, heart, skeletal muscle, brain, pancreas, adrenal gland, spinal 
cord, more 
Cytosol 
16A1 kidney, liver, blood Potential transmembrane 
protein 
18A1 kidney, heart, skeletal muscle, pancreas, testis, prostate, spleen, ovary, 
thymus, more 
Mitochondria 
 
_______________________________________________________________ 
Table 1.2 Human ALDHs: tissue distribution and subcellular location. Table adapted from 
Sladek et al. (Sladek, 2003). 
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The primary, if not sole, role of these enzymes appears to be catalysing the 
biotransformation of single endobiotics for which they are relatively specific and 
where the resultant metabolite is essential to the organism (Sladek, 2003). Most 
of the human ALDHs for which the relevant information is available fall into this 
category. 
 
I.5.2 Aldehyde dehydrogenase activity 
The activity of mammalian ALDHs was first observed in bovine liver more than 
50 years ago (Raker, 1949) and thereafter several types of ALDHs were 
distinguished on the basis of their physico-chemical characteristics, 
enzymological properties, subcellular localization, and tissue distribution.  Since 
the primary structures of human cytosolic (Hempel et al., 1984) and 
mitochondrial (Hempel et al., 1985) ALDHs are known, a structurally based 
classification has been adopted. The most adopted classification is grouped into 
three distinct, but related, structural families: class 1 and class 3 ALDHs are 
cytosolic, while class 2 ALDHs are mitochondrial isoenzymes. Despite this 
distinction, the common function is the irreversible oxidation of a wide spectrum 
of endogenous and exogenous aldehydes.   
Class 1 and class 2 ALDHs preferentially oxidise small aliphatic aldehydes such 
as propionaldehyde, acetaldehyde, and retinaldehyde (Vasiliou et al., 2004) and 
require a NAD+ cofactor (Sladek, 2003). Class 3 (also called “tumour-
associated”) ALDHs are cytosolic or microsomal enzymes that appears to prefer 
aromatic aldehydes such as benzaldehyde as substrate. This class can utilize 
NADP+ as cofactor in addition to NAD+ (Jelski and Szmitkowski, 2008). Class 3 
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ALDHs also efficiently oxidise lipid aldehydes which can arise from lipid 
peroxidation and thus may play a physiological role in the cell under conditions 
of oxidative stress (Sladek, 2002).  
 
Ethanol Acetaldehyde Acetate
ADH ALDH
AD+ ADH AD+ ADH
 
_______________________________________________________________ 
Figure 1.7 Ethanol metabolism by ADH and ALDH. Ethanol is firstly converted into 
acetaldehyde via NAD-dependent oxidation mediated by ADH and acetaldehyde is the 
substrate for NAD-dependent reaction by ALDH to produce acetate, as harmless product. 
 
The role of ALDHs in alcohol metabolism (see Figure 1.7), vitamin A absorption, 
and resistance against oxazaphosphorines (Sladek, 1999) are some of the most 
studied aspects of their activities. Although preferred substrates and cofactors 
have been identified for several ALDHs, most are able to catalyse, albeit less 
efficiently, the oxidation of a wide range of aldehydes as well as to use the 
alternate cofactor. The overall reaction catalysed by the ALDHs is: 
RCHO + NAD+(P) + H2O RCOOH + NADH (P) + H
+
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In this NAD(P)+ dependent reaction, the aldehyde enters the active site through 
a channel located on the outside of the enzyme. The active site contains a 
Rossman fold (a protein structural motif found in proteins that bind nucleotides, 
especially the cofactor NAD) and interactions between the cofactor and the 
Rossman fold allow the enzyme to keep the active site functional (Liu et al., 
1997). The mechanism is elucidated in detail in Figure 1.8.  
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_______________________________________________________________ 
Figure 1.8 ALDH proposed mechanism of aldehyde metabolism. Cys-302 residue is found to be 
determinant for the interaction with the substrate (Hempel et al., 1985). 
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I.5.3 Aldehyde dehydrogenase as a functional biomarker 
A biomarker is defined as a characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic processes, 
or pharmacological responses to a therapeutic intervention (Ruddon, 2007). 
Identification of selective biomarkers will facilitate new selective strategies for 
isolation and treatment of normal and cancer SCs in a target-orientated manner 
to enable further investigation of this precious cellular population. Unfortunately, 
attempts to establish a SC molecular signature using gene profiling have been 
hampered by the difficulty of obtaining a pure population of SCs. 
A potential strategy for identifying normal or CSC populations involves 
measurement of ALDH activity (Jiang et al., 2009; Ma and Allan, 2011). The 
retinoic acid signalling of the ALDH is linked to cellular differentiation during 
development and plays a role in SC self-protection throughout an organism’s 
lifespan (Croker AK 2008). Furthermore, the role of ALDHs in drug resistance 
(Sladek, 1999) and retinoic acid generation is potentially crucial for the 
protection of SCs against toxic endogenous and exogenous aldehydes and for 
their ability to differentiate respectively (Bunting and Townsend, 1996). 
Hematopoietic SCs have been shown to express high levels of ALDHs (Storms 
et al., 1999) and many studies have demonstrated successful isolation of 
normal human hematopoietic progenitor cells (Jones et al., 1995), using an 
ALDH activity-based strategy alone or in combination with cell surface markers 
(i.e. CD133).  
A crucial study by Ginestier’s group has demonstrated that expression of 
ALDH1 in breast tumours is a predictor of poor clinical outcome (Ginestier et al., 
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2007), and that high ALDH activity is present in both normal and tumourigenic 
human mammary epithelial cells with stem or progenitor properties. Therefore, 
the use of ALDH activity as a purification strategy allows non-toxic and efficient 
isolation of subpopulations based on a developmentally conserved 
stem/progenitor cell function.  
 
I.5.4 Heterogeneity of ALDH isoforms and biological implications 
Several ALDH isoenzymes have been identified for their role in the protection of 
SCs against endogenous and exogenous aldehydes and for their role in 
differentiation. The most studied ALDH1A1 is a well established marker for 
hematopoietic SC progenitors (Moreb et al., 2008) and its function in retinoic 
acid formation has been extensively investigated in dopaminergic neuron 
differentiation and survival (Jacobs et al., 2007). Although many studies point to 
ALDH1 as the candidate marker for SCs (Ginestier et al., 2007; Kastan et al., 
1990), it is becoming apparent that other isoforms may contribute to the ALDH 
activity being used to identify SC progenitors. For example, the recent 
identification of several ALDH1 isoforms (ALDH1A1, ALDH1A2, ALDH1A3) in 
the SC compartment suggests that the ALDH activity observed in SCs is not 
exclusively related to the 1A1 isoform. Moreover, retinoic acid synthesis by 
ALDH1A2 promotes differentiation, cell growth arrest and apoptosis and has 
been suggested as a candidate TSG in prostate cancer (Kim et al., 2005). 
ALDH1A3 expression is downregulated in human breast cancer MCF7 cells 
(Marcato et al., 2011) and a recent study has shown that ALDH1A3 deficiency 
may play a critical role in cancer and metastasis. Studies into the role of retinoic 
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acid in granulocyte differentiation of hematopoietic SCs revealed that ALDH1A1 
and 1B1, but not ALDH1A2 or 1A3, were expressed in CD34+ hematopoietic 
progenitors (Moreb et al., 2008).  
ALDH2 is the primary enzyme involved in ethanol metabolism and several 
mutant ALDH2 alleles have indicated a potential mechanism of DNA damage 
and cancer development (Matsuda et al., 2006), but not SC specific implication 
has been found. In vitro, ALDH3A1 has been shown to prevent DNA damage 
and reduce apoptosis from various toxins (hydrogen peroxide, mitomycin C and 
etoposide) (Lassen et al., 2006) and over-expression of ALDH3A1 together with 
ALDH1A1 in cell lines and normal hematopoietic progenitors results in a 
significant increase in resistance to the active metabolites of cyclophosphamide 
(Sreerama and Sladek, 2001). Furthermore, it has been proven that down-
regulation of ALDH1A1 and 3A1 using antisense RNA results in increased 
sensitivity of tumour cells to 4-hydroperoxycyclophosphamide, an active 
derivative of cyclophosphamide (Moreb et al., 2000). 
Recently ALDH7A1, also known as antiquitin, has been shown to be a 
candidate marker for human prostate cancer. It has been identified in the 
overlap gene profile of different SC populations and it may be required for the 
acquisition of a metastatic stem or progenitor cell phenotype in prostate cancer 
(van den Hoogen et al., 2011b).  
In summary, with the increasing number of reports on ALDH isoforms, it has 
become apparent that there is a need for a better understanding of the 
importance of their expression and function in both normal and cancer tissues.  
Chapter I                                                                                                       - 29 - 
_______________________________________________________________________ 
 
 
I.5.5 The use of ALDH activity to isolate stem cell populations 
Previous techniques for ALDH detection, including measurement of substrate 
oxidation in whole cell lysates or reaction of fixed cells with antibodies, have 
been lethal to the cells being studied (Russo et al., 1989). A technique that can 
measure cytosolic ALDH in intact, viable cells is of interest as part of a strategy 
to isolate normal and cancer SCs. Furthermore, isolating viable CSCs by their 
cytosolic ALDH levels could have important implications for studying drug 
resistance, including cyclophosphamide (Jones et al., 1995). 
 
I.5.6 Aldefluor-based cell sorting 
Multiple studies (see section I.5.4) have been published using ALDH1 as a 
marker to select normal or cancer SCs (Ginestier et al., 2007; Jones et al., 
1995). This has been greatly facilitated by Aldefluor, a functional flow cytometric 
assay. Aldefluor assay (StemCell Technologies) is based on a fluorescent 
compound that is able to undergo intracellular metabolism. The active form of 
this fluorescent dye, known as BODIPY-amino-acetaldehyde (BAAA) (see 
Figure 1.9), is recognised and metabolised by ALDH. The result is an ALDH-
dependent intracellular accumulation of BODIPY-aminoacetate (BAA) with 
intense fluorescence of viable cells that express high levels of ALDH activity 
(Storms et al., 1999). Aldefluor is supplied in the form of a protected aldehyde, 
BODIPY-aminoacetaldehyde diethyl acetal (BAAA-DA), which itself is not a 
substrate of ALDH1. However, when BAAA-DA is exposed to aqueous acid 
prior to cell-treatment and converted into BODIPY-amino-acetaldehyde (BAAA), 
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metabolism by ALDH is possible. BAAA is uncharged and can easily diffuse 
across the cellular membrane of intact viable cells.  
The net negative charge, generated by ALDH via aldehyde oxidation to form the 
oxidised BODIPY-aminoacetate (BAA) product, does not reduce the ability for 
transport across the cellular membrane. Indeed, the BODIPY chromophore is a 
good substrate for the multidrug resistance (MDR) transporter family, and hence 
successful application of the Aldefluor assay is possible only when samples are 
co-treated with a MDR inhibitor (i.e. verapamil) (StemCellTechnologies. 2004), 
which blocks the efflux and allows the detection of fluorescence signal (Pearce 
and Bonnet, 2007). The laser source to analyse the positive cells is determined 
by having a control sample that is treated similarly except for addition of 
diethylaminobenzaldehyde (DEAB), an ALDH inhibitor, which will prevent the 
formation of fluorescent BAA (see Figure 1.10).  
Thus, the Aldefluor assay, for the first time, allows the identification and 
isolation of viable cells that expresses high ALDH activity (Alison et al., 2010). 
These cells are referred to as ALDH bright. The assay reaction is detected 
using a flow cytometer equipped with a 488 nm argon laser for excitation and an 
optical filter set to detect 515-545 nm emission fluorescence. 
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_______________________________________________________________ 
Figure 1.9 Proof of principle of BODIPY-DA functionality. Structures of BAAA-DA, BAAA, 
and BAA are reported. BAAA-DA is converted to BAAA in the presence of 2 M hydrochloric acid 
for 30 min. ALDH then converts BAAA into BAA, which is trapped intracellularly due to 
concurrent use of the MDR inhibitor verapamil. 
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Aldefluor-based cell sorting, alone or in combination with tissue-specific cell 
surface markers (see Table 1.1) is now an established technique for isolating 
normal and cancer SC fractions. Nonetheless, as elucidated above, the 
question is which ALDH isoenzyme(s) contribute to the ALDH activity in SCs 
and whether these are expressed differently depending on the tissue that is 
being analysed. 
 
 
_______________________________________________________________ 
Figure 1.10 The basis of the Aldefluor reaction. Cells are incubated with BAAA in the 
presence of verapamil to inhibit efflux by ABC transporter. In the presence of DEAB, ALDH 
activity is abolished and no intense green fluorescent subpopulation can be detected. Both plots 
are theoretical FACS histograms. Adapted from (Alison et al., 2010). 
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I.5.7 Aldefluor and ALDH selectivity 
In the past five years, literature has been intensively populated with studies on 
SC isolation using the Aldefluor method. Several reports have addressed the 
question regarding which isozyme(s) contribute to the ALDH activity detected by 
Aldefluor (Sladek et al., 2002). As stated in the section I.5.4 (Kastan et al., 
1990), ALDH1A1 is the main isoform in hematopoietic SCs and in normal and 
cancerous tissue of the breast while ALDH3A1 is also detected (Sladek et al., 
2002). Similar data exist in both normal and malignant colon tissue (Yin et al., 
1994). Furthermore, the presence of very high ALDH activity such as in A549 
cells exposed a new limitation to the assay. This limitation was most likely 
related to the limited ability of DEAB to inhibit the activity of large amounts of 
ALDH1A1 and ALDH3A1. Indeed, according to the manufacturer’s 
recommendations, Aldefluor staining is optimised in cells with low levels of 
ALDH activity. Recent studies have shown that the enzymatic activity of 
ALDH1A2 alone (Yokota et al., 2009) or in combination with ALDH2 can be 
detected by the Aldefluor assay (Moreb et al., 2012). In addition, ALDH1A3 has 
been found of primary importance for Aldefluor activity in the isolation of breast 
CSCs from patient tumour samples (Marcato et al., 2011).  
In light of these findings, it is worthwhile to assess the potential regulation of 
ALDH1A1 and other selected ALDH isoforms, as it may have important 
prognostic revelations in cancers. 
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I.6 Anthraquinone-based ALDH targeting reagents 
As discussed in section I.5.5, the challenge of developing selective fluorescent 
probes able to identify SC populations via targeting of the ALDHs is still 
unaccomplished. As is the case with the use of the Aldefluor assay, the 
production of metabolites that may be substrates for the ABC transporter family 
of proteins, is considered as a further marker for SC population identification 
(Patrawala L, 2005).  
The concept of design reporter molecules with distinct and informative 
fluorescence profiles that can rapidly form equilibrium within nuclear 
compartments can aid the building of pharmacokinetic models to support drug 
development and deployment (Njoh KL, 2006). Many synthetic small molecules 
are currently being explored as sophisticated and biologically safe bioimaging 
probes to detect specific biomolecules with the purpose of visualising cellular 
and molecular events in living cells. One class of agent, that includes DRAQ5, 
is used successfully to stain both fixed and live cells is based on the tricyclic 
anthraquinone chromophore. DRAQ5 (discussed in further details in section 
V.1.2) is already in the market as a non-invasive cytometric tool for tracking 
molecular interactions in live cells. This current work focuses on the potential 
that an anthraquinone fluorescent chemical probe can be developed to target 
ALDH expressed in normal or CSCs. A deep understanding of the design and 
the utility of the anthraquinones as fluorophores or as anticancer agents 
(discussed in section II.1) provides an opportunity to develop small molecules 
with improved features over Aldefluor that can be used to probe and identify the 
CSC (see sections II.1-2 for more details). 
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I.7 The concept of probe design for a dynamic assay 
There are several characteristics of a successful optical molecular probe for live 
cell imaging, including wavelength, brightness, bio- and photo-stability, and 
cellular loading including eventual specific or non-specific affinity for cellular 
components (Kobayashi et al., 2009). Design of a small molecule fluorophore 
as a functional assay is a combination of these features. Generally, those that 
are bright, small, and hydrophilic, contain no net charge are better candidates 
for live imaging. For example, key advantages of DRAQ5 exploited in section I.6 
include a simple labelling protocol, spectral compatibility with other markers (i.e. 
GFP, FITC) and a capacity to rapidly enter and intercalate with the DNA of living 
cells. However, a major concern for DRAQ5 cell loading is its toxicity, which 
does not allow recovering the cells after staining. Therefore, a major challenge 
with molecular probes is synthesing agents that are selective for a cellular 
target while minimising toxicity by having affinity for an extrusion mechanism to 
rescue the pool of cells after analysis. Interestingly, low molecular weight 
fluorophores can be designed to be sensitive to enzymatic catalysis, i.e. ALDH 
affinic, so that they activate in specific environments. Other conditions such as 
acidic pH and the presence of singlet oxygen or other reactive species can 
influence the performance of small molecule fluorophores.  In this thesis, all 
these requirements will be carefully brought together to design a functional 
probe with specific properties to use successfully within a cell-based assay. 
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I.8 Aims of the thesis 
There is currently a poor knowledge of how the ALDH family of enzymes is 
expressed and regulated (see section I.5.4). This includes a limited 
understanding on substrate selectivity of ALDHs and an insight into the 
competitive extrusion mechanisms of their metabolites. Although the Aldefluor 
assay is frequently used in isolating cell populations with SC properties by 
targeting ADH1A1, its utility as a functional assay is somewhat hampered by 
lack of ALDH isoform selectivity. Accordingly, this project is in part undertaken 
to better understand the ALDH expression in vitro, with specific focus on 
potential epigenetic regulation of this class of enzymes (see section I.4.4).  
In addition, ABC transporters will also be assessed for potential epigenetic 
regulation, as these are often responsible for mediating anthraquinone-based 
efflux outside of cells. Overall, the current lack of knowledge poses difficult 
challenges in the design and development of effective molecular fluorescent 
probes targeting specific ALDH isoforms. Therefore, the main goals of this PhD 
project are (i) to contribute to the understanding of ALDH expression and 
regulation, and (ii) to carry out synthetic and biological investigations of novel 
anthraquinone-based small molecules that can be used to explore the 
possibility of targeting ALDHs. The specific aims are as follows: 
1. To design and synthesise a novel library of 1,4-di-substituted 
acetalanthraquinones (AAQs) (Chapter II); 
2. To investigate whether the AAQs are susceptible to acidic hydrolysis and 
ALDH-dependent metabolism (Chapter III); 
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3. To assess the DNA binding properties and cytotoxicity of the AAQs and 
their hydrolysed (HAAQ) counterparts (Chapter IV); 
4. To investigate the fluorescent properties, cellular uptake and 
compartmentalisation of the designed AAQs and selected HAAQs in order 
to understand their potential as functional assay (Chapter V); 
5. To investigate the expression and epigenetic regulation of isoforms 
selected from the ALDH 1-3 family (ALDH1A1, 2 and 3A1) and two 
principal ABC transporters (ABCB1 and ABCG2) which are known to 
pump anthraquinones out of cells (Chapter VI); 
6. To investigate the expression and epigenetic regulation of ALDH1A1, 2 
and 3A1 in prostate cell lines (normal and malignant) and in clinical 
specimens containing SC populations. 
Each individual chapter in this thesis will further provide pertinent overviews to 
frame the context of more detailed experimental objectives and provide details 
of the specific methodologies employed. Finally, overall conclusions and 
directions for future research will be discussed in Chapter VIII. 
 
  
 
 
 
 
Chapter II 
 
Design and synthesis of 1,4-di-
substituted acetalanthraquinones  
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II.1 Introduction and Aims 
II.1.1 Symmetrical and non-symmetrical 1,4-di-substituted anthraquinones 
Over the last 30 years, a plethora of anthraquinones have been synthesised 
and biologically evaluated aiming to understand their interaction with DNA and 
develop applications for subsequent biological application. DNA intercalators, 
including anthracyclines and anthraquinones, contain an electron-deficient 
chromophore that stabilises the binding of these planar compounds between 
the electron rich bases of DNA in a non-covalent manner. The driving force is 
the stacking and electron donor/acceptor interactions, due to van der Waals and 
electrostatic forces (Neidle and Abraham, 1984). The interaction between DNA 
and 1,4-di-substituted anthraquinones has been extensively studied and 
molecular modelling has been used to aid the understanding of the various 
binding mode differences (Figure 2.1). The strong DNA binding leads to various 
biological effects including chromatin compaction, topoisomerase II poisoning 
and DNA strand breaks (Bailly et al., 1996). In regard to the DNA binding, 
previous studies (Islam SA, 1985; Lerman, 1961; Murdock K. C., 1979) have 
confirmed that it is possible to increase or decrease the DNA affinity and the 
potential anticancer activity by making modifications to the anthraquinone 
chromophore or to the sidechain positions attached to the chromophore.  
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_______________________________________________________________ 
Figure 2.1 Intercalation models for 1,4-bis[(diethylaminoethyl)amino]anthraquinone. (A) 
'Straddle’ intercalation model. (B) Major groove intercalation model (Islam SA, 1985).  
 
Some of the most interesting modifications have included 5,8-dihydroxylation of 
the aromatic nucleus, which substantially increased biological activity due to a 
slower dissociation from the DNA macromolecule (Pors et al., 2003; Routier et 
al., 1996). 
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Not all chromophore modifications have resulted in potent in vitro activity as 
evidenced by lack of activity from 5,6-dihydroxyl, 6-methyl, 6-carboxyl or 6,7-
dichloro substituted anthraquinones. Increased chain length between the key 
nitrogen atoms reduced (n = 3) or abolished (n = 4, 5) activity and the optimal 
distance between the two N atoms was established to be 3-carbon linker (n = 2) 
(Figure 2.2). 
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Figure 2.2 1,4-di-substituted anthraquinone structure with possible modification sites. 
 
Terminal N-substituted pyridyl, N-aryl or N-acyl derivatives are often inactive 
and it has been demonstrated that the N-terminal atoms must be fully basic to 
bind efficiently to phosphodiester residues of the DNA backbone (Murdock K. 
C., 1979). Further studies demonstrated that insertion of a methyl group at the 
chromophore aniline nitrogen led to decreased activity (Krapcho et al., 1990; 
Krapcho et al., 1991), probably because the substituent is forced out of the 
plane defined by the aromatic system interfering with the DNA intercalation 
process. Furthermore, modification of the ethylenediamine sidechains by 
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insertion of N-(hydroxyalkyl) substituents led to improved biological activity, 
suggesting that high hydrophilicity is more important than “mere steric brevity” 
(Murdock K.C., 1979). Compounds containing the N,N-dimethylethylenediamine 
sidechain structure in position 1, such as “AQ4” or “AQ6” derivatives (Figure 
2.3) have been shown to be excellent DNA binders and cytotoxic agents (Smith 
et al., 1997).  
O
O
NH
NH
OH
OH
N
N
O
O
NH
NH
OH
OH
N
N
H
(A) (B)
OH
 
_______________________________________________________________ 
Figure 2.3 Chemical structures of exemplars of 1,4-di-substituted symmetrical and non-
symmetrical anthraquinone-based compounds with high DNA affinity. (A) AQ4 and (B) AQ6. 
 
II.1.2 Rationale for the design of ALDH-targeting anthraquinone-based 
agents 
Based on the existent knowledge of (i) structure-activity relationships (SARs) of 
1,4-di-substituted anthraquinones reviewed above, (ii) the understanding of the 
fluorescent properties of anthraquinones as functional molecular probes 
(exemplified by DRAQ5, section V.1.2) and (iii) the structural composition of 
Aldefluor (see section 1.5.6), this project was initially established to synthesise 
and biologically evaluate novel 1,4-di-substituted symmetrical and non-
symmetrical anthraquinone-based compounds as chemical probes with 
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potential use as ALDH-targeting fluorescent reagents. The design of such 
chemical probes was focussed on the modification of the chemical 
functionalities in the β-position to the terminal acetal group as outlined in Figure 
2.4. 
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Figure 2.4 1,4-di-substituted acetalanthraquinone LC- and HA- libraries of compounds. 
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II.1.3 Aims of the chapter 
The aim of this chapter is to synthesise novel 1,4-di-substituted 
acetalanthraquinones (AAQs) with potential of targeting ALDH expressed in 
SCs. Specifically, acetal-incorporating sidechains were designed to create a 
range of different DNA binding affinities, which could lead to chemical probes 
targeting different cellular compartments in the cell.  In the present chapter, the 
“LC-AAQ” library consisting of twelve compounds is discussed in detail and the 
“HA-AAQ” library consisting of four compounds is presented here, but the 
synthesis is not discussed, as it was carried out by Dr. Hamdy M. Abdel-
Rahman. Both libraries of AAQs are important in regard to deriving meaningful 
SARs, which will be investigated and discussed in Chapters III-V. 
 
 
 
 
 
 
 
 
 
 
 
Chapter II                                                                                                     - 46 - 
_______________________________________________________________________ 
 
 
II.2 Results and Discussion 
II.2.1 Synthesis of acetalamino-sidechains  
Three different sidechains were prepared using synthetic routes comprising 3-5 
steps. The sidechains (see Figure 2.5) were subsequently reacted with 
anthraquinone chromophores to afford a novel library of acetalanthraquinones.  
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_______________________________________________________________ 
Figure 2.5 Structural modifications of the sidechains to insert 1,4-di-substituted 
acetalanthraquinones.   
 
II.2.1.1 Sidechain 1: 5, 5-dimethoxypentan-1-amine  
Following a method reported by Sall et coll. (Sall et al., 1997), commercially 
available 5-aminopentanol was N-protected using phthalic anhydride. The 
intermediate, isolated in quantitative yield, was oxidised at the primary alcohol 
with pyridinium chlorochromate (PCC) to afford the respective aldehyde product 
in 83% yield. The aldehyde group was subsequently protected into dimethyl 
acetal. Acetal derivatisation was obtained using the method reported by 
Cameron et al. (Cameron A., 1953). To avoid the usage of harmful dry HCl 
reported by Cameron et al., the acid catalyst employed was a cationic exchange 
resin (Amberlite IR-120). The dimethyl acetal was obtained without a need for 
any purification steps. Hydrazinolysis of the phthalamide protective group 
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(Sasaki et al., 1978) lead to the desired compound being obtained in 
quantitative yield (Scheme 2.1).  
H2N OH + O
O
O
N
O
O
OH
ii, iiia or iiib
N
O
O
O
H2N O
O
i
iv
O  
_______________________________________________________________ 
Scheme 2.1 Route to synthesise 5,5-dimethoxypentan-1-amine. (i) 138 °C 20 h;  (ii) CH2Cl2, 
MgSO4, PCC,  RT 1.5 h ; (iiia) dry HCl  2 min, reflux 15 min;  (iiib) anh. CH3OH, cationic 
exchange resin, RT 4 days; (iv) CH3OH, hydrazine, reflux  4 h. 
 
II.2.1.2 Sidechain 2:  3-amino-N-(2,2-dimethoxyethyl)propanamide 
Z-Amino protected β-alanine was coupled with commercially available 2,2-
dimethoxyethanamine (Scheme. 2.2).  
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_______________________________________________________________ 
Scheme 2.2 Adopted synthetic route with Z-β-alanine. (i) Dry DMF, EDC, triethylamine, RT, 36 
h. 
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The coupling reaction was performed using 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide to activate the terminal carboxylic acid towards coupling with the 
amine terminal group. The reaction was completed after two days at RT.  The 
mechanism of the reaction is shown in Scheme 2.3. 
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_______________________________________________________________ 
Scheme 2.3 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) reaction mechanism. EDC 
activates the carboxylic acid towards amide formation. 
 
The advantage of using the Z-β-Alanine was related to the required conditions 
for the deprotection. Conveniently, the catalytic hydrogenation needed to cleave 
the Z-group had no effect on the stability of the acetal moiety; following 
hydrogenation the desired compound was afforded in quantitative yields. 
The last step involved deprotection of the amino group using catalytic 
hydrogenation in the presence of 10% palladium-carbon and hydrogen or 
cyclohexene at atmospheric pressure as hydrogen donors (Scheme 2.4). 
Hydrogen was preferred to cyclohexene because the crude product was 
afforded in quantitative yield and without any need for a purification step. 
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_______________________________________________________________ 
Scheme 2.4 Synthetic route for Z-amino group deprotection. (i) Dry CH3OH, cyclohexene, 10% 
Pd-C, reflux 2 h; (ii) dry CH3OH, H2, 10% Pd-C, reflux, 2h. 
 
II.2.1.3 Sidechain 3: N-(2-Aminoethyl)-3,3-dimethoxypropanamide 
The N-(2-aminoethyl)-3,3-dimethoxypropanamide sidechain was prepared in 
two steps. Basic cleavage of 3,3-dimethoxypropanoate using a 1:1 mixture of 
sodium hydroxide and methanol at RT yielded a colourless oily carboxylic acid 
as the first intermediate (Scheme 2.5). 
 
O
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O O
OO
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i
 
_______________________________________________________________ 
Scheme 2.5 Synthetic route for 3,3-dimethoxypropanoic acid preparation. (i) NaOH: MeOH, 
overnight at room temperature. 
 
The second intermediate to prepare the target sidechain needed to be a 
monoprotected ethylenediamine. In an attempt to obtain this compound, several 
protecting groups were used to favour the selective reaction of 3,3-
dimethoxypropanoic acid with one of the two amino groups on the 
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ethylenediamine. Carbamate-based protecting groups were chosen according 
with preferential monoprotection and easiness of deprotection. According to the 
literature (Greene T. W., 1999), several protective groups are known to be 
cleaved under basic conditions but a few of them are able to give 
monoprotected products.  
Following the method of Alfred et al. (Alfred J.C., 1996), 2-bromoethylamine 
was N-protected using di-tert-butyl dicarbonate (BOC2O) in the presence of 
triethylamine (Scheme 2.6). Purification by flash chromatography afforded the 
product in 63% yield.   
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_______________________________________________________________ 
Scheme 2.6 Synthetic route for 2-(1,3-dioxoisoindolin-2-yl)ethanaminium chloride synthesis. (i) 
BOC2O, triethylamine, dry CHCl3, reflux, 1 h, (ii) potassium phthalamide, dry DMF, 75 °C, 2 
days, (iii) 3 M dry HCl/EtOAc, RT, 1 h.  
 
The substitution of the phthalamide group for bromide was performed by 
reaction of the BOC-protected intermediate in anhydrous DMF with potassium 
phthalamide salt. The potassium bromide generated with the reaction was 
removed by filtration and the desired compound was isolated in 80% yield. The 
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deprotection of the BOC-amino group was achieved by treating the intermediate 
with a saturated solution of dry HCl in anhydrous ethyl acetate. The 
phthalamide-protected ethylenediamine was isolated as the HCl salt in 84% 
yield. 
The 3,3-dimethoxypropanoic acid (Scheme 2.5) and the monoprotected 
ethylenediamine were reacted to form the amide bond using EDC as coupling 
reagent (see Figure 2.3 for detailed mechanism). The product was obtained 
after extraction from dichloromethane (46% yield). Deprotection with hydrazine 
monohydrate yielded the final sidechain in 80% yield (Scheme 2.7). 
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_______________________________________________________________ 
Scheme 2.7 Coupling reaction and deprotection of the amino group to yield N-(2-aminoethyl)-
3,3-dimethoxypropanamide. (i) Dry DMF, EDC, triethylamine, RT, 36 h; (ii) dry methanol, 
hydrazine monohydrate, reflux, 4 h. 
 
II.2.2 Synthesis of chromophores 
The library of compounds described in detail in this section includes two 
different chromophores (see Figure 2.10A-B).  
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_______________________________________________________________ 
Figure 2.6 Chemical structures of 1,4-difluoro-anthraquinones. (A) 1,4-difluoro-anthraquinones; 
(B) 1,4-difluoro-5,8-dihydroxyanthraquinone. 
 
Chromophore A was supplied by Sigma, but chromophore B was prepared 
following the procedure described by Krapcho et al. (Krapcho et al., 1990) by 
reacting 1,4-dihydroxybenzene and 3,6-difluorophthalic anhydride in the 
presence of a mixture of ground AlCl3 and NaCl at 220 °C (Scheme 2.8).  
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_______________________________________________________________ 
Scheme 2.8 Preparation of 1,4-difluoro-5,8-dihydroxyanthraquinone. (i) AlCl3, NaCl, 220 °C, 3 
h. 
 
After 3 h, the reaction was quenched by pouring the melt onto a mixture of ice 
and concentrated HCl. Without any purification step, the desired compound was 
obtained in excellent yield (92%). 
Chapter II                                                                                                     - 53 - 
_______________________________________________________________________ 
 
 
Non-symmetrical chromophores were prepared by first reacting N-N-
dimethylethylenediamine either with 1,4-difluoroanthraquinone or 1,4-difluoro-
5,8-dihydroxyanthraquinone in pyridine (Scheme 2.9).  
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Scheme 2.9 Formation of non-symmetrical AAQs. (A) Synthesis 1-{2-[N,N-
(dimethyl)amino]ethylamino]-4-fluoro-5,8-dihydroxy-anthraquinone. (i) Pyridine, RT, 24 h; (B) 
Synthesis of 1-{2-[N,N-(dimethyl)amino]ethylamino]-4-fluoro-5,8-dihydroxy-anthraquinone; (i) 
Pyridine, RT, 24 h. 
 
The intermediate target compounds were isolated in 75% (A) and 67% (B) yield 
respectively after purification by column chromatography (see Experimental 
Details at the end of the chapter). 
Generally, compounds such as halobenzenes show resistence to nucleophilic 
attack due to the electron rich nature of the aryl system. However, as reported 
in the literature (Kikuchi et al., 1982), the insertion of a  strong electron-
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withdrawing group in the ortho and/or para position to the halogen can favour a 
substitution with an addition/elimination sequence. As shown in Scheme 2.10, 
the nucleophilic primary amine forms a bond with the chromophore producing a 
negatively charged sigma complex (also known as Meisenheimer complex).  
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_______________________________________________________________ 
Scheme 2.10 Proposed mechanism for nucleophilic aromatic substitution by addition-
elimination reaction, via Meisenheimer complex. 
 
In this intermediate, the two electron-withdrawing quinones of the 
anthraquinone structure participate in the electron flow, activating the ring 
towards nucleophilic attack and the departure of the halide. Strong electron-
withdrawing nature of fluorine also helps with this – promotes attack and 
stabilises intermediate carbanion by inductive effect. 
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II.2.3 Synthesis of and symmetrical and non-symmetrical 1,4-di-
substituted-acetalanthraquinones (AAQ) 
The synthesis of the desired compounds was achieved by reaction of the novel 
sidechains of interest with symmetrical and non-symmetrical anthraquinone 
chromophores. 
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_______________________________________________________________ 
Scheme 2.11 Synthesis of symmetrical 1,4-di-substituted-anthraquinones. 
 
The symmetrical 1,4-di-substituted anthraquinones were prepared by reacting 
the respective chromophores with the aminoalkylacetal sidechains 
(Schemes2.11-2.12). The reaction conditions used to generate all target 
compounds consisted of mixing starting materials and reagents in dry pyridine 
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and heating to reflux for 3 h, providing the desired compounds in a range of 
yields (see Table 2.1). 
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Scheme 2.12 Synthetis of symmetrical 1,4-di-substituted-5,8-dihydroxy-anthraquinones.  
 
Non-symmetrical anthraquinones were obtained by reacting the intermediate 1-
(dimethylamino)ethylamino-4-fluoro-5,8-dihydroxyanthraquinone with the 
sidechain of interest (Scheme 2.13-2.14) to afford the non symmetrical target 
compounds in a range of yields (see Table 2.1). 
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Scheme  2.13 Synthetis of non-symmetrical 1,4-di-substituted-anthraquinones.  
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Scheme  2.14 Synthetis of non-symmetrical 1,4-di-substituted-5,8-dihydroxy-anthraquinones.  
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Compound
*
 Scheme reference Formula MW [g/mol] Yield  [%] 
LC-103 2.10 C28H38N2O6 498.6 44 
LC-105 2.13 C25H33N3O6 471.5 49 
LC-106 2.10 C28H36N4O8 556.2 59 
LC-107 2.10 C28H36N4O8 556.2 30 
LC-055 2.11 C28H38N2O8 530.3 52 
LC-108 2.11 C28H36N4O10 588.6 66 
LC-109 2.11 C28H36N4O10 588.6 40 
LC-110 2.12 C25H33N3O4 439.5 70 
LC-111 2.13 C25H32N4O7 500.5 90 
LC-112 2.12 C25H32N4O5 468.5 33 
LC-113 2.12 C25H32N4O5 468.5 60 
A
A
Q
s
 
 
LC-114 2.13 C25H32N4O7 500.5 60 
 
_______________________________________________________________ 
Table 2.1 Yields obtained from preparation of 1,4-di-substituted anthraquinones.  
 
To summarise, three novel amino sidechains containing acetal functionalities 
were synthesised and substituted onto two fluorinated anthraquinone building 
blocks to give a library of twelve LC-AAQs for biological evaluation. The results 
of these studies are discussed in Chapters III-V.  
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II.3 Experimental Details 
II.3.1 Chemicals, Reagents and Instrumentations 
All reagents were supplied by Sigma. Chromatography column silica: particle 
size 35-70 µm and 20-35 µm, was supplied by Fisher Scientific. Thin layer 
chromatography plates (Aluminium backed) supplied by Merck. All solvents 
were of standard grade. Dichloromethane, petroleum ether 40-60, chloroform, 
ethanol, methanol, diethylether, hexane, toluene, ethylacetate and acetonitrile 
were supplied by Fisher Scientific. Anhydrous DMF was purchased from 
Aldrich.  Proton Nuclear Magnetic Resonance (1H NMR) spectra were recorded 
using Bruker AMX400 (400 MHz) spectrometer. Carbon Nuclear Magnetic 
Resonance (13C and NMR) were performed on the same machines operating at 
101 MHz. Deuterated chloroform (CDCl3) was used as the NMR solvent unless 
otherwise stated. Chemical shifts are reported in parts per million (δ, ppm). 1H 
NMR chemical shifts are reported relative to an internal reference 
(tetramethylsilane) or residual proton signals of the solvent. Coupling constants 
(J) are expressed in Hertz (Hz). The splitting patters in NMR spectra are 
reported with the following abbreviations; singlet (s), doublet (d), triplet (t), 
quartet (q), quintet (quint.), multiplet (m) and broad (br). 13C NMR chemical 
shifts are reported relative to the signal of the solvent. Routine mass spectra 
was carried out by Andrew Healey and were run on a Micromass Quattro Ultima 
spectrometer in the electron impact (EI), chemical ionisation (CI) or positive (+) 
electrospray mode as stated. High resolution mass spectrometry (HRMS) was 
carried out at the ESPRC National mass spectrometry service centre located in 
Swansea University. Purity of the final LC-compounds was performed by HPLC 
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analysis on Agilent Technologies 1200 HPLC system with diode array detection, 
using C18 reversed phase columns (Agilent Eclipse XDB - analytical: 4.6 x 100 
mm). Solvent A: H2O + 0.045% TFA; Solvent B: MeCN 90%; H2O 10% + 
0.045% TFA. 
 
II.3.2 Synthesis of 1,4-disubstituted-acetalanthraquinones 
II.3.2.1 Synthesis of acetalamino sidechains 
2-(5-Hydroxypentyl)isoindoline-1,3-dione                      
N
O
O
OH
 
A stirred mixture of 5-aminopentanol (1 g, 9.69 mmol) and phthalic anhydride 
(1.44 g, 9.75 mmol) was heated to 138 °C for 20 h to yield (quantitative) the title 
compound as yellow oil. No work-up was performed and the product was 
directly used for following reaction step. Rf 0.06 (EtOAc:PE, 3:7); δΗ (CDCl3, 
400 MHz) 7.83 (2H, dd, J 3.0, 5.6 Hz), 7.71 (2H, dd, J 3.0, 5.6 Hz), 3.69 (2H, t, 
J 7.3 Hz), 3.64 (2H, t, J 6.6 Hz), 1.87 (1H, br s, OH), 1.71 (2H, qn, J 7.3 Hz), 
1.58-1.65 (2H, m), 1.38-1.45 (2H, m). Results agreed with data reported by 
Cameron et al. (Cameron A. , 1953). 
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5-(1,3-Dioxoisoindolin-2-yl)pentanal 
N
O
O
O
 
To a stirred solution of 2-(5-hydroxypentyl)isoindoline-1,3-dione (1.72 g, 7.37 
mmol) in CH2Cl2 (35 mL) was added MgSO4 (3.5 g) and PCC (4.77 g, 22.11 
mmol) and the resulting suspension was stirred at RT for 1.5 h. The reaction 
mixture was filtered through Celite™, concentrated in vacuo and purified by 
flash column chromatography (EtOAc:PE, 2:3) to yield the title compound (1.41 
g, 83%) as a colourless oil. Rf 0.22 (EtOAc:PE, 2:3); δΗ (CDCl3, 400 MHz) 9.58 
(1H, t, J 1.5, CHO), 7.84 (2H, dd, J 3.0, 5.6 Hz), 7.71 (2H, dd, J 3.0, 5.6), 3.71 
(2H, t, J 7.1 Hz), 2.50 (2H, dt, J 1.5, 7.1 Hz), 1.63-1.77 (4H, m); m/z (ES+) 
233.2 (M, 17%), 232.2 (M+H, 100). 
2-(5,5-Dimethoxypentyl)isoindoline-1,3-dione 
N
O
O
O
O  
To a stirred solution of 5-(1,3-dioxoisoindolin-2-yl)pentanal (1.98 g, 8.5 mol) at 
RT in anhydrous CH3OH (70 mL) was added Amberlite IR-120. After 4 days, the 
reaction mixture was filtered, washing with MeOH. The filtrate was concentrated 
in vacuo to yield the title compound as a colourless oil (1.4 g, 60%). δΗ (CDCl3, 
400 MHz) 7.77 (2H, m, J 2.02, 5.0 Hz), 7.63 (2H, dd, J 3.0, 5.5 Hz), 4.27 (1H, t, 
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J 7.0 Hz), 3.61 (2H, t, J 7.1 Hz), 3.22 (6H, s, O(CH3)2), 1.54-1.66 (4H, m), 1.29-
1.36 (2H, m);  m/z (ES+) 278.3 (M, 17%), 277.3 (M+H, 100). 
5,5-Dimethoxypentan-1-amine 
H2N O
O
 
To a stirred solution of 2-(5,5-dimethoxypentyl)isoindoline-1,3-dione (1.4 g, 5.05 
mmol) in CH3OH (25 mL) was added hydrazine (1.01 mL, 20.19 mmol) and the 
reaction mixture was heated at reflux temperature for 4 h. The solvent was 
removed in vacuo and the reaction mixture was dissolved in 10 mL of CH2Cl2, 
washed with H2O (3 x 10 mL) and dried over MgSO4. Filtrate was concentrated 
in vacuo to yield the title compound (580 mg, 78%) as a light yellow oil. δΗ 
(CDCl3, 400 MHz) 4.29 (1H, t, J  5.5, 6.0 Hz), 3.24 (6H, s, O(CH3)2), 2.62 (2H, t, 
J 7.1 Hz), 1.56-1.51 (2H, m), 1.43-1.36 (2H, m), 1.34-1.27 (2H, m);  δC (CDCl3, 
100 MHz) 104.4, 52.6, 41.9, 33.5, 33.2, 24.0; m/z (ES+) 147.9 (M+H, 100). 
Benzyl 3-(2,2-dimethoxyethylamino)-3-oxopropylcarbamate 
O N
H
NH
O O
O
O
 
Method of Jackson (Jackson A. E., 1976): To a stirred solution of Z-β-Alanine 
(4.0 g, 20 mmol) in anh. DMF (50 mL) was added 2,2-dimethoxyethanamine 
(2.83 g, 0.03 mol), ethyl-(N’,N’-dimethylamino)propylcarbodiimide hydrochloride 
(EDC) (6.86 g, 0.04 mol) and triethylamine (4.92 mL, 0.04 mol). The resulting 
mixture was stirred for 36 h at RT, and then the solvent was evaporated under 
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reduced pressure. The resulting solid was dissolved in CH2Cl2 (20 mL) and 
washed with 5% citric acid (2 x 5 mL), 5% NaHCO3 (2 x 5 mL) and brine (1 x 10 
mL) before being dried over MgSO4. The solution was filtered and concentrated 
in vacuo to yield the crude final compound as a colourless oil (3 g, 54%). δΗ 
(CDCl3, 400 MHz) 7.27 (5H, m), 5.02 (2H, s,), 4.28 (1H, t, J 5.1 Hz), 3.4 (2H, t, J 
2.5 Hz), 3.32 (2H, J 5.5 Hz), 3.30 (6H, s), 2.35 (2H, t, J 6.1 Hz); δC (CDCl3, 100 
MHz) 128.5, 128.1, 128.0, 102.5, 54.4, 40.9; m/z (ES+) 311 (M+H, 100). 
3-Amino-N-(2,2-dimethoxyethyl)propanamide 
H2N N
H
O
O
O
 
To a solution of benzyl 3-(2,2-dimethoxyethylamino)-3-oxopropylcarbamate 
(100 mg, 0.32 mmol) in CH3OH (3 mL) was added cyclohexene (264 mg, 3.22 
mmol) and commercial 10% Pd-C catalyst (20 mg). The mixture was heated 
under reflux for 2 h then the solution was filtered through Celite™. The catalyst 
was washed with CH3OH and the combined filtrates were concentrated under 
reduced pressure to give the deprotected crude product (54 mg, 95%). δΗ 
(CDCl3, 400 MHz) 7.05 (1H, br s, NH), 4.41 (1H, t, J 5.5 Hz), 3.41 (2H, t, J 5.5 
Hz), 3.4 (6H, s), 3.03 (2H, t, J  5.5 Hz), 2.38 (2H, t, J 4.04 Hz), 2.19 (2H, br s, 
NH); δC (CDCl3, 100 MHz) 172.4, 102.6, 54.2, 50.7, 40.7, 38.3, 38.1;  m/z (ES+) 
177 (M+H, 100). 
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3,3-Dimethoxypropanoic acid 
O OH
O O
 
Methanol was added dropwise to a solution of NaOH (2 M) in order to prepare a 
NaOH-CH3OH (1:1) solution. The methyl 3,3-dimethoxypropanoate (1 g, 6.75 
mmol) was stirred at RT overnight in 10 mL of the prepared NaOH: CH3OH 
(1:1) solution. The reaction mixture was treated with Amberlite IR-120 until pH 
reached 6. The resin was washed several times with CH3OH and H2O and 
concentrated under vacuum. The remaining H2O was removed by lyophilisation 
to yield the title compound as colourless crude oil (1 g, quantitative). δΗ (CDCl3, 
400 MHz) 6.14 (1H, br s, NH), 4.79 (1H, t, J 5.6 Hz), 3.33 (6H, s), 2.58 (2H, d, J 
5.6 Hz). 
Tert-butyl 2-bromoethylcarbamate 
O
H
N
Br
O  
To a stirred slurry of 2-bromoethylamine (200 mg, 0.98 mmol) and triethylamine 
(0.14 mL, 0.976 mmol) in CHCl3 (5mL) was added a solution of (BOC)2O 
(213mg, 0.98 mmol) in CHCl3 (5 mL). After addition, the reaction mixture was 
heated for 1 h under reflux, cooled to RT and the solution was washed with H2O 
(3 x 15 mL) and dried over Na2SO4. The organic solvent was evaporated under 
vacuum and the crude compound was purified by column chromatography 
(CHCl3:CH3OH, 9:1) to yield the title compound (128 mg, 63%). δΗ (CDCl3, 400 
MHz) 6.76 (1H, CONH), 3.57 (2H, t, J 4.5 Hz), 3.31 (2H, t, J 4.5 Hz), 1.46 (9H, 
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s);  δC (CDCl3, 100 MHz) 155.7, 83.7, 56.53, 53.20, 48.8, 32.5, 28.0; m/z (ES+) 
305.2, 306.2 (M+H, 100). 
Tert-butyl 2-(1,3-dioxoisoindolin-2-yl)ethylcarbamate 
N
H
N O
O
O
O
 
A solution of tert-butyl 2-bromoethylcarbamate (5.6 g, 0.03 mol) in anhydrous 
DMF (20 mL) was added to a stirred slurry of potassium phtalamide (4.93 g, 
0.03 mol) in anhydrous DMF (20 mL), and the mixture was heated at 75 °C for 2 
days. After cooling, KBr was filtered off and the DMF was evaporated under 
vacuum. The residue was dissolved in CH2Cl2 (100 mL) and the solution was 
washed with H2O (3 x 100 mL), dried over Na2SO4 and evaporated under 
vacuum to yield a white powder (6.16 g, 80%). δΗ (CH3OD, 400 MHz) 7.70 (4H, 
m), 6.60 (1H, brs, NH), 3.65 (2H, t, J 5.8 Hz), 3.23 (2H, t, J 5.8 Hz), 1.11 (9H, 
s).  
2-(1,3-Dioxoisoindolin-2-yl)ethanaminium chloride 
N
NH3
O
O
Cl
 
To a 3 M solution of dry HCl in anhydrous ethyl acetate (1 mL) at 0 °C was 
added tert-butyl 2-(1,3-dioxoisoindolin-2-yl)ethylcarbamate (60 mg, 0.21 mmol). 
The slurry mixture was allowed to warm up to RT and stirred for 1 h. The 
solution was filtered and the precipitate was collected and washed with ether to 
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yield the crude title compound as a white powder (50 mg, quantitative). δΗ 
(CD3OD, 400 MHz) 7.86 (4H, s), 3.94 (2H, t, J 5.55 Hz), 3.45 (2H, t, J 5.55 Hz). 
δC (CDCl3, 100 MHz) 167.7, 133.2, 132.0, 126.7, 41.9, 36.7. 
N-(2-(1,3-Dioxoisoindolin-2-yl)ethyl)-3,3-dimethoxypropanamide 
N
O
O
H
N
O O
O
 
To a stirred solution of 3,3-dimethoxypropanoic acid (1.54 g, 0.012 mol) in DMF 
(15 mL) at RT was added 2-(1,3-dioxoisoindolin-2-yl)ethylammonium chloride 
(3.84 g, 0.02 mol), EDC (4.49 g, 0.02 mol) and triethylamine (6.6 mL, 0.05 mol). 
The resulting mixture was stirred for 36 h. The solvent was evaporated under 
reduced pressure and the resulting solid was dissolved in CH2Cl2 (20 mL) and 
washed with 5% citric acid (2 x 5 mL), 5% NaHCO3 (2 x 5 mL) and brine (1 x 10 
mL) before being dried over MgSO4. The solution was filtered and concentrated 
in vacuo to yield the final compound (1.68 g, 46%). δΗ (CDCl3, 400 MHz) 7.75 
(4H, s), 7.4 (1H, brs, NH), 4.5 (1H, t, J 5.6 Hz), 3.69 (2H, t, J 5.6 Hz), 3.37 (2H, 
t, J 5.6 Hz), 3.21 (2H, t, J 5.6 Hz), 3.1 (6H, s). δC (CDCl3, 100 MHz) 173.3, 
165.4, 132.3, 130.2, 125, 100.2, 53.1, 49.2, 39.6, 36.2; m/z (ES+) 329 (M+H, 
100). 
N-(2-Aminoethyl)-3,3-dimethoxypropanamide 
N
H
O
OO
H2N
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To a stirred solution of N-(2-(1,3-dioxoisoindolin-2-yl)ethyl)-3,3-
dimethoxypropanamide (1.68 g, 5 mmol) in CH3OH (60 mL) was added 
hydrazine monohydrate (1.06 mL, 0.02 mol) and the resulting mixture was 
stirred under reflux for 4 h. The mixture was cooled to RT and the solvent was 
evaporated under reduced pressure. The resulting solid was dissolved in 
CH2Cl2 (20 mL) and the undissolvable phthalazide was removed by filtration. 
The solution was concentrated in vacuo to yield the title compound (756.5 mg, 
80%). δΗ (CDCl3, 400 MHz) 6.44 (1H, brs, NH), 4.63 (1H, t, J 5.1 Hz), 3.32 (6H, 
s), 3.23 (2H, t, J 6.1 Hz), 2.76 (2H, J 4.5 Hz); δC (CDCl3, 100 MHz) 169.4, 
162.5, 102.2,  54.2, 42.1, 41.0, 40.9;  m/z (ES+) 177 (M+H, 100). 
 
II.3.2.2 Synthesis of chromophores 
1,4-Difluoro-5,8-dihydroxyanthraquinone  
 
O
O
OH F
FOH  
A mixture of ground AlCl3 (2.95 g, 22.16 mmol), NaCl (432 mg, 7.39 mmol), 1,4-
dihydroxybenzene (224 mg, 2.03 mmol) and 3,6-difluorophthalic (340 mg, 1.85 
mmol) were mixed in a round bottom flask and heated to 220 °C for 3 h. The oil-
bath was removed and the reaction quenched by addition of ice and 
concentrated hydrochloric acid (10 mL). The final aqueous solution was filtered 
under suction and the residue was solubilised in acetonitrile followed by freeze-
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drying to yield the title compound as a brown solid (470 mg, 92 %). δH (CDCl3, 
400 MHz) 7.3 (s, 2H), 7.55 (m, 2H), 12.90 (s, 2H); m/z (ES+) 277 (M+H, 100). 
1-(2-(Dimethylamino)ethylamino)-4-fluoroanthracene-9,10-dione 
O
O
HN
F
N
 
To a stirred solution of 1,4-difluoro-anthraquinone (300 mg, 1.23 mmol) in 
pyridine (1 mL) was added N,N-dimethylethane-1,2-diamine (108 mg, 1.23 
mmol) and the resulting solution was heated under reflux for 15 min. The 
solvent was evaporated under reduced pressure and the reaction mixture was 
purified by flash chromatography using gradient elution (CH3OH:CH2Cl2, 
1:99→4:96) to yield the title compound (236 mg, 75%). δH (CDCl3, 400 MHz); 
9.90 (1H, s), 8.15 (2H, dd, J 1.51, 7.5 Hz), 8.14 (2H, dd),  7.30 (1H, dd, J 1.51, 
7.5 Hz), 3.32 (2H, q, J 6.0 Hz), 2.59 (2H, t, J 6.5 Hz), 2.28 (6H, s). δC (CDCl3, 
100 MHz) 182.4, 154.5, 151.9, 148.7, 134.3, 133.0, 131.2, 130.2, 130.0, 126.6, 
120.2, 119.9, 111.5, 57.9, 45.6, 42.0, 41.1; m/z (ES+) 313 (M+H, 100). 
1-(2-(Dimethylamino)ethylamino)-4-fluoro-5,8-dihydroxyanthracene-9,10-
dione 
O
O
OH HN
FOH
N
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To a stirred solution of 1,4-difluoro-5,8-dihydroxyanthracene-9,10-dione (600 
mg, 2.17 mmol) in pyridine (7 mL) was added N,N-dimethylethane-1,2-diamine 
(238 mg, 2.17 mmol) and the resulting solution was stirred at 90 °C for 15 min. 
The mixture was cooled down to RT and the solvent was evaporated under 
reduced pressure. The reaction mixture was dissolved in CH2Cl2 (30 mL) and 
washed with saturated NaHCO3 (2 x 20 mL). The organic layer was collected 
and dried over MgSO4. After evaporation of the solvent, the crude compound 
was purified by flash chromatography using gradient eluent (CH3OH:CH2Cl2, 
0:100→6:94) to yield the title compound (300 mg, 40%).  δH (CDCl3, 400 MHz); 
13.4 (2H, s, OH), 10.7 (1H, s), 7.4 (1H, dd, J 1.5, 7.5 Hz ), 6.8 (2H, s), 6.7 (2H, 
s),  3.4 (2H, q, J 6.5 Hz), 2.7 (2H, t, J 6.5 Hz), 2.35 (6H, s). δC (CDCl3, 100 MHz) 
182.1, 154.2, 144.2, 124.8, 123.1, 120.3, 119.2, 118.5, 110.8, 59.1, 46.2, 43.2; 
m/z (ES+) 344 (M+H, 100). 
 
II.3.2.3 Synthesis of symmetrical 1,4-di-substituted anthraquinones 
1,4-Bis(5,5-dimethoxypentylamino)anthracene-9,10-dione 
O
O
HN
HN
O
O
O
O  
To a stirred solution of 1,4-difluoro-anthraquinone (74 mg, 0.29 mmol) in 
pyridine (1 mL) was added 5,5-dimethoxypentanamine (261 mg, 1.72 mmol) 
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and the resulting solution was stirred at 70 °C for 3 h. The solvent was 
evaporated under reduced pressure and the reaction mixture was purified by 
flash chromatography using gradient eluent (EtOAc:PE, 0:100→3:7) to yield the 
title compound as a dark blue powder (62 mg, 44%). δΗ (CDCl3, 400 MHz) 8.24 
(2H, dd, J 3.5, 6.0 Hz), 7.6 (2H, dd, J 3.5, 6.0 Hz), 7.14 (2H, s), 4.32 (2H, t, J  
5.6), 3.62 (4H, t, J 6.5 Hz), 3.36 (4H, t, J 5.5 Hz), 3.25 (12H, s, O(CH3)2), 1.75-
1.45 (12H, m);  δC (CDCl3, 100 MHz) 181.3, 145, 133.5, 130.7, 125.3, 122.1, 
108.7, 103.4, 51.7, 41.2, 30.8, 28.5, 21.1; m/z (ES+) 499 (M+H, 100). 
3,3'-(9,10-Dioxo-9,10-dihydroanthracene-1,4-diyl)bis(azanediyl)bis(N-(2,2-
dimethoxyethyl)propanamide) 
O
O
HN
HN
N
H
O
H
N
O
O
O
O
O
 
To a stirred solution of 1,4-difluoro-anthraquinone (80 mg, 0.33 mmol) in 
pyridine (1 mL) was added 3-amino-N-(2,2-dimethoxyethyl)propanamide (345.7 
mg, 1.96 mmol) and the resulting solution was stirred at 70°C for 4 h. The 
solvent was evaporated under reduced pressure and the reaction mixture was 
purified by flash chromatography using gradient eluent (CH3OH:CH2Cl2, 
1:99→1:9 to yield the title compound as a dark blue powder (107 mg, 59%). δΗ 
(CDCl3, 400 MHz) 8.15 (2H, dd J 3.5, 6.0 Hz), 7.6 (2H, dd J 3.5, 6.0 Hz), 7.12 
(2H, s), 4.32 (2H, t, J  5.6 Hz), 3.61 (4H, t, J 6.5 Hz), 3.37 (4H, t, J 5.6 Hz), 3.28 
(12H, s, O(CH3)2), 2.53 (4H, t, J 6.5 Hz);  δC (CDCl3, 100 MHz) 182.2, 170.8, 
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145.6, 134.2, 132.1, 126.0, 123.3, 110.3, 102.8, 54.2, 41.2, 36.5, 39.1; m/z 
(ES+) 557 (M+H, 100). 
N,N'-(2,2'-(9,10-Dioxo-9,10-dihydroanthracene-1,4-
diyl)bis(azanediyl)bis(ethane-2,1-diyl))bis(3,3-dimethoxypropanamide) 
O
O
HN
HN
H
N O
N
H
O
O
O
O
O
 
To a stirred solution of 1,4-difluoro-anthraquinone (80 mg, 0.33 mmol) in 
pyridine (1 mL) was added N-(2-aminoethyl)-3,3-dimethoxypropanamide (346 
mg, 1.96 mmol) and the resulting solution was stirred at 70 °C for 4 h. The 
solvent was evaporated under reduced pressure and the reaction mixture was 
purified by flash chromatography using gradient eluent (CH3OH:CH2Cl2, 
1:99→1:9). After the chromatographic purification residual acidic aliphatic 
impurities were removed by washing with 0.1 M NaOH (2 x 10mL), and brine (1 
x 10mL) before being dried over MgSO4. After filtration, the solvent was 
concentrated in vacuo to yield the title compound as a dark blue powder (25 
mg, 29%). δΗ (CDCl3, 400 MHz) 8.10 (2H, dd, J 3.5, 6.0 Hz), 7.57 (2H, dd, J 
3.0, 5.5 Hz), 7.06 (1H, br s, NH), 6.98 (2H, s), 5.20 (2H, s), 4.69 (2H, t, J  5.6 
Hz), 3.51 (4H, t, J 6.0 Hz), 3.25 (12H, s, O(CH3)2), 2.60 (4H, d, J  5.6 Hz);  δC 
(CDCl3, 100 MHz) 182.2, 169.9, 168.3, 134.2, 132.1, 126.0, 123.2 ,109.9, 
102.3, 54.3, 42.1, 40.9, 39.2; m/z (ES+) 557 (M+H, 100). 
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1,4-Bis(5,5-dimethoxypentylamino)-5,8-dihydroxyanthracene-9,10-dione 
O
O
OH
OH
HN
HN
O
O
O
O  
To a stirred solution of 1,4-difluoro-5,8-dihydroxyanthracene-9,10-dione (47 mg, 
0.17 mmol) in pyridine (1 mL) was added 5,5-dimethoxypentan-1-amine (200 
mg, 1.36 mmol) and the resulting solution was heated under reflux for 3 h. The 
reaction mixture was diluted with CH2Cl2 (20 mL) and washed with cold brine (2 
x 10 mL). The organic solution was dried with MgSO4, filtered and the remaining 
solution was concentrated in vacuo. The crude solid was purified by flash 
chromatography using gradient eluent (EtOAc:PE, 1:9→1:1) to yield the title 
compound as a dark blue powder (47 mg, 52%). δΗ (CDCl3, 400 MHz) 13.14 
(2H, s), 10.28 (2H, br s), 6.99 (2H, s), 6.96 (2H, s), 4.33 (2H, t, J  5.6 Hz), 3.27 
(12H, s, O(CH3)2), 1.73-1.44 (8H, m), 1.19 (4H, s);  δC (CDCl3, 100 MHz) 183.8, 
154.3, 145.4, 123.5, 122.7, 114.4, 107.6, 103.3, 51.8, 41.8, 28.3, 21.67, 13.1; 
m/z (ES+) 531 (M+H, 100). 
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3,3'-(5,8-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-1,4diyl)bis 
(azanediyl)bis(N-(2,2-dimethoxyethyl)propanamide) 
O
O
HN
HN
N
H
O
H
N
O
O
O
OH
OH
O
O
 
To a stirred solution of 1,4-difluoro-5,8-dihydroxyanthracene-9,10-dione (80 mg, 
0.29 mmol) in pyridine (1 mL) was added 3-amino-N-(2,2-dimethoxyethyl) 
propanamide (306. mg, 1.74 mmol) and the resulting solution was heated under 
reflux for 3 h. The solvent was evaporated under reduced pressure and the 
reaction mixture was purified by flash chromatography using gradient eluent 
(CH3OH:CH2Cl2, 1:99→1:9) to yield the title compound as a dark blue powder 
(112 mg, 66%). δΗ (DMSO, 400 MHz) 13.4 (2H, s, OH), 10.6 (2H, br s, NH), 
8.15 (2H, br s, NH), 7.47 (2H, s), 7.11 (2H, s), 4.32 (2H, t, J  5.55 Hz), 3.73 (4H, 
q, J 5.5 Hz), 3.30 (12H, s, O(CH3)2), 3.25 (4H, t, J 5.5 Hz), 2.43 (4H, m);  δC 
(DMSO, 100 MHz) 183.3, 170.2, 154.5, 146.8, 125.4, 124.3, 114.9, 107.2, 
102.1, 53.2, 40.5, 38.9, 35.2; m/z (ES+) 589 (M+H, 100). 
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N,N'-(2,2'-(5,8-Dihydroxy-9,10-dioxo-9,10-dihydroanthracene-1,4-
diyl)bis(azanediyl)bis(ethane-2,1-diyl))bis(3,3-dimethoxypropanamide) 
O
O
HN
HN
H
N O
N
H
O
O
O
O
O
OH
OH
 
To a stirred solution of 1,4-difluoro-5,8-dihydroxyanthracene-9,10-dione (71 mg, 
0.26 mmol) in pyridine (1 mL) was added N-(2-aminoethyl)-3,3-
dimethoxypropanamide (272mg, 1.54 mmol) and the resulting solution was 
heated under reflux for 4 h. The solvent was evaporated under reduced 
pressure and the reaction mixture was purified by flash chromatography using 
gradient eluent (CH3OH:CH2Cl2, 1:99→1:9) to yield the title compound as a 
dark blue powder (10 mg, 37%). δΗ (DMSO, 400 MHz) 13.5 (2H, s, OH), 10.7 
(2H, br s, NH), 8.13 (2H, br s, NH), 7.64 (2H, s), 7.21 (2H, s), 4.72 (2H, t, J  5.5 
Hz) 3.53 (4H, q, J 5.5 Hz), 3.35 (4H, t, J 5.5 Hz), 3.25 (12H, s, O(CH3)2); δC 
(DMSO, 100 MHz) 182.3, 172.2, 154.5, 140.9, 124.4, 124.3, 115.9, 108.5, 
103.1, 53.7, 44.5, 38.9, 34.2; m/z (ES+) 589 (M+H, 100). 
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II.3.2.4 Synthesis of non-symmetrical 1,4-di-substituted anthraquinones 
1-(5,5-Dimethoxypentylamino)-4-(2-(dimethylamino)ethylamino) 
anthracene-9,10-dione 
O
O
HN
HN
N
O
O  
To a stirred solution of 1-(2-(dimethylamino)ethylamino)-4-fluoroanthracene-
9,10-dione (60 mg, 0.19 mmol) in pyridine (1 mL) was added 5,5-
dimethoxypentan-1-amine (113  mg, 0.77 mmol) and the resulting solution was 
stirred at 70 °C for 4 h. The solvent was evaporated under reduced pressure 
and the reaction mixture was purified by flash chromatography using gradient 
eluent (CH3OH:CH2Cl2, 1:99→1:9) to yield the title compound as a dark blue 
powder (59 mg, 70%). δΗ (CDCl3, 400 MHz) 10.7 (2H, br s, NH), 8.3 (2H, dd, J 
4.0, 5.5 Hz), 7.6 (2H, dd, J 4.0, 5.5 Hz), 7.3 (2H, dd, J 6.0, 15.6 Hz), 4.32 (1H, t, 
J  5.6 Hz), 3.53 (2H, t, , J  5.6 Hz), 3.33 (2H, t,  J  6.5 Hz), 3.26 (6H, s), 2.72 
(2H, t, J  6.5 Hz), 2.33 (6H, s), 1.7 (2H, m), 1.63 (2H, m), 1.42 (2H, m);  δC 
(CDCl3, 100 MHz) 182.7, 182.4, 146.6, 145.6, 134.5, 134.4, 132.1, 132.0, 
126.2, 126.0, 123.6, 123.5, 110.2, 109.8, 104.4, 58.4, 52.9, 45.4, 45.39, 42.8, 
40.7, 32.3, 29.5, 22.3; m/z (ES+) 440 (M+H, 100). 
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N-(2,2-Dimethoxyethyl)-3-(4-(2-(dimethylamino)ethylamino)-9,10-dioxo-
9,10-dihydroanthracen-1-ylamino)propanamide  
O
O
HN
HN
N
H
N
O
O
O
 
To a stirred solution of 1-(2-(dimethylamino)ethylamino)-4-fluoroanthracene-
9,10-dione (60 mg, 0.19 mmol) in pyridine (1 mL) was added 3-amino-N-(2,2-
dimethoxyethyl)propanamide (135 mg, 0.77 mmol) and the resulting solution 
was stirred at 70 °C for 6 h. The solvent was evaporated under reduced 
pressure and the reaction mixture was purified by flash chromatography using 
gradient eluent (CH3OH:CH2Cl2, 1:99→6:94) to yield the title compound as a 
dark blue powder (56 mg, 70%). δΗ (CDCl3, 400 MHz) 10.6 (2H, br s, NH), 8.2 
(2H, d, J 6.0 Hz), 7.5 (2H, d, J 5.5 Hz), 5.95 (1H, br s, NH), 4.37 (1H, t, J 5.3 
Hz), 3.71, (2H, t, J 5.5 Hz), 3.5 (2H, t, J 5.5 Hz), 3.3 (2H, t, J 6.5 Hz), 3.25 (6H, 
s), 2.76 (2H, t, J 6.5 Hz), 2.54 (2H, t, J 5.5 Hz), 2.41 (6H, s);  δC (CDCl3, 100 
MHz) 181.7, 181.7, 169.7, 144.7, 144.5, 133.3, 131.1, 125.1, 124.9, 122.5, 
122.3, 109.2, 109.2, 101.5, 57.0, 53.4, 44.1, 40.0, 39.2, 38.1, 35.8; m/z (ES+) 
469 (M+H, 100). 
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N-(2-(4-(2-(dimethylamino)ethylamino)-9,10-dioxo-9,10-dihydroanthracen-
1-ylamino)ethyl)-3,3-dimethoxypropanamide 
O
O
HN
HN
N
N
H
O
OO
 
To a stirred solution of 1-(2-(dimethylamino)ethylamino)-4-fluoroanthracene-
9,10-dione (50 mg, 0.16 mmol) in pyridine (1 mL) was added N-(2-aminoethyl)-
3,3-dimethoxypropanamide (112 mg, 0.64 mmol) and the resulting solution was 
heated under reflux for 4 h. The solvent was evaporated under reduced 
pressure and the reaction mixture was purified by flash chromatography using 
gradient eluent (CH3OH:CH2Cl2, 1:99→6:94) to yield the title compound as a 
dark blue powder (45 mg, 60%). δΗ (CDCl3, 400 MHz);  10.7 (1H, br s, NH), 
10.6 (1H, br s, NH), 8.2 (2H, dq, J 4.5, 9.0 Hz), 7.64 (2H, dd, J 2.0, 4.0 Hz), 7.2 
(2H, dd, J 9.6, 25.2 Hz), 6.71 (1H, NH br s), 4.6 (1H, t, J 5.5 Hz), 3.5 (2H, t, J 
5.5 Hz), 3.2 (6H, s), 2.73 (2H, t, J 6.5 Hz), 2.59 (2H, t, J 6.5 Hz), 2.43 (2H, t, J 
5.5 Hz), 2.37 (6H, s); δC (CDCl3, 100 MHz) 182.7, 182.4, 169.8, 169.2, 169.1, 
146.0,  145.9, 134.4, 134.3, 132.2, 126.0, 125.9, 123.4, 110.0, 102.3, 102.2, 
101.9, 58.3, 54.1, 51.4, 45.4, 41.9, 40.7, 39.4, 37.0; m/z (ES+) 469 (M+H, 100). 
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1-(5,5-Dimethoxypentylamino)-4-(2-(dimethylamino)ethylamino)-5,8-
dihydroxyanthracene-9,10-dione 
O
O
HN
HN
N
O
O
OH
OH
 
To a stirred solution of 1-(2-(dimethylamino)ethylamino)-4-fluoro-5,8-
dihydroxyanthracene-9,10-dione (60 mg, 0.17 mmol) in pyridine (1 mL) was 
added 5,5-dimethoxypentan-1-amine (102.61 mg, 0.7 mmol) and the resulting 
solution was stirred at 70 °C for 6 h. The solvent was evaporated under reduced 
pressure and the reaction mixture was purified by flash chromatography using 
gradient eluent (CH3OH:CH2Cl2, 1:99→6:94) to yield the title compound as a 
dark blue powder (40 mg, 49%). δΗ (CDCl3, 400 MHz) 13.3 (2H, brs, OH), 10.3 
(2H, br s, NH), 7.16-6.96 (4H, m), 4.32 (1H, t, J 5.5 Hz), 3.45 (2H, t, J 6.5 Hz), 
3.21 (6H, s), 2.74 (2H, t, J 6.5 Hz), 2.45 (6H, s), 1.74-1.42 (6H, m);  δC (CDCl3, 
100 MHz) 185.6, 185.2, 155.5, 155.46, 146.6, 145.9, 125.0, 124.8, 123.9, 
123.7, 115.3, 115.2, 109.4, 108.8, 104.4, 57.7, 52.9, 45.0, 42.9, 40.2, 32.2, 
29.4, 22.2; m/z (ES+) 472 (M+H, 100). 
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N-(2,2-Dimethoxyethyl)-3-(4-(2-(dimethylamino)ethylamino)-5,8-dihydroxy-
9,10-dioxo-9,10-dihydroanthracen-1-ylamino)propanamide 
O
O
HN
HN
N
H
N
O
O
OH
OH
O
 
To a stirred solution of 1-(2-(dimethylamino)ethylamino)-4-fluoro-5,8-
dihydroxyanthracene-9,10-dione (60 mg, 0.17 mmol) in pyridine (1 mL) was 
added 3-amino-N-(2,2-dimethoxyethyl)propanamide (123 mg, 0.7 mmol) and 
the resulting solution was stirred at 70 °C for 6 h. The solvent was evaporated 
under reduced pressure and the reaction mixture was purified by flash 
chromatography using gradient eluent (CH3OH:CH2Cl2, 1:99→6:94) to yield the 
title compound as a dark blue powder (79 mg, 90%). δΗ (CDCl3, 400 MHz) 13.3 
(2H, brs, OH), 10.1 (2H, br s, NH), 6.93 (2H, d, J 6.0 Hz), 6.82 (2H, t, J 6.0 Hz), 
6.23 (1H, br s, NH), 4.37 (1H, t, J 5.7 Hz), 3.45 (2H, t, J 6.5 Hz), 3.41 (2H, t, J 
5.2 Hz), 3.31 (6H, s), 2.64 (2H, t, J 6.5 Hz), 2.52 (2H, t, J 5.2 Hz), 2.33 (6H, s);  
δC (CDCl3, 100 MHz) 184.9, 184.8, 170.6, 155.3, 155.2, 146.1, 145.9, 124.7, 
124.5, 123.6, 123.3, 115.2, 115.1, 108.9, 108.7, 102.5, 58.1, 54.3, 45.5, 41.1, 
40.8, 39.2, 36.5; m/z (ES+) 501 (M+H, 100). 
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N-(2-(4-(2-(Dimethylamino)ethylamino)-5,8-dihydroxy-9,10-dioxo-9,10-
dihydroanthracen-1-ylamino)ethyl)-3,3-dimethoxypropanamide 
O
O
HN
HN
N
N
H
O
OO
OH
OH
 
To a stirred solution of 1-(2-(dimethylamino)ethylamino)-4-fluoro-5,8-
dihydroxyanthracene-9,10-dione (54 mg, 0.16 mmol) in pyridine (1 mL) was 
added N-(2-aminoethyl)-3,3-dimethoxypropanamide (111 mg, 0.63 mmol) and 
the resulting solution was stirred at 70 °C for 6 h. The solvent was evaporated 
under reduced pressure and the reaction mixture was purified by flash 
chromatography using gradient eluent (CH3OH:CH2Cl2, 1:99→5:95) to yield the 
title compound as a dark blue powder (45 mg, 60%). δΗ (CDCl3, 400 MHz) 13.3 
(2H, br s, OH), 10.2 (2H, br s, NH), 6.92 (2H, t, J 5.9 Hz), 6.82 (2H, t, J 5.9 Hz), 
6.2 (1H, br s, NH), 4.62 (1H, t, J 5.5 Hz), 3.47 (2H, q, J 6.4 Hz), 3.41 (2H, t, J 
5.5 Hz), 3.33 (6H, s), 2.63-2.54 (4H, m), 2.52 (2H, t, J 5.5 Hz), 2.27 (6H, s);  δC 
(CDCl3, 100 MHz) 184.8, 184.5, 169.8, 169.2, 155.2, 155.1, 146.2, 124.5, 
124.2, 123.6, 123.4, 115.2, 115.1, 108.8, 108.5, 102.2, 58.1, 51.4, 45.5, 40.8, 
40.8, 37.0, 36.8; m/z (ES+) 501 (M+H, 100). 
 
  
 
 
Chapter III 
 
Chemical hydrolysis and enzymatic 
metabolism of novel 1,4-di-substituted 
acetalanthraquinones 
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III.1 Introduction and Aims 
Acetal groups are often employed in organic chemistry to protect alcohols 
(Greene T. W., 1999), but their stability and susceptibility to undergo enzymatic 
metabolism is not well researched. Acetal groups can also be used to protect 
aldehyde functionalities, which can be unmasked when exposed to acidic 
conditions (Greene T. W., 1999). In this context, it is important to understand 
whether the 1,4-di-substituted acetalanthraquinones (AAQs) synthesised in 
Chapter II are prone to undergo acidic hydrolysis and generate corresponding 
aldehyde substrates suitable for ALDH mediated oxidation (see Figure III.1).  
O
O HN
OH
OH
H
N
O
O
O
    Acid
O
O HN
OH
OH
H
N
OH
O
O
O
O HN
OH
OH
H
N
O
O
NH
NH R
-HCHO -CH3 OH
N
N
N
Parental Acetal Active Aldehyde
Hemiacetal
ALDH  ?
 
_______________________________________________________________ 
Figure 3.1 Proposed mechanism for acetal conversion. ALDH mediated transformation of the 
acetal into the active aldehyde via the hemiacetal intermediate. 
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Furthermore, the acetal moiety located at the terminal position of the aliphatic 
sidechains may be a target for oxidative metabolism by ALDH per se; hence it is 
important to also investigate their metabolic stability. 
As outlined in Figure 3.1 the mechanism is proposed to occur via the formation 
of a hemiacetal species as an instable intermediate, which rapidly converts into 
the aldehyde. The development of the AAQs examined in this thesis is based 
on the principle that after exposure to acidic hydrolysis they may be 
metabolically transformed into carboxylic acid via ALDH reaction. As stated 
above, the acetal group can be chemically hydrolysed under acidic conditions, 
but its susceptibility to undergo this transformation may be subject to functional 
groups in neighbouring α-δ positions. Accordingly, this chapter is focussed on 
the investigations concerning the potential selectivity of ALDH towards 
aldehydes lined to anthraquinones using cell extracts and recombinant proteins 
as sources of enzyme. Therefore, the specific aims of this chapter are: 
1. To assess the acidic stability of the novel AAQs to HCl, in order to 
identify compounds that can chemically generate an aldehyde moiety;  
2. To investigate LC-111 properties as prototype AAQ to understand the 
metabolic profile generated by acidic hydrolysis and compare the acid 
hydrolysis of LC- and HA-libraries and to assess the requirements for the 
hydrolysis step to achieve ALDH selectivity; 
3. To determine the metabolic fate of selected LC-AAQs before and after 
chemical hydrolysis in several ALDH sources and to isolate the potential 
metabolic products for LC-MS identification. 
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III.2 Materials and Methods 
III.2.1 Chemical hydrolysis of AAQs 
III.2.1.1 Chemicals and reagents 
All the tested compounds were stored in dry powder form at -20°C until required 
for investigation. DMSO, methanol, trifluoroacetic acid (TFA) and HCl were all 
supplied by Sigma. Analytical HPLC-grade acetonitrile and deionised water 
were supplied by Fisher Scientific. Ammonium formate and formic acid were 
purchased from VWR international Ltd. Plastic consumables and 96-flat 
bottomed well plates were purchased from Corning. 
III.2.1.2 Chemical hydrolysis of AAQs 
The acidic hydrolysis was performed using the same conditions for all the AAQs 
(see section II.4 for name and structures). The investigational compound was 
dissolved in DMSO to 10 mM final concentration. Working solutions were 
prepared by diluting the compound to 100 µM in deionised water to a final 
volume of 100 µL and the mixture was vortexed for 2 min. Finally, 100 µL of 2 M 
HCl was added and the mixture was heated in a heating block at 37 °C for 30 
min. Specifically for LC-111, fractions were collected at 15 min and thereafter 
every 30 min up to 2.5 hours total incubation time. Immediately after collection, 
the fractions were freeze dried at -56 °C until dry powder was obtained (typically 
18h) using Alpha 1-2 LQ lyophiliser (Martin Christ). Compounds were used for 
LC/MS analysis.  
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III.2.1.3 Acidic stability assessment via LC/MS  
Conditions for AAQ analysis using methanol as the organic solvent of the 
mobile phase: 
The samples were analysed by HPLC (High Pressure Liquid Chromatography) 
in gradient elution mode. Mobile phase A (MPA) consisted of 10% methanol 
and 90% deionised water containing 0.05% TFA. Mobile phase B (MPB) 
consisted of 90% methanol and 10% deionised water containing 0.05% TFA.  
Analysis was performed on a Waters C8 10 cm Acquity column 1.7 µm (10 cm x 
2.1 mm) (Waters Ltd.) with a flow rate of 0.3 mL/min. Pumps were run with a 
gradient of 20% MPB and 80% MPA to 70% MPB and 30% MPA. The total run 
time was 40 min. The flow rate was maintained and 2 µL of sample was injected 
using a Waters Acquity Separation Module (Waters Ltd.). Partial loop injections 
were made and the loop size was 10 µL. Detection was performed using a 
Waters Quattro Premier MS/MS (Waters Ltd.) in parallel with diode array UV-
Vis absorbance detection. 
Conditions for AAQ analysis using acetonitrile as organic solvent of the mobile 
phase: 
The samples were analysed by HPLC in gradient elution mode. MPA consisted 
of 10% acetonitrile and 90% deionised water containing 0.05% TFA. MPB 
consisted of 90% acetonitrile and 10% deionised water containing 0.05% TFA.  
Analysis was performed on a Waters C8 10 cm Acquity column 1.7 µm (10 cm x 
2.1 mm) (Waters Ltd.) with a flow rate of 0.3 mL/min. Pumps were run with a 
gradient of 20% MPB and 80% MPA to 70% MPB and 30% MPA. The total run 
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time was 40 min. The flow rate was maintained and 2 µL of sample was injected 
using a Waters Acquity Separation Module (Waters Ltd.). Partial loop injections 
were made and the loop size was 10 µL. Detection was performed using a 
Waters Quattro Premier MS/MS (Waters Ltd.) in parallel with diode array UV-
Vis absorbance detection. 
Mass spectrometry conditions:  
A MRM (multiple reaction monitoring) channel was extracted in electrospray 
positive (ESI+) mode at 600.0>58.1 m/z. Capillary voltage was set to 3.05 kV, 
cone 29 V, extraction 3 V, source temperature 150 °C, desolvation temperature 
250 °C, collision energy 62 V and collision gas flow 0.35 mL/min. 
 
III.2.2 Metabolism of AAQs 
III.2.2.1 Chemicals and reagents 
All the reagents and cofactors were supplied by Sigma unless otherwise stated. 
Human recombinant ALDH1A1 was purchased from R&D Systems. Plastic 
consumables were purchased from Corning. 
III.2.2.2 Isolation of cytosolic fraction from rat liver homogenate 
Two adult male Sprague Dawley rats were sacrificed and livers were isolated, 
rinsed twice with PBS to clean the blood residues and cut into small slices. PBS 
was added in 2x 50 mL falcon tubes and the tissue slices were transferred 
using sterile forceps. The mixture was homogenised with a T25 Ultra-Turrax 
basic homogeniser (IKA) and transferred to ultracentrifuge tubes. The liver 
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homogenate was centrifuged to produce S9 fraction at 9,000 g for 30 min at 4 
°C in a Beckman Ultracentrifuge. The supernatant was transferred in fresh 
ultracentrifuge tubes and centrifuged at 105,000 g for 70 min at 4 °C. The white 
lipid layer on top of the supernatant was removed and the supernatant 
containing the cytosolic fraction was aliquoted in cryovials (Thermo). 10% of 
glycerol was added to each vial and the samples kept at -80 °C till required. 
Prior to experimental use, protein quantification was assessed using the 
Bradford assay (Spector, 1978). 
III.2.2.3 Metabolism of AAQs in cytosolic fraction of rat liver homogenate 
The incubations comprised of 0.1 mM pyrazole, 5 mM glutathione and 4 mM 
NAD+ as co-factors in 1 mL PBS-EDTA pH 7.4. All the co-factor concentrations 
were optimised to achieve velocity rate comparable to reported literature 
(Schomburg D, 2004). Cytosolic fraction was added at a final concentration of 1 
mg/mL. Control substrates for investigations in these experiments were 
propionaldehyde and acetaldehyde at concentration range between 100 and 5  
µM. Diethylaminobenzaldehyde (DEAB), an ALDH inhibitor (Ma et al., 2010), 
was used as the negative control. Bromoacetal, LC-111, and its hydrolysed 
product mixture (after 30 min hydrolysis, see section III.2.1.2) were tested at 
concentration range between 1 and 100 µM. 
Two identical quartz cuvettes (Thermo Fisher Scientific) were set up for each 
experiment: one cuvette containing the complete incubate as described above 
with the selected substrate and the other excluding NAD+ as control blank. Both 
incubation mixture were prepared initially without NAD+ and pre-incubated at 37 
°C for 2 min. The metabolism was then started by addition of NAD+ to the 
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appropriate cuvette. Determination of NAD+ to NADH conversion was assessed 
spectrophotometrically in a temperature controlled Cary 400-Bio UV-Vis system 
(Varian), using the “scan” function to read the absorbance spectrum between 
200 and 800 nm for 60 min.  The enzymatic activity was assessed at 37 °C by 
reduction of the NAD+ peak at 260 nm and formation of NADH peak at 340 nm. 
Furthermore, reaction velocity (∆A/min) was calculated in the “enzyme kinetics” 
mode by setting the absorbance wavelength at 340 and monitoring the reaction 
for 30 min. 
III.2.2.4 Metabolism of AAQs in yeast ALDH 
Lyophilised ALDH enzyme from baker's yeast (S. Cerevisiae) (Sigma) was 
dissolved in 50 mM Tris-HCl pH 8.0 with 0.02% BSA. As described in the 
literature (Wang et al., 2009), the reaction mixture contained 4U/mL of enzyme, 
3 mM NAD+, 1 mM EDTA, 200 mM KCl, 1.7% (v/v) acetonitrile (as a solvent 
carrier for aldehydes), 100 mM mercaptoethanol and varied concentrations of 
substrates (10-0.01 mM) (Bostian and Betts, 1978; Wang et al., 2009). 
Propionaldehyde was used as a positive substrate control. Substrate 
concentrations and pH were optimised (as showed in section III.3.4.2) to a total 
reaction volume of 100 µL. The reaction mixtures were prepared in a flat-
bottomed 96 well plate and incubated at 37 °C for 2 min, before adding NAD+ 
and starting to measure the kinetic rate of NADH formation. The plate was read 
in kinetic mode at 340 nm in a Multiskan Spectrum plate reader (Thermo) and 
temperature was maintained at 37 °C.  
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III.2.2.5 Metabolism of AAQs in human recombinant ALDH1A1 
Recombinant human ALDH1A1 (rh ALDH1A1) (Abnova) was dissolved in 20 
µg/mL of deionised water. The reaction mixture was prepared as follows 
according to the manufacturer protocol: 100 µL 1 M Tris pH 8.5, 50 µL 2 M KCl, 
50 µL 20 mM NAD+, 50 µL 40 mM DTT, 200 µL deionised water and the 
selected substrate at the appropriate concentration [propionaldehyde (10 mM), 
LC-111 AAQ and LC-111 (HAAQ) (0.1  µM)]. The HAAQ was generated after 30 
min hydrolysis (see section III.2.1.2). 50 µL of the reaction mixture was 
combined with the same volume of enzyme mixture (20 µg/mL final enzyme 
concentration) directly in the 96 flat-bottomed well plate. A blank containing 50 
µL deionised water (instead of the enzyme mixture) and 50 µL of reaction 
mixture was also added to the plate. The reaction was monitored for 20 min at 
340 nm and RT using the kinetic mode in a Multiskan Spectrum plate reader 
(Thermo). 
III.2.2.6 Evaluation of specific activity for enzyme metabolism 
The concentration of NADH produced by the reaction was calculated using the 
Beer-Lambert law (or Beer's law), which considers the linear relationship 
between absorbance and concentration of an absorbing species. The general 
Beer-Lambert law is usually written as: A = εcl, where A is the measured 
absorbance, ε is a wavelength-dependent absorptivity coefficient (ε340 nm= 6,220 
M−1cm−1 for NADH), l is the cell-path length (1 cm in this experimental 
condition), and c is the analyte concentration.  
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Specific activity was used to measure the rate of the enzymatic reaction. This 
term was defined as the amount of substrate the enzyme converts (reaction 
catalyzed), per mg protein in the enzyme preparation, per unit of time. The 
specific activity was expressed as units of activity/amount of enzyme and it was 
calculated with the following formula: 
∆Abs/min
ε x P
Specific Activity =
(nmol/min/mg )
x 106
 
Where ∆Abs/min is the amount of activity, ε340 nm is the extinction coefficient of 
NADH (6,220 M−1cm−1) and P is the amount of enzyme in the reaction (mg). 
 
III.2.2.7 AAQ metabolite identification by LC/MS 
Metabolism was carried out for LC-111 and its hydrolysed product (HAAQ) after 
30 min hydrolysis as described in section III.2.4.5. The final concentration of the 
incubation was: 100 mM Tris pH 8.5, 200 mM KCl, 4 mM NAD+ 2 mM DTT, 20 
µg/mL rhALDH1A1 and 1 µM LC-111 or the corresponding HAAQ with a total 
assay volume of 100 µL in deionised water.  
After the metabolism was monitored spectrophotometrically, protein was 
precipitated out from the reaction mixture. Mixture was centrifuged at 13,000 
rpm for 15 min to sediment the enzyme before the supernatant was injected into 
the LC/MS system. The mobile phase composition containing acetonitrile and 
mass spectrometry settings was as described in section III.2.1.3.  
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III.3 Results 
III.3.1 Chemical hydrolysis of AAQs 
According to the HPLC analysis (see Figure 3.2), parental AAQs were 
completely hydrolysed after 60 min of exposure to 2 M HCl. Using HPLC 
conditions including methanol in the mobile phase composition (see section 
III.2.1.3), a sharp peak was identified for all the analysed AAQs and retention 
time values varied according to the chemical features (refers to Figure 3.2A).  
In this chapter, LC-111 is used as an exemplar of typical hydrolysis formation 
(for HPLC spectrum of LC-110, see Supplementary Information III.A.1; for LC-
107 HPLC spectrum see III.B). 
Analysis of LC-111 revealed one major peak, which was detected at 260 nm 
with a retention time of 13.13 min (see Figure 3.3). After 30 min of acidic 
hydrolysis, total conversion of parental AAQ was detected with appearance of a 
new broad peak visible at 260 nm with a retention time of 9.40 min. The same 
peak was also observed after 60, 180 and 210 min of exposure to this acidic 
environment. However, after 60 min of acidic treatment, two secondary peaks 
were detected at 260 nm at retention times 12.53 and 13.57 min respectively. 
The intensity of these secondary peaks showed an enhancement after 60 min 
of acidic treatment, suggesting that exposure to these acidic conditions 
generate other unwanted by-products with time. The amount of hydrolysed 
derivative formed after 60 min was 100% of the parental AAQ compound, as 
measured by disappearance of LC-111 at 260 nm.  
Chapter III                                                                                                   - 92 - 
_______________________________________________________________________ 
 
 
 
_______________________________________________________________ 
Figure 3.2 HPLC spectra of hydrolysis profile of LC-111. Spectra of hydrolysed compounds 
were collected after incubation at 37°C with 2 M HCl. Analysis of the (C) LC-111 and the 
corresponding HAAQ products were performed at 260 nm after (B) 30 min and (A) 60 min 
hydrolysis.  
 
A more detailed analysis of LC-111 was performed to evaluate the hydrolysis 
products at intermediate time-points. Acidic treatment was monitored via HPLC 
at 15 and 30 min. The determination was performed using the conditions 
reported in section III.2.1.3.  As shown in Figure 3.3A, LC-111 showed a major 
peak at 15.8 min (red peak). After 15 min of exposure to these acid conditions, 
the intensity of the peak at 15.8 min was considerably decreased (see Figure 
3.3B) and a new intense peak appeared with a retention time of 6.27 min.  
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Figure 3.3 HPLC analysis of LC-111 short term hydrolysis. Spectra were collected at 260 
nm after treatment with 2 M HCl for (B) 15 min and (C) 30 min. (A) LC-111 (t = 0). The column 
used on this experiment was different from the one used in Figure 3.2, therefore the retention 
times were not maintained. 
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The same peak was confirmed after 30 min (see Figure 3.3C), but some minor 
peaks, respectively at 4.50 and 3.56 min, seemed to appear with protracted 
acidic exposure. The results suggest, as stated above for longer exposure 
times, that LC-111 require 30 min incubation with acid to achieve the maximum 
rate of hydrolysis conversion. 
However, β-positioned secondary and tertiary amines (HA-AAQs, see Table II.3 
for structures) revealed an increased resistance to the acidic hydrolysis of the 
acetal moiety (refers to Supplementary Information III.B.1-2 for HPLC spectra of 
HA-222 and HA-252). Here HA-218 is reported as an exemplar of the HA-AAQ 
series. Elution of HA-218 produced a very sharp peak with a retention time of 
15.79 min (Figure 3.4A).  
 
acetal
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Hydrolysis products
 
_______________________________________________________________ 
Figure 3.4 HPLC analysis of HA-218 before and after hydrolysis. (A) HA-218 spectrum prior 
to hydrolysis. (B) Spectrum of hydrolysed HA-218 product, collected at 260 nm after treatment 
with 2 M HCl for 60 min.  
 
Indeed, after 210 min at 37 °C these compounds did not generate any 
hydrolysis products (data not showed). The treatment was repeated heating the 
mixture at 75 °C for 210 min and the LC-MS analysis showed only partial 
conversion of the acetal moiety. As shown in Figure 3.4B, HA-218 was 
converted into two peaks observed at 5.61 and 28.28 min respectively, 
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revealing that only 20-30% of the parental compound peak was converted into 
unidentified hydrolysis products.  
 
III.3.2 Identification of chemical hydrolysis products via mass 
spectrometry 
Tandem mass spectrometry (MS) analysis was used to identify the 
fragmentation pattern for the AAQs and hydrolysed species. In this section only 
LC-111 MS spectra are shown as exemplar of the hydrolysis formation (see 
Figure 3.5A-B), but, MS analysis of LC-110 can be found in Supplementary 
Information III.A.2.    
As described in the section III.3.1, HPLC separation of LC-111 revealed a sharp 
peak at 260 nm with a retention time of 13.13 min (see Figure 3.2). This peak 
corresponded to a mass of 501 m/z, as shown in the MS in Figure 3.5A. After 
30 min of acidic hydrolysis, total conversion of LC-111 was detected with the 
appearance of a new broad peak visible at 260 nm and with a retention time of 
9.40 min. As shown in Figure 3.5B, two intense peaks were related to the broad 
peak at 9.40 min and MS analysis revealed masses of 487 and 455 m/z, which 
were correlated with hemiacetal and aldehyde formation respectively. Further 
analysis was performed on LC-111 in order to obtain a MS spectrum with a 
unique aldehyde fragmentation peak; however, no separation was achieved. 
The results suggest that either (i) co-existence of the two species is real or (ii) is 
an artefact which cannot be resolved using LC-MS due to instability of the 
aldehyde product under the mobile phase conditions employed. 
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Figure 3.5 MS spectra of LC-111 before and after exposure to acidic environment. (A) LC-
111 and (B) HAAQ product after treatment with 2 M HCl for 30 min.  
 
III.3.3 Sensitivity of hydrolysis products to mobile phase composition 
In order to explore whether the hydrolysis products were stable in the 
methanol/water system used for HPLC chromatography, a further elution 
system was tested in LC-111 to perform the separation. Methanol/water was 
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replaced by acetonitrile/water on the basis of the possible implication of 
methanol in reversing the aldehyde formation, generating the hemiacetal 
intermediate of acid hydrolysis (see Figure 3.1 for proposed mechanism). As 
enclosed in the spectra in Supplementary Informations III.C1-2 at the end of the 
present chapter, no difference was observed on the LC/MS analysis of LC-111. 
The retention time of LC-111 and the corresponding HAAQ were maintained 
almost identical in both systems. Moreover, the MS analysis of the eluted peaks 
in the methanol/water and acetonitrile/water systems revealed the same mass 
for AAQ (500.87 and 500.79) and the corresponding HAAQ derivatives (454.88 
and 454.91) respectively, suggesting that these systems can be interchanged 
without alteration of the separation outcome. This suggests that the co-
existence of hemiacetal and aldehyde is present after acidic hydrolysis and 
exclude any potential artefacts as explained in section III.1. 
 
III.3.4 Metabolism studies 
III.3.4.1 Metabolism studies using cytosolic fraction from rat liver 
homogenate 
The cytosolic fraction from rat liver homogenate was used in this study to 
evaluate the possible metabolism of AAQs and their corresponding HAAQ 
products in a multi-enzymatic complex containing several ALDH isoforms 
(Tottmar et al., 1973). In this study, the cytosolic fraction was isolated from rat 
liver and an assay was designed and optimised to evaluate whether NAD+-
dependent conversion of the novel analogues could be detected by a 
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spectrophotometric analysis. Microsomal fraction was removed via differential 
centrifugation (see section III.2.2.2) to avoid any interference from metabolism 
by cytochrome P450s.  
The assay was optimised by adding pyrazole to inhibit alcohol dehydrogenase 
activity (Moon et al., 2005) and glutathione to optimise the protein folding of the 
ALDHs (Chakravarthi et al., 2006).  
                    A                                               B 
 
_______________________________________________________________ 
Figure 3.6 Metabolism of propionaldehyde (10 µM) in rat liver cytosol. NADH production 
was measured at 340 nm as described in section III.2.2.3. 
  
Several substrates were tested at different concentrations. Propionaldehyde (1-
100 µM) was used as positive control (Shum and Blair, 1972) and bromoacetal 
was tested to investigate whether the cytosolic fraction was able to metabolise 
the acetal moiety per se. Propionaldehyde was a good substrate and the 
reaction velocity using 10 µM propionaldehyde is presented in Figure 3.6A. An 
enzyme blank, containing the entire reaction component except for the enzyme, 
was coupled to each reaction measurement showing no detectable activity (see 
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Figure 3.6B), suggesting that none of the components of the mixture were 
interfering with the determination. 
Analysis of the full spectrum (200-800 nm) also showed the detection of a 
characteristic peak at 460 nm (see Figure 3.7) due to the presence of bilirubin, 
which is a breakdown product of haemoglobin in red cells of rat liver.  
 
_______________________________________________________________ 
Figure 3.7 UV/Vis spectrum of NAD+ supplemented rat liver cytosol in presence of 
propionaldehyde.  
 
Diethylaminobenzaldehyde (DEAB), a known inhibitor of ALDH activity (Chute 
et al., 2006), was added to the reaction mixture to establish whether the 
conversion was ALDH-dependent or whether other cytosolic enzymes such as 
glutamate dehydrogenase, monoamine oxidase or xanthine oxidase (Tottmar et 
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al., 1973) were responsible for the NAD+ to NADH formation. Interestingly, 
addition of DEAB with or without propionaldehyde led to a rapid increase of 
enzyme activity within the first 2-3 min of incubation and a subsequent steady 
state was reached (see Supplementary Information III.D for kinetic plots). 
Furthermore, bromoacetal was tested to verify the presence of cytosolic 
enzymes capable of converting the acetal via NAD+ consumption. As reported 
in Figure 3.8, activity was measured with 100 µM bromoacetal with drop in 
activity at lower concentrations, suggesting the presence of enzymes in the 
cytosolic fraction capable of reacting with the acetal moiety in a NAD+-
dependent mode. 
 
_______________________________________________________________ 
Figure 3.8 Kinetic analyses of several substrates (10-100 µM) in the cytosolic fraction of 
rat liver homogenate. Every determination was coupled with an enzyme blank reading. The 
enzymatic rate (nmol/mg/min) was calculated using Beer-Lambert law (see section III.2.2.6). 
The data are expressed as the mean of three independent experiments ±SD. 
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The same experiment was repeated to investigate the potential metabolism of 
LC-111 and its corresponding HAAQ. Intriguingly, greater activity was reported 
with the parental AAQ compared to its HAAQ product (see Figures 3.8-3.9).   
As reported in Figure 3.8, specific activity values of bromoacetal and LC-111 
varied independently from the substrate concentration. The finding that both LC-
111 and its corresponding HAAQ product revealed enzymatic activity suggested 
the possibility of side-reactions occurring that may not be related to ALDH 
metabolism. As a consequence of this complex metabolism, the use of cytosol 
fractions from rat liver homogenate was deemed not suitable as a source to 
study the metabolism of novel AAQs and HAAQs. Therefore, other sources of 
ALDHs were explored.  
 
       A                                                               B 
 
_______________________________________________________________ 
Figure 3.9 Kinetic analysis of LC-111 and its corresponding HAAQ using cytosolic 
fraction of rat liver homogenate. Reaction was measured at 340 nm with substrate 
concentration of 10 µM. Every determination was coupled with an enzyme blank reading. 
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III.3.4.2 Yeast ALDH metabolism 
Yeast ALDH was used as its active region is 95-100% homologous to that of the 
mammalian ALDHs. Veverka et al. (1997) also used yeast ALDH for studies 
related to the mechanism of ALDH inhibition by disulfiram (Maninang et al., 
2009). As previously described (Wang et al., 2009), yeast ALDH has been 
shown to oxidise preferentially small aliphatic aldehydes such as acetaldehyde 
and propionaldehyde. In this study, propionaldehyde was mainly used as 
control because of the limitations of handling acetaldehyde (volatile liquid). In 
addition, propionaldehyde has also been shown as the preferred substrate 
(Wang et al., 2009). 
 
_______________________________________________________________ 
Figure 3.10 Optimisation of yeast ALDH kinetic analysis. Reaction was assessed using 
acetaldehyde and propionaldehyde at several concentrations in the presence of 
mercaptoethanol. Reaction was typically run at pH 8.0 although pH 8.5 was also evaluated. 
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As reported in Figure 3.10, the ALDH enzymatic reaction was initially tested at 
several pH conditions, but pH 8.0 was found to be the optimal option for both 
propionaldehyde and acetaldehyde. Furthermore, the role of mercaptoethanol, 
to stabilise the enzyme conformation on its reduced state, was revealed to be 
fundamental for obtaining a greater velocity rate. The reaction rate using 
mercaptoethanol and propionaldehyde as substrate appeared to reach the best 
rate at 10 mM of substrate concentration (Figure 3.10, green line). The reaction 
velocity decreased in the absence of mercaptoethanol (Figure 3.10, purple line).  
As Maninang’s group reported (Maninang et al., 2009), the presence of  0.02% 
of BSA improved the ALDH reaction rate, but only up to 5 mM substrate 
concentration (see Figure 3.11, blue line).  
 
_______________________________________________________________ 
Figure 3.11 Optimisation of yeast ALDH kinetic analysis using propionaldehyde. Several 
concentrations were tested (0-25 mM). BSA activity and reaction volume were added in order to 
evaluate the impact on the reaction rate.  
Chapter III                                                                                                   - 105 - 
_______________________________________________________________________ 
 
 
In this study, a concentration above 5 mM led to substrate inhibition, suggesting 
that addition of BSA reduced the optimal substrate concentration. Furthermore, 
the velocity of the reaction was reduced by scaling down the reaction volume to 
50 µL (see Figure 3.11, red line). Although the shape of the kinetic was 
consistent, use of half of the original volume (100 µL) resulted in reduction of 
almost a third of the original rate at 5 mM substrate concentration (0.55 vs. 0.18 
Abs/min). As reported in Table 3.1, lactones, isocyanate and acetal- derivative 
were not substrates for ALDH. Aromatic aldehydes, such as tolualdehyde or p-
anisaldehyde, showed similar specific activity but catalytic efficiency of aliphatic 
aldehydes was greater than aromatic substrates. Interestingly, propionate ester 
gave a specific activity of 4.42 ±0.66 suggesting some esterase activity of the 
yeast ALDH, which is in agreement with a previous published report (Blackwell 
et al., 1983; Marchitti et al., 2008). 
LC-111 and its corresponding HAAQ were tested using the optimised conditions 
reported in section III.2.4.4 at concentrations between 0.1-100 µM. Due to the 
deep blue colour of the AAQs, the final test volume could not contain substrate 
concentration higher than 100 µM. Several AAQs were tested in this ALDH 
yeast model, but no NADH formation was observed for either AAQ or its 
corresponding HAAQ.  
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Name Structure  rate 
(∆Abs/min) 
Specific Activity ±SD 
(nmol/min/mg protein) 
Propionaldehyde 
H
O
 
0.22 8.87±0.72 
3-Isochromanone O
O  
no reaction - 
δ- Valerolactone OO
 
no reaction - 
Tolualdehyde 
O  
0.10 4.02±0.34 
Ethyl-3-bromo-
propionate 
Br O
O
 
0.11 4.42±0.66 
Ethyl-isocyanate 
N
O
 
no reaction - 
Valeraldehyde O  
0.20 8.06±0.89 
p-Anisaldehyde 
O
O
 
0.14 5.63±0.28 
Bromoacetal 
Br
O
O
 
no reaction - 
 
_______________________________________________________________ 
Table 3.1 Kinetic analyses of several substrates using yeast ALDH as source of enzyme. 
Several concentrations were tested (1-100 µM). The kinetic rate was calculated as Abs/min and 
specific activity was generated at 10 µM using the Beer-Lambert law (see section III.2.2.6). 
Specific activity values were generated as average of three experiments ±SD.  
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III.3.4.3 Metabolism of AAQs using human recombinant ALDH1A1 and 
metabolites identification via LC-MS 
Human recombinant ALDH1A1 (hrALDH1A1) kinetic assay was tested using 
propionaldehyde as control sample, as recommended by the R&D System 
rhALDH1A1 manufacturer protocol. LC-111 and its corresponding HAAQ were 
analysed in duplicate as test substrates at a final concentration of 1 µM. 
Metabolism was monitored measuring the NADH formation at 340 nm for 5 
min., but the results as shown in Figure 3.12, revealed almost undetectable 
activity for LC-111 and its corresponding HAAQ product.  
_______________________________________________________________ 
Figure 3.12 Kinetic profiles of selected substrates using hrALDH1A1. Propionaldehyde, 
LC-111 parental and the corresponding hydrolysed derivative were tested at 1 µM 
concentration. All the curves were blank corrected. Sp Act: specific activity, calculated as 
reported in section III.2.2.6. 
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Indeed, data showed that under the tested experimental conditions, 
propionaldehyde was a substrate for human ALDH but LC-111 compounds 
were poor substrates. After kinetic analysis, the hrALDH1A1 protein was 
precipitated and both LC-111 and HAAQ metabolites were analysed via LC/MS.  
      A 
B  
 
 
Chapter III                                                                                                   - 109 - 
_______________________________________________________________________ 
 
 
 C 
 
_______________________________________________________________ 
Figure 3.13 HPLC analysis of the metabolic profile of LC-111 following incubation with 
hrALDH1A1. Analysis was performed at 612 nm. (A) LC-111; (B) hydrolysed LC-111 (HAAQ) 
before incubation with hrALDH1A1; (C) hydrolysed LC-111 (HAAQ) product after metabolism. 
The peaks indicated (A, B, C, D) were analysed by MS. 
 
Metabolism of LC-111 produced one major sharp peak at 612 nm (retention 
time of 13.69 min, see Figure 3.13A) whereas the HAAQ product (hydrolysed 
for 30 min) produced a single broad peak at 612 with a retention time of 11.76 
min (see Figure 3.13B). After incubation of the hydrolysed LC-111 with 
hrALDH1A1 several peaks were obtained and a very complex mixture of 
potential metabolites was identified through MS analysis (see Figure 3.13C). 
Although, several peaks were observed with retention times between 8.0 and 
17.0 min, in the present study MS analysis was performed only for most intense 
signals (see Figure 3.14A-D).  
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The expected fragmentation pattern of oxidation catalysis, as carboxylic acid, 
for hydrolysed LC-111 derivative was calculated to be 470.48 m/z. However, 
none of the produced fragments could be correlated that expected carboxylic 
acid mass. 
 
 
_______________________________________________________________ 
Figure 3.14 MS analysis of LC-111 hydrolysed derivative after hrALDH1A1 metabolism. 
Spectra A-D refers to the corresponding labelled peak from the HPLC analysis (see Figure 
3.13C). The red dotted line represents the expected m/z value for the main carboxylic acid 
metabolite. 
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III.4 Discussion 
In this study, the sensitivity of novel AAQs to acidic hydrolysis has been 
investigated. The investigated LC-AAQs were all prone to hydrolysis via 
hemiacetal formation (refers to Supplementary Information III.B for additional 
HPLC spectra). The presence of an amide bond in the sidechain structure had 
no effect on the acetal to aldehyde conversion (see Figure 3.15 for structures).  
O
O
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_______________________________________________________________ 
Figure 3.15 Overview of the structural modification on the AAQ sidechains.  Acetal hydrolysis 
sensitivity was highly dependent on the secondary amine substitution. 
 
Symmetrical and non-symmetrical compounds showed a similar hydrolysis 
profile. A more detailed stability test was performed on the non-symmetrical 
derivatives, because of the ease of monitoring conversion of a mono-acetal 
sidechain. Isolation and identification of the hydrolysis product revealed 
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production of an aldehyde moiety, as a unique product after 30 min hydrolysis. 
The HA-library of compounds showed more resistance to acidic hydrolysis than 
the LC-AAQs, suggesting a protective role of the neighbouring β-positioned 
tertiary amine with different substituents (such as hydrogen, methyl, and 
benzyl). However, prolonged acid exposure (up to 60 min) at higher 
temperatures (75 °C) allowed aldehyde conversion on the HA-derivatives as 
demonstrated by HPLC analysis. Therefore, our findings suggested that the 
acetal moiety was a very efficient masking group to deliver an active aldehyde 
as single product of the hydrolysis reaction; however, as demonstrated for HA-
AAQs, the sidechain skeleton plays a crucial role on the sensitivity to acidic 
hydrolysis, revealing that β-positioned tertiary amine induces resistance to 
hydrolysis even at high temperature. 
We then investigated the potential metabolism of the active aldehyde using 
several sources of ALDH. Firstly, a preliminary screening was assessed using 
cytosolic fraction from rat liver as a rich source of target enzyme. Indeed, 
numerous studies have indicated the presence of several isoforms of hepatic 
ALDHs in mammals (Deitrich et al., 1975; Shum and Blair, 1972; Tottmar et al., 
1973). For example, Shum et coll. demonstrated (Shum and Blair, 1972) that at 
least two NAD+-dependent ALDH isoenzymes were characterised and partially 
purified from rat liver cytosol. Furthermore, Lindahl et al. extensively 
investigated rat liver ALDHs (Lindahl, 1980; Lindahl and Evces, 1984, 1987), 
providing evidence for multiple molecular forms in microsomal and cytosolic 
fractions.  
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We analysed spectrophotometrically ALDH-dependent NADH production. 
Indeed, both NAD+ and NADH strongly absorbed near UV-light due to the 
aromaticity of the adenine moiety. Specifically, peak absorption of NAD+ was at 
a wavelength of 260 nm, with an extinction coefficient of 16,900 M−1cm−1. NADH 
also absorbed at higher wavelengths, with a second peak detected by UV 
absorption at 340 nm and with an extinction coefficient of 6,220 M−1cm−1 
(Dawson, 1985). The amount of NADH produced was considered as 
proportional to the oxidation rate of aldehyde into its respective carboxylic acid 
(see Figure 3.16) 
O
O HN
OH
OH
H
N
O
O
O
O HN
OH
OH
H
N
OH
O
NH R
N N
LC-111 hydrolysed
(aldehyde)
Principal metabolite
(carboxylic acid)
O
ALDH
NAD+ NADH
 
_______________________________________________________________ 
Figure 3.16 Proposed metabolism of hydrolysed LC-111 derivative. The aldehyde was 
converted into a correspondent carboxylic acid (molecular weight: 470.48) via NAD-dependent 
ALDH catalysis. 
 
Several compounds were tested using this enzymatic source but no conclusive 
results were obtained because metabolism was observed with aldehydes as 
well as with acetal substrates. The results suggest the potential co-existence of 
other enzymatic entities within the rat liver cytosol that are able to react with 
acetal groups in a NAD-dependent manner. Indeed, it was presumed that 
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metabolites were the product of sidechain oxidation, since the anthraquinone 
chromophore has been shown to be refractory to oxidation (Smyth et al., 1986; 
Wolf et al., 1986).  
From these initial studies, it was therefore of interest to explore a different 
enzymatic model to determine whether ALDH could be involved in the 
metabolism of the novel AAQs. Hence, further investigations were attempted 
using yeast K+-activated ALDH, which was selected as a model protein because 
its catalytic site is 95-100% homologous to that of mammalian ALDHs (Saigal et 
al., 1991; Devaraj et al., 1997). The validity of yeast ALDH has been 
demonstrated in studies related to the mechanism of ALDH-inhibition by 
disulfiram, where high similarity with mammalian proteins was revealed 
(Veverka et al., 1997). Yeast ALDH, designated mitochondrial ALDH2 according 
to Wang’ s group (Wang et al., 1998), demonstrated high catalytic efficiency 
with small aliphatic and aromatic aldehydes, such as propionaldehyde, 
valeraldehyde, tolualdehyde and p-anisaldehyde (see Table 3.1 for structures 
and kinetics). Interestingly, this study demonstrated esterase activity by yeast 
ALDH, as proven with the metabolism of ethyl-propionate ester. Ester 
metabolism by ALDHs is not an unknown phenomenon as some ALDHs have 
been shown to catalyse ester hydrolysis (Marchitti et al., 2008). Human ALDH2, 
in particularly, has been demonstrated to also possess the ability to hydrolyse 
p-nitrophenyl esters (Sidhu and Blair, 1975).  
After optimisation of the reaction conditions, a kinetic analysis was performed 
using LC-111. Unfortunately, no metabolism of LC-111 or its corresponding 
HAAQ product was observed in a range of concentrations (0.1-100 µM). In vitro 
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metabolism of aldehydes using this yeast model system was not successful, 
maybe be due to intense blue colour of the anthraquinone, which prevent high 
enough concentrations to be used for metabolism to occur. Certainly, the yeast 
model system has been used in previous studies with demonstration of both 
qualitative and quantitative differences in substrate specificity between yeast 
and human ALDH (Wang et al., 2009; Wang et al., 1998).  
Further studies were subsequently carried out with hrALDHs to explore whether 
human ALDH was able to produce a carboxylic acid. Despite the affinity of 
ALDH1A1 for several aliphatic aldehydes (Gross et al., 2009; Lovold et al., 
2006), our findings demonstrated no measurable NAD-dependent activity using 
LC-111 or its corresponding HAAQ product. However, isolation of the 
metabolites after hrALDH1A1 incubation and subsequent identification of 
potential metabolites via LC-MS did demonstrate the disappearance of the 
aldehyde peak of hydrolysed LC-111. This suggest either that (i) ALDH1A1 
metabolism did occur but the corresponding carboxylic acid was not detectable 
or (ii) secondary reactions unrelated to ALDH1A1 occurred and prevented the 
desired ALDH-metabolism in being produced. 
 
 
 
  
 
 
Chapter IV 
 
Evaluation of the DNA binding 
properties and cytotoxic effects of 1,4-
di-substituted acetalanthraquinones 
and their corresponding hydrolysed 
products 
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IV.1 Introduction and Aims 
IV.1.1 Anthraquinones as DNA intercalating agents 
In 1961, Lerman et al. (Lerman, 1961) proposed the theory of DNA intercalation 
based on observations from studying DNA-acridine complexes. DNA 
intercalators now comprise one of the most significant classes of agent that bind 
in a non-covalent manner with DNA. DNA intercalators include anticancer drugs 
such as doxorubicin, epirubicin and mitoxantrone, which possess a planar 
aromatic chromophore that is able to insert itself between adjacent base pairs 
within the DNA double helix. Stacking forces between the DNA bases and 
intercalators provide a stable interaction, which is further strengthened via 
hydrogen bonding between the basic alkylamino sidechains and the 
phosphodiester backbone (Islam SA, 1985) (further explained in section II.3).  
DNA intercalation is often insufficient to cause cytotoxicity in cells, however long 
residence time at the DNA often interfere with the DNA strand-breakage-
reunion reaction of topoisomerase II. This result in conversion of the enzyme 
into a poison (Pratt W. B., 1994) and leads to DNA double strand breaks, which 
are difficult to repair and therefore lethal to the cell.  
 
IV.1.2 Mitoxantrone, a 1,4-di-substituted anthraquinone with significant 
clinical activity 
Anthraquinone-based compounds in anticancer drug discovery are well 
described in the literature (Cheng et al., 1979; Cheng et al., 1983; Johnson et 
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al., 1979; Murdock KC et al., 1979; Zee-Cheng and Cheng, 1978). Mitoxantrone 
(see Figure 4.1), a 1,4-di-substituted anthraquinone anticancer drug 
(Shenkenberg and Von Hoff, 1986), was the lead molecule discovered in this 
class of synthetic compounds. Today, it is clinically used in the treatment of 
haematological malignancies, breast cancer and in advanced hepatic or ovarian 
carcinoma (Faulds et al., 1991). Further studies have consolidated its role in the 
treatment of prostate cancer in combination with prednisone (Tannock et al., 
2004).  
O
O
HN
HN
OH
OH
H
N
OH
N
H
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_______________________________________________________________ 
Figure 4.1 Chemical structure of mitoxantrone. This compound contains a 5,8-OH di-
substitution and amino-sidechains with a polar ethyl-alcohol feature. 
 
Mitoxantrone binds to DNA through a high-affinity intercalation process, but also 
a low-affinity binding sustained through electrostatic forces contributes to the 
overall DNA binding (Pratt W. B., 1994). Mitoxantrone is cytotoxic primarily to 
cells in late S phase with arrest of cells in G2 due to topoisomerase II inhibition 
(Faulds et al., 1991). The major resistance mechanisms are associated with 
drug efflux mediated by P-glycoprotein (ABCB1) and ABCG2 (Doyle and Ross, 
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2003b), but also changes in topoisomerase II and DNA-repair activity contribute 
to drug resistance (Pratt W. B., 1994).  
 
IV.1.3 DNA-binding affinity via DNA melting studies 
1,4-di-substituted alkylamino-anthraquinones are often potent DNA-binding 
agents due to protonation at physiological pH of their basic secondary or tertiary 
amine functionalities, which allow stabilisation of the chromophore-DNA 
interaction (Patterson et al., 1994). The acetalanthraquinones (AAQs) 
synthesised in this study have been designed to bind weak-to moderately with 
DNA in order to reduce the cytotoxicity compared with mitoxantrone and 
improve their potential as “non-toxic” molecular fluorescent probes. Their affinity 
for DNA can be evaluated in various biochemical assays, but in this study, a 
DNA thermal denaturation assay is used to assess DNA-AAQ binding. In 
principal, this assay informs about what occurs when DNA in solution is heated 
in the absence or presence of DNA-affinic agents, such as 1,4-di-substituted 
anthraquinones. The denaturation of DNA is measured at 260 nm using a UV-
spectrophotometer (Marmur and Doty, 1962). In a typical melting experiment, 
the increase in UV absorbance corresponds to the unwinding and denaturation 
of DNA (Figure 4.2), which occur due to the temperature increase. The melting 
temperature (Tm) of the DNA can be used as an indication of the strength of the 
interaction between DNA and the compounds to be investigated (Schallon et al., 
2011). 
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A=T
A=T
G≡C
 
_______________________________________________________________ 
Figure 4.2 DNA denaturation model. The scheme depicts the melting process of a DNA 
double helix. A-T-rich regions melt first, and then additional basepairs melt and unwind the 
helix. Finally G-C-regions melt to arrive at unwound single-stranded DNA region. Figure 
adapted from (Fox, 1997). 
 
IV.1.4 Cytotoxic effect of anthraquinones and resistance mechanism 
The success of aromatic anthraquinone-based anticancer agents has mainly 
been associated with their capacity to function as efficient DNA intercalators 
(see section II.1). The chemosensitivity of anthraquinone-based DNA 
intercalators are affected by common resistance mechanisms related to the 
expression of ABCB1 and ABCG2 transporters (Borst et al., 1999), also 
discussed above with mitoxantrone. As described in section I.3, overexpression 
of ABC transporters has been reported as a phenotypic marker of SCs and as a 
selective advantage to obtain cell protection. Therefore, an intimate balance 
between DNA targeting and cellular xenobiotic extrusion needs to be addressed 
in order to develop suitable fluorescent anthraquinone-based chemical probes.  
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IV.1.5 Aims of this study  
Based on previous findings as described above and in section II.3, the 
cytotoxicity of the novel AAQs is expected to be related to their DNA-binding 
efficacy. However, it is not clear the impact that the incorporation of the acetal 
or chemically hydrolysed aldehyde modification has on the DNA binding, 
cellular distribution and cytotoxicity. Accordingly, the aims of this chapter are 
two-fold: 
1. To assess the DNA affinity of the novel AAQs and their hydrolised 
counterparts (HAAQs) using calf thymus DNA (CT-DNA) thermal 
denaturation assay; 
2. To evaluate the potential cytotoxicity of AAQs and their hydrolysed 
counterparts (HAAQs) in the human lung A549 (+ALDH1A1) and breast 
MCF7 (-ALDH1A1) carcinoma cell lines. 
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IV.2 Materials and Methods 
IV.2.1 AAQs stock solutions 
Compound stock solutions were prepared for use by dissolving 1 mg of AAQ or 
corresponding hydrolysed HAAQ in 1.2 mL of DMSO (Sigma). The final 
concentration of the DMSO in the test volume did not exceed 1%, as a 
concentration greater than 1% DMSO can act to destabilise DNA secondary 
structures (Doyle and Ross, 2003). Hydrolysis of AAQs was carried out as 
described in section III.2.1.2. 
IV.2.2 Melting curve assays for DNA binding analysis  
Calf thymus DNA (CT-DNA, Sigma) solutions were prepared for use by 
dissolving 21-23 mg in 20 mL of CT-DNA melting buffer (see Appendix II for 
composition) and stored at 4ºC. Mitoxantrone (Sigma) was solubilised in 
DMSO, diluted to desired concentrations in 10 mM Tris-HCl buffer (pH 7.4) and 
used as control. Its concentration was determined spectrophotometrically using 
a molar extinction coefficient of 8,360 M-1 cm-1 at 608 nm (Enache and 
Volanschi, 2010).  
The CT-DNA thermal melting assay mixtures were prepared by adding sufficient 
CT-DNA stock solution to CT-DNA melting buffer, to ensure the preparation of a 
50 µM CT-DNA solution. AAQ stock solution was then added to the 50 µM CT-
DNA solution, to ensure the final concentration of compound in the mixture was 
10 µM. All UV absorbance experiments were conducted on a Cary 400Bio 
Spectrophotometer (Varian, Agilent) equipped with a Peltier Temperature 
Controller. This was attached to a Cary Thermostatable Multicell Block, to 
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provide stable, continuous temperature control. A pair of masked quartz 1.2 mL 
microcells cells with a 4 mm width, and 10 mm path length was used for all 
absorbance studies. 1.2 mL of CT-DNA melting buffer was added to the 
reference cuvette and 1.2 mL of DNA-anthraquinone mixture was added to the 
reaction cuvette. Absorbance versus temperature profiles were measured at 
260 nm with melting temperature (Tm) measurements initiated at 40 ºC. The 
temperature of the test solution was increased at 1 ºC/min till 95 ºC was 
reached. 
Melting curves generated by the computer software were printed out and the 
melting points were determined using the published graphical method by Fox et 
al. (Brown and Fox, 1997). The Tm was the mean of two separate 
determinations within 0.2 ºC range. The assay was performed initially by 
incubating 50 µM of calf thymus DNA (CT-DNA), in the presence of 10 µM of 
mitoxantrone, to validate the assay and to have a positive control for 
comparison. 10 µM solutions of AAQ and HAAQs counterparts were incubated 
with 50 µM CT-DNA. 
IV.2.3 Mammalian cell lines culture 
IV.2.3.1 Maintenance of mammalian cell lines 
Mammalian cell lines were cultured as outlined in Table 4.1. The two cell lines 
were obtained from the American Type Culture Collection (ATCC) and grown in 
a monolayer in R10 media (see Appendix II) supplemented with 1 mM sodium 
pyruvate (Sigma). All cells were grown at 37 °C, 5% CO2 and 100% humidity. 
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Cell culture plastics were from Corning. Cells were kept at subconfluent levels 
and were typically passaged when 70–80% confluent. 
Cell line Origin of cell line 
Approx. frequency of 
subculture 
Dilution upon 
subculture 
A549 
Human lung 
adenocarcinoma  
4 days 1:5-1:10 
MCF7 
Human breast 
adenocarcinoma 
4-5 days 1:10 
 
_______________________________________________________________ 
Table 4.1 Culture of mammalian cell lines. 
 
IV.2.3.2 Mammalian cell passaging 
The old media was aspirated carefully and discarded from each 75 cm2 flask. 
The cells were washed with 10 mL Hank’s Balanced Salt solution (Sigma), 
which was then aspirated and discarded. To break down cellular attachments to 
the flask, 2 mL trypsin in EDTA (Sigma) (1:10 dilution) was added to cover all 
cells. The flasks were incubated for 3-5 min, and the contents of the flask were 
checked under light microscope to ensure that the cells were mobile and not 
clumped. The trypsin was quenched with 8 mL of media, which was added 
slowly to avoid the formation of bubbles. The cells were then centrifuged at 
1,000 rpm for 5 min. The supernatant was discarded and cells were 
resuspended in culture media to the appropriate volume. 
IV.2.3.3 Determination of live cell number  
To determine live cell counts, 0.5 mL 0.4% Trypan Blue Stain (Sigma), 0.3 mL 
Hank’s balanced salt solution and 0.1 mL cell suspension were assembled in a 
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tube, mixed vigorously by vortexing and incubated at room temperature for 5 
min. Total cell number (non-stained cells and blue cells) and live cell number 
(non-stained cells) were then determined using a haemocytometer. 
IV.2.3.4 Cryopreservation of mammalian cells  
For storage in liquid nitrogen, mammalian cells were trypsinised, sedimented by 
centrifugation and suspended in ice-cold standard freezing media (see 
Appendix II for media). 
IV.2.3.5 Cellular proliferation assessment using MTT assay  
The viability of A549 or MCF7 in response to novel 1,4-AAQ-based compounds 
(see Appendix III leaflet attached) was determined using the MTT (3-(4,5-
dimethylthiazolyl-2-)-2, 5-diphenyltetrazolium bromide) assay (Mosmann, 1983). 
In living cells, the membrane permeable yellow MTT tetrazolium salt is reduced 
to purple formazan, which is membrane impermeable. MTT reduction is 
generally attributed to mitochondrial activity, but it has also been related to non-
mitochondrial enzymes as well as to endosomes and lysosomes (Berridge and 
Tan, 1993). Initially, cells were seeded into a rounded-bottom 96 well plate 
(Corning) at six different cell seeding densities (0.5x104, 1x104, 2x104, 3x104, 
4x104, and 5x104) per mL of R10 (cells/mL) in order to optimise the assay and 
establish the most suitable seeding assay. Cell number was calculated 
according to section III.3.1.3. Concentration of 1x104 cells/mL was determined 
to be the optimum seeding density for both cell lines for 96 h total incubation. A 
control lane contained supplemented R10 only. The 96 well plates were 
incubated overnight at 37 °C, 5% CO2 and 100% humidity to allow cell 
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adhesion. Cells were then treated respectively with novel AAQs (0.25-100 µM) 
or doxorubicin (supplied as doxorubicin hydrochloride, Sigma) (0.005-100 µM) 
as a positive cytotoxic control. The cells were incubated with the AAQs or 
corresponding HAAQ counterparts for 72 h. All anthraquinones were dissolved 
in DMSO (Sigma), ensuring that the DMSO concentration was no more than 
0.1% per well. A control of 0.1% DMSO was included to make certain that any 
observed effect was due to only the tested anthraquinone. Following the 72 h 
incubation period, media containing the respective test compound was removed 
and replaced with supplemented R10 containing a 1:10 dilution of 5 mg/mL of 
MTT solution in water. Cells were incubated for a further 4 h. The MTT solution 
was removed and the resulting purple formazan crystals were resuspended in 
150 µl/well of DMSO and absorbance was read at 540 nm.  The cytotoxicity was 
extrapolated by comparing drug treated cell data with an untreated control, and 
curves were determined as percentage of survival. Finally, IC50 (concentration 
that inhibits the control growth by 50%) values were calculated using Microsoft 
Excel software. 
IV.2.3.6 Statistical analysis 
Statistical significance of the results was evaluated on data from at least three 
independent experiments. The means of IC50 values were calculated and 
plotted using Microsoft Excel software. R2 coefficient determination was used to 
give information about the accuracy of the obtained results.  
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IV.3 Results  
IV.3.1 DNA melting temperature as an indicator of DNA  
In the present study, assessment of variation in Tm due to possible interaction 
between CT-DNA and anthraquinones was carried out using a thermal DNA 
denaturation assay (results shown in Table 4.2).  
 
 
 
 
 
 
 
 
 
 
 
_______________________________________________________________ 
Table 4.2 CT-DNA/AAQs melting temperatures before and after acidic hydrolysis.* Excess 
of interference, hence any calculation of Tm was inaccurate. ** Solubility issues in the working 
buffer, therefore no experiment was performed. Melting curve plots can be found in 
Supplementary Information IV.A. 
Compound AAQ Tm (ºC) HAAQ Tm (ºC) 
Mitoxantrone >95 - 
LC-103 69.0 69.7 
LC-105 74.0 71.9 
LC-106 69.0 70.0 
LC-107 69.4 70.1 
LC-108 69.6 ** 
LC-109 69.0 ** 
LC-110 72.1 * 
LC-111 76.4 * 
LC-112 72.0 72.9 
LC-113 72.0 71.6 
LC-114 71.6 74.6 
HA-218 74.2 70.4 
HA-222 70.8 * 
HA-236 70.0 70.0 
HA-252 73.0 72.6 
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Naked CT-DNA showed a Tm of 69.1 ºC and addition of mitoxantrone 
increased this value to higher than 95ºC (∆Tm > 30 ºC). In comparison, the 
effect of the novel AAQs on Tm values was weak to moderate with Tms falling 
between 69 and 76 ºC. Furthermore, hydrolysis of the majority of the LC-AAQs 
was demonstrated to have adverse or no effect on the Tm of CT-DNA.   
The same experiment was performed with the HA-AAQ derivatives and the 
parent compounds showed a moderate increase in Tm compared with the LC-
AAQ congeners. The most DNA-affinic compounds, HA-218 and HA-252, 
produced ∆Tm= 6.06 and 4.86 ºC respectively. However, compared with 
mitoxantrone, this was a moderate effect on CT-DNA. Hydrolysed HA-AAQs 
were investigated in the same conditions, however no significant effect on the 
DNA affinity was observed. Furthermore, solubility issues and post-hydrolysis 
precipitations of some AAQs (noted with * on Table 4.2) created a loss of 
accuracy and potential artefacts in the absorbance readings.  
 
IV.3.2 Effect of novel AAQs and HAAQ counterparts on cell viability  
Symmetrical and non-symmetrical AAQs were tested with a concentration range 
between 0.25 and 100 µM for 72 h and doxorubicin, as positive cytotoxic 
control, was tested in parallel at the same doses (complete IC50 values list was 
reported in Tables 4.3-4.4).  
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AAQ MCF7 (µM) R
2
 value A549 (µM) R
2
 value  
Doxorubicin 0.028 0.1831 0.05 0.1759 
LC-103 0.750 0.7865 >100 0.9034 
LC-055 >100 0.7199 >100 0.6439 
LC-106 1.75 0.6174 >100 0.2725 
LC-107 >100* 0.1835 >100* 0.7433 
LC-108 >100 0.4418 >100 0.5332 S
y
m
m
e
tr
ic
a
l 
LC-109 >100 0.6994 83.2 0.9444 
LC-110 11.3 0.5697 11.7 0.568 
LC-105 1.66 0.5541 17.5 0.9475 
LC-111 1.44 0.4437 1.7 0.7563 
LC-112 15.70 0.7976 22.5 0.7371 
LC-113 19.5 0.7258 22.3 0.9473 
N
o
n
-s
y
m
m
e
tr
ic
a
l 
LC-114 1.8 0.757 38.2 0.9546 
HA-218 1.73 0.6857 7.5 0.7395 
HA-222 37.3 0.6787 12.4 0.6857 
HA-236 >100 0.9528 >100 0.3755 
O
th
e
rs
 
HA-252 1.2 0.4871 1.37 0.3569 
 
_______________________________________________________________ 
Table 4.3 Growth inhibition (IC50) of LC-AAQ and HA-AAQ libraries against MCF7 and 
A549 cancer cell lines. * Solubility problems, blue crystals appeared after 48 h of treatment. R2 
is a statistical measure of how well the regression line approximates the real data points. R2 of 
1.0 indicates that the regression line perfectly fits the data. 
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 Hydrolysed compound MCF-7 (µM) R
2
 value A549 (µM) R
2
 value 
LC-103 56.73* 0.9434 >100 0.9621 
LC-055 >100 0.9651 >100 0.51 
LC-106 < 0.250* 0.8793 >100* 0.8352 
LC-107 >100* 0.5492 >100* 0.6735 
LC-108 >100* 0.7382 >100* 0.6318 
S
y
m
m
e
tr
ic
a
l 
LC-109 >100 0.7128 >100 0.7946 
LC-110 40* 0.933 >100* 0.8502 
LC-105 29.51 0.7825 12.7 0.7826 
LC-111 < 0.250 0.3528 1.24 0.6786 
LC-112 2.26 0.5933 34 0.8435 
LC-113 20.11 0.723 45.2 0.8345 
N
o
n
-s
y
m
m
e
tr
ic
a
l 
LC-114 8.60 0.6085 32.3 0.6153 
HA-218 < 0.250 0.7012 1.74 0.7028 
HA-222 < 0.250 0.9027 5.3 0.5976 
HA-236 ND 0.9778 >100 0.727 
O
th
e
rs
 
HA-252 0.35 0.3797 0.54 0.5141 
 
_______________________________________________________________ 
Table 4.4 Growth inhibition (IC50) of hydrolysed AAQs (HAAQs) against MCF7 and A549 
cancer cell lines. * Solubility problems, blue crystals appeared after 48 h of exposure. ND: not 
determined. R2 is a statistical measure of how well the regression line approximates the real 
data points. R2 of 1.0 indicates that the regression line perfectly fits the data.  
 
Some impact on cell viability was dictated by structural modifications to the 
chromophore skeleton as pointed out in Figure 4.3 (top panel). The addition of 
hydroxyl groups at carbon 5 and 8 positions in the chromophore was generally 
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correlated with improved DNA affinity and cytotoxicity compared with the 5,8 
non-hydroxylated derivatives, which is in agreement with other similar studies 
(Bailly et al., 1996).  
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_______________________________________________________________ 
Figure 4.3 Structure activity relationships with selected LC-AAQ derivatives. This 
representation points out two possible key modifications (black box) within the AAQ structure 
responsible of enhanced cellular cytotoxicity.   
 
 
The tethering of a basic N,N-dimethylethylamine sidechain with high affinity for 
DNA (as exemplified in AQ4 and AQ6, see section II.1.1) to generate non-
symmetrical derivatives led to enhanced cytotoxicity in all the LC-AAQ 
compounds. For example, non-symmetrical configured compounds such as LC-
105, LC-111 and LC-113 exhibited enhanced cytotoxic effects when compared 
with their symmetrical counterparts LC-055, LC-108 and LC-107, probably 
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because of the stronger interaction of the N,N-dimethylethylamine moiety with 
the DNA sugar backbone as well as higher solubility (see Figure 4.3 bottom 
panel). Moreover, hydrolysis of the symmetrical AAQs generally led to an 
observable enhanced cytotoxicity, whereas loss of cytotoxic activity was 
revealed with non-symmetrically configured AAQs. Modifications to the carbon 
sidechain structure were found to affect the potency (see Figure 4.4 for 
structural variations).  
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_______________________________________________________________ 
Figure 4.4 Modification of the carbon sidechain skeleton of LC-105, LC-112 and LC-108. 
Black boxes represent the modification points. 
 
LC-108 and LC-112, containing amide and “reverse” amide bond respectively, 
were less potent than the LC-105 congener.  The results are in agreement with 
a previous study concerning incorporation of non-basic heteroatoms into the 
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sidechain of anthraquinones, which also showed a reduction in chemosensitivity 
(Krapcho et al., 1990). Incorporation of bulky substituents at the terminal 
nitrogen of the HA-AAQ library revealed a decrease in cytotoxic effect (see 
Figure 4.5 for structural modifications): HA-236 (benzyl) < HA-222 (methyl) < 
HA-218 (H).  
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Figure 4.5 Modifications of the secondary amine in the HA-AAQ library.  
 
As discussed in section III.3.1, HA-AAQs were resistant to hydrolysis at 37 ºC, 
so exposure to 2M HCl at 75 ºC was necessary. Hydrolysed HA-AAQ products 
showed an enhanced activity on cell viability compared with their AAQ 
counterparts, except for HA-236. Indeed, the benzyl group in HA-236 was 
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shown to have no effect under the tested conditions, which is likely to be due 
the bulkiness of the benzyl moiety which prevents DNA binding (Murdock et al., 
1979). 
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IV.4 Discussion 
The experiments conducted in this chapter have provided information about 
how AAQs and their corresponding hydrolysed counterparts bind with DNA and 
whether this DNA binding can be correlated with their cytotoxic potential.  
We have investigated two libraries of AAQs and none of the test compounds 
were shown to possess high affinity for CT-DNA as measured by a thermal 
DNA denaturation assay. A few compounds including HA-218, HA-252, LC-105 
and LC-111 showed moderate affinity for DNA, but in comparison with 
mitoxantrone this binding was negligible. The results clearly indicate that 
although the anthraquinone is an excellent DNA intercalator (Lerman, 1961; 
Lown et al., 1985), its strength in binding is almost exclusively related to the 
nature of sidechains inserted onto the anthraquinone chromophore. 
It was proposed that a stronger interaction between the aldehyde moiety of the 
HAAQs and the DNA (see Fig. 3.5 for the activation scheme) would enhance 
the DNA affinity via potential for generating DNA crosslinks (Hilton, 1984; 
Kuykendall and Bogdanffy, 1992). The electron-rich guanine or adenine bases 
are known nucleophiles capable of generating covalent bonds to drugs via 
Schiff base formation (Kurtz and Lloyd, 2003). However, the results suggested 
that no increased DNA binding occurred with the HAAQs. Indeed, it may be that 
the failure to increase ∆Tm was due to depurination occurring at elevated 
temperatures, induced by Schiff base formation (see Figure 4.6) (Goffin et al., 
1984).  
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Figure 4.6 Proposed DNA cleavage via Schiff’s base formation. Reaction mechanism 
between 2’-deoxyguanosine and the aldehyde moiety of the hydrolysed AAQ. 
 
Depurination has been defined as an alteration of DNA in which the purine base 
(adenine or guanine) is removed from the deoxyribose sugar by hydrolysis of 
the beta-N-glycosidic bond (Holmquist, 1979). After depurination, the sugar 
phosphate backbone remained intact with the sugar ring displaying a hydroxyl (-
OH) group in the place of the purine.  At elevated temperatures as employed in 
the thermal denaturation assay, the Schiff base linkage may induce 
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depurination at the DNA-drug interaction site. This phenomenon could explain 
the lowering in absorption and Tm values of the HAAQs.  
All novel compounds were investigated in A549 (high ALDH expression) (Moreb 
JS, 2008) and MCF7 (low expression of ALDH) (Bunting KD, 1994). From the 
cytotoxicity plots (reported in Supplementary Information IV.B) and IC50 values 
(see Tables 4.3-4.4) it is evident that MCF7 generally showed an increased 
sensitivity to AAQs compared with A549 cell line.  
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Figure 4.7 ALDH-mediated conversion of aldehyde moiety into a carboxylic acid. The 
carboxylic acid is known to be a good substrate for efflux pump proteins. 
 
A factor contributing to higher resistance in A549 cell line is possibly related to 
the higher expression of ALDH. The presence of these chemoprotecting 
enzymes are likely to convert aldehyde moieties into carboxylic acid, which are 
poor components for DNA binding as well as better substrate for ABC 
transporters (see Figure 4.7) (Zhou et al., 2002). Although this loss in activity is 
explainable for the HAAQs, it is not clear why the parental AAQs are less 
cytotoxic in A549 cell line. Unless, the acetal moiety is prone to oxidative 
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metabolism as experiments using cytosolic fractions from rat liver, enriched in 
ALDHs, may suggest (see section III.3.4.1).  
In general, convincing SARs between AAQs and their hydrolysed counterparts 
are difficult. However, a general classification of the AAQ or HAAQ effect on cell 
viability may distinguish the compounds as cytotoxic (below 12% cell survival), 
growth inhibiting (between 25-75% cell survivals) or cytostatic agents (above 
75% cell survival). On this basis, the shape of the cytotoxicity curves was 
analysed. The non-symmetric derivatives with an amide bond in the sidechain 
(i.e. LC-111, LC-112, LC-113, and LC-114) revealed a relatively higher cytotoxic 
profile in both cell lines. Similarly, HA-AAQs revealed a cytotoxic response 
independently from the cell line model, except for HA-236, which had a 
consistent cytostatic effect. However, these results may be due to lack of cell 
penetration. An interesting behaviour was revealed with LC-110, which was 
shown to be a cytostatic compound. However its hydrolysed product was 
classified as cytotoxic without cell-type discrimination. Furthermore, as reported 
in Table 4.4, some derivatives revealed solubility issues after hydrolysis, which 
impacts the AAQ availability in solution and potential to interact with DNA-
binding and cell viability. 
In summary, the novel AAQs revealed to be weak to moderate DNA binders. 
Hydrolysed AAQs were not significantly different to the parental AAQs in DNA 
binding or in generating cytotoxic activity. In comparison with doxorubicin, the 
anthraquinones were less cytotoxic and in many cases not toxic under the 
conditions investigated. Accordingly, their utility as molecular fluorescent probes 
to study live cells can be further studied. 
  
 
 
 
 
 
Chapter V 
 
Evaluation of fluorescent properties of 
novel 1,4-di-substituted 
acetalanthraquinones as potential 
ALDH-targeting probes
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V.1 Introduction and Aims 
V.1.1 The development of fluorescent probes to explore live cells 
Since the nineteenth century, optical microscopy has been a leading technology 
to observe living cells, but the lack of contrast in several tissues soon led to the 
introduction of dyes, for their ability to stain or label various cell structures with a 
different grade of selectivity (McCutcheon and Lucre, 1924; Tsien, 2005). It was 
common that these dyes could not cross intact cell membranes and had to be 
applied at high concentration because of their low affinity for intracellular 
targets. Therefore, until 1930 biological microscopy became widely the study of 
dead or fixed tissues and consequently a relatively static discipline. In 1942, 
Coons et al. introduced fluorescently labelled antibodies to recognise any target 
endogenous protein with high affinity and selectivity (Ploem, 1971). This 
converged with the development of a new microscopy configuration that 
enabled the attachment of an epi-illumination for the excitation and detection of 
fluorescent probes.  
Fluorescence consists of the ability of reagents not just to absorb light (Williams 
and Bridges, 1964) but also to re-emit light at longer wavelength (Lakowicz et 
al., 1992). It is a cyclical process that occurs in a very small percentage of light-
absorbing molecules, called fluorophores or fluorescent dyes, as most just 
convert the light into heat (Tsien, 2005). A fluorescent probe is a fluorophore 
designed to respond to a specific stimulus or to specifically localize within a 
biological specimen and detectable with much greater sensitivity than non-
fluorescent dyes. A desirable property for such fluorescent probes used to study 
living cells is that it must not impair normal cell function (Taylor and Wang, 
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1980). Therefore, the approach of probing live cells to investigate highly 
dynamic and transitory cellular mechanisms has presented an active and 
exciting research field in its own right (Coling and Kachar, 2001).   
Since the early ‘70s, when Waggoner demonstrated the potential dependent 
partition of cyanine-dye molecules between the cells and the extracellular 
medium in blood cells (Sims et al., 1974; Waggoner and Stryer, 1970), the 
concept of using fluorescent compounds to address biological questions started 
to become a promising approach. In the same years, Haugland founded 
Molecular Probes with the intention to make fluorescent dyes available for 
biological research and this had crucial impact on the application of 
fluorescence to cellular biology (Haugland, 1999). Moreover, another  
paradigm-shif that occurred during the 90s was the cloning and expression of 
the jellyfish Green Fluorescent Protein (GFP), which resulted in the expression 
of a fluorescent marker as a result of gene expression and protein targeting in 
intact cells and organisms (Tsien, 1998; Tsien, 2003).  
Thus, these and many other discoveries in molecular tagging, cellular labelling 
have resulted in an ongoing grand challenge of developing fluorophores as 
small molecules that can be part of a molecule (intrinsic fluorophores) or added 
to it (extrinsic fluorophores) and so they can be used as natural indicators to 
study the structure, dynamics, and metabolism of living cells.  In recent date, 
the fluorescence tagging of antibodies has become a routine part of the 
characterization of tumour biomarkers for delivering an "image and treat" 
concept in patient diagnosis (Ardeshirpour Y, 2012). At the same time, there is 
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a need for tissue-based multivariate biomarker assays to improve the accuracy 
of diagnostic, prognostic, and predictive testing (Nederlof et al., 2011).    
In this chapter, studies are focussed on the development and assessment of 
fluorescence-based assays for the analysis of many important live-cell 
functions, suitable for determining apoptosis, cell adhesion, multi-drug 
resistance, endocytosis, secretion and signal transduction. As reported in Table 
5.1, the number of such probes within a functional assay design has been 
rapidly growing and these approaches are becoming critical tools for detection 
of diverse cell processes (Dailey M.E. , 2006).  
Diverse platforms have been designed and engineered to detect fluorescent 
probes in cells (Errington et al., 2005).  Many of the assays revealed above can 
be analyzed on a cell-by-cell basis and some are equally suitable for detection 
with a classic fluorescence microscope,  a flow cytometer or a microplate reader 
with the advantage that the majority of the assays have the capacity for high-
throughput analysis (Held et al., 2010). 
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Table 5.1 Exemplar fluorescent labels commonly used for the functional analysis of living cells. 
 
Probe Name Functional Assay Reference 
Blue-green illumination 
AlamarBlue Cell health indicator (Nakayama et al., 1997) 
Aldefluor ALDH activity (Jiang et al., 2009) 
BCECF Cytoplasm pH changes indicator (Han and Burgess, 2009) 
Carboxy-
DCFDA 
Hypoxia detector; pH sensor         
 
(Hagar et al., 1996) 
CFSE Live cell marker           
Lineage tracker 
(Weston and Parish, 1990) 
Fluo-4AM Calcium indicator (Ma et al., 2010b) 
JC-1 Mitochondrial  depolarization;   
Cellular apoptosis 
(Smiley et al., 1991) 
MitoSOX 
Red 
Mitochondrial superoxide indicator (Zielonka et al., 2008) 
MitoTracker  
Green FM 
Mitochondrial membrane depolarisation (Pendergrass et al., 2004) 
RedoxSensor 
Red CC-1 
Cytosolic redox sensor   Hypoxia detector            
Free radicals detector 
(Chen and Gee, 2000) 
(Oksvold et al., 2002) 
Rhodamine 
123 
Mitochondrial  depolarization              
Cellular apoptosis 
ABCB1-mediated exclusion 
(Emaus et al., 1986; Johnson 
et al., 1980)  
(Eytan et al., 1997; Yumoto et 
al., 1999) 
SNARF-1,-
4F,-5F 
pH indicators (Han and Burgess, 2009) 
TMRM and 
TMRE 
Mitochondrial depolarization  related to 
cytosolic calcium   
ABCB1-mediated exclusion 
(Loew et al., 1994; Loew et 
al., 1993)  
(Eytan et al., 1997) 
MTT, MTS, 
XTT 
Redox potential of cells 
Cell viability 
(Peeters et al., 2008) 
(Mosmann, 1983) 
Red illumination 
CellROX Cellular oxidative stress 
Reactive oxygen species measurement 
(Beazley et al., 2011) 
DRAQ5 Cell cycle 
DNA content 
(Smith PJ, 2000; Smith et al., 
1999) 
MitoTracker 
Red FM 
Mitochondria depolarisation (Ba et al., 2010; Csiszar et 
al., 2009; Hailey et al., 2010) 
UV illumination 
CellTrace 
Violet 
Proliferative indicator 
Lineage tracker 
(Jones et al., 2010) 
ER-Tracker 
Blue-White 
DPX 
Endoplasmic Reticulum labelling (Abodeely et al., 2009) 
Hoechst 
33342 
SP discrimination (Goodell et al., 1996) 
MCB Glutathione depletion 
reactive oxygen species measurement 
(Abramov et al., 2007) 
ThiolTracker  Glutathione localisation 
detection cellular redox status  
(Mandavilli and Janes, 2001) 
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V.1.2 Anthraquinone-based fluorescent probes - seeking a functional 
readout 
The concept of fluorescence detection using an anthraquinone quencher dye 
conjugated to a variety of biologically relevant compounds became of interest in 
1970s (Donati et al., 1973; Morsi and Williams, 1977).  The chromophores of 
DNA-binding agents have been exploited extensively in spectroscopic and live 
cell studies to probe features of the nucleus and to explore the dynamics of 
ligand binding. Tracking DNA-ligand interactions in live cells also facilitates the 
design of anticancer agents, since many drugs are auto-fluorescent (Njoh KL, 
2006).  
Anthracycline antibiotics are an important class of anticancer therapeutics and 
are known for their ability to bind DNA as intercalating agents and act as 
topoisomerase II inhibitors (Tewey et al., 1984). 1,4-Dihydroxyanthraquinone is 
the smallest unit in the anthracycline structures to possess the characteristic of 
the chromophore: a broad UV-visible absorbance spectrum (360-515 nm). The 
binding of 1,4-dihydroxyanthraquinone to DNA shifts the absorption spectrum to 
longer wavelength, as a consequence of the red-light excitation of the 
chromophore (Eriksson M, 1988). Indeed, nuclear DNA is believed to be the 
primary target of anti-tumour activity of the anthracyclines, resulting in inhibition 
of DNA transcription and replication (Cozzarelli and Wang, 1990). In vitro, the 
anthracycline-DNA interaction mainly occurs by intercalation of the planar ring 
system between DNA basepairs (see section II.1). In vivo, anthracycline 
biofunction has been documented by several structure-activity relationship 
studies and many compounds that have reached the clinical stage, for example, 
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generally belong to the group with the highest affinity for DNA (Crow and 
Crothers, 1994). Mitoxantrone is another example of anticancer anthraquinone 
drug, structurally related to the DNA intercalating anthracycline antibiotics. The 
auto-fluorescence of such agents, such as anthracyclines, has enabled uptake 
studies or pharmacokinetic studies to be performed using flow cytometry or 
fluorescence microscopy (Krishan and Ganapathi, 1980). Critically, both the 
development of novel drugs with DNA binding properties and target specificity, 
and molecular probes with desired chromophore performance must address the 
sequence preferences of ligands and the modes of DNA interaction (Njoh KL, 
2006).  
Anthraquinone-based fluorescent probes are already in use and been patented 
by Biostatus Ltd. The lead agent DRAQ5™ (see Figure 5.1), a 1,5-bis[2-
(methylamino)ethyl]amino-4,8-dihydroxy anthracene-9,10-dione, and its 
derivatives were demonstrated with DNA binding capability through intercalation 
(Smith PJ, 2000; Smith et al., 1999). The 1,5-di-substituted derivatives 
intercalate with each substituent positioned in each groove and the intercalation 
is stabilized by electrostatic interactions between the protonated tertiary amino 
group of the sidechain and the phosphate backbone of the DNA (Njoh KL, 
2006). Molecular dynamics simulation of the DNA–DRAQ5 complex (see Figure 
5.1B) without any constraints leads to DRAQ5 protrusion into the interface of 
two A-T (adenine-thymine) pairs by displacing the aromatic rings of two base 
pairs out of the DNA backbone and DRAQ5 stacking between those aromatic 
rings (Islam SA, 1985). 
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Figure 5.1 DRAQ5™ fluorescent probe. An anthraquinone molecule that enters live cells, 
binds to the nucleus and provides a quantitative fluorescence readout for DNA content: (A) 
DRAQ5 chemical structure; (B) DNA-DRAQ5 complex indicates DRAQ5 protrusion into the 
interface of two A-T pairs in the DNA minor grove (figure adapted from Dr Zloh M., University of 
London); (C) DRAQ-5 nuclear staining using widefield-microscopy (kindly provided by Sally 
Chappell, Cardiff University). 
 
DRAQ5 achieves good nuclear discrimination (calculated high 
nucleus/cytoplasm ratio) by its high affinity for DNA and does not show 
fluorescence enhancement with DNA in free solution (Errington et al., 2005). 
With an excitation at 647 nm, DRAQ5 has a fluorescence spectrum extending 
from 665 nm to 780 nm (see spectra in Figure 5.2). This far-red emission shows 
little overlap with other commonly used green emitting cellular dyes (Smith et 
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al., 2000). However, mitoxantrone-like chromophores have been found to have 
very weak fluorescence (Krishan and Ganapathi, 1980). 
 
    A                                                            B 
 
 
_______________________________________________________________ 
Figure 5.2 DRAQ5 spectral analysis. (A) Absorbance and (B) fluorescence spectra.  
 
Although it has been classified as a weak fluorophore (quantum yield ranging 
from 0.003 to 0.004, demonstrating that most of the absorbed photon energy 
translates to nonradiative decay) (Njoh KL, 2006), the high DNA binding affinity 
of this “red-shifted” molecule has ability to identify cell cycle position through 
DNA content analysis. Moreover, the stoichiometric DNA binding and the high 
membrane penetrance of this molecular probe results in a valid and robust tool 
for live cell analysis (Smith et al., 1999). Therefore, DRAQ5 represents an 
innovation, progressing a fluorescent agent into a fluorescent label suitable for 
assaying DNA content in a live cell. 
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V.1.3 Cell model systems for novel probe screening 
Two extensively characterised cell lines are selected for the study: the human 
osteosarcoma cell line U-2 OS and the human lung adenocarcinoma cell line 
A549.  
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Figure 5.3 Hoechst 33342 chemical structure and nuclear staining in A549 cells. Figure 
adapted from Motiwala et al. (Motiwala et al., 2004). Hoechst 33342 does not bind DNA by 
intercalation or ionic interaction with the phosphate groups, but it has high specificity for DNA 
minor groove of double-stranded DNA. 
 
The U-2 OS cell line has been selected as it represents a cell line widely used 
in biomedical research. Two tumour suppressive genes, p53 and pRb, are 
functional in U-2 OS cells, whereas in other, more aggressive, osteosarcoma 
cell lines such as Saos-2, these genes are mutated (Ponten and Saksela, 1967) 
and they are routinely used for drug screening purposes and high-through-put 
analysis (Vollmers et al., 2008; Zhuang et al., 2011). Moreover, no pumps and 
no ALDH isoforms have been detected in U-2 OS cell system ( Zhuang et al., 
2011).  
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A database survey of 59 cancer cell lines from the NCI60 panel (kindly donated 
by collaborator Smith PJ) has been undertaken to evaluate the prevalence and 
patterns of ABCG2 and ALDH1A1 over-expression in established human 
tumour lines, and A549 cell line shows high expression of both proteins (see 
Figure 5.4).  In this study, A549 cell line is also chosen as an established cell 
model with ability to maintain side populations (SPs), identified by a reduced 
accumulation of Hoechst dye 33342 (see Figure 5.3A for structure) attributable 
to ABCG2-mediated efflux (Scharenberg et al., 2002). Hoechst 33342 dye has 
been used as vital probe for nuclear location, however, as a substrate for efflux 
-pumps it is not well retained in many cell types (see Figure 5.3A) (Morgan et 
al., 1990), and the combination of nuclear staining with ABCG2-dependent 
discrimination results in a quantitative functional assay for attributes of drug 
resistance or SC-like properties. The SP phenotype has been characterized by 
low violet and red fluorescence intensity on a dot-plot displaying dual-
wavelength fluorescence of blue versus red detected at 424 and 675 nm 
(Scharenberg et al., 2002), respectively. 
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_______________________________________________________________ 
Figure 5.4 Database survey of 59 human tumour NCI60 panel cell lines. The study allocates 
cell lines into four groups according to ALDH and ABCG2 degree of expression (adapted from 
Smith PJ; personal communication). 
 
As shown in Figure 5.5, only A549 cells exhibited a significant SP of Hoechst 
33342 low cells trailing to the origin of the plot and thus displaying low 
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fluorescence in both the violet and red channels. SP experiments (Wiltshire M; 
unpublished data) were performed with Hoechst 33342 that showed significant 
shifts in uptake with these cells after addition of ABCG2 inhibitor Fumitremorgin 
C, (FTC). 
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Figure 5.5 A549 SP-detection. A549 cell line sustains a background of SP cells identified by 
reduced Hoechst 33342 uptake defined at 40 min exposure using flow cytometry (work 
conducted by Marie Wiltshire, at Cardiff University). 
 
 
Moreover, the heterogeneity of lung cancer cell line on ALDH expression has 
been extensively studied using Aldefluor assay (Moreb et al., 2007) and A549 
cells have been reported to have very high ALDH activity (Stuelten et al., 2010) 
and therefore appear to be a valid model system to test the novel AAQs. 
 
V.1.4 Aims of this study 
The already established labelling and assay development with DRAQ5, together 
with the understanding of an SP-enrichment technique using Hoechst 33342, 
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provides the benchmark, non-invasive cytometric tools for tracking molecular 
interactions in live cells. However, there is an ongoing demand and effort 
required to develop fluorescent, photostable dyes with high affinity for a target 
enzyme, as ALDH, in order to discriminate sub-populations in heterogeneous 
cellular samples. The potential of the anthraquinone chromophore have been 
already assessed with DRAQ5 (see section V.1.2) and the fundamental concept 
of ALDH-based cell isolation has been established with the commercially 
available kit ‘Aldefluor assay’ (see section I.5.6). Here, the overall goal has 
been to combine both these two features within the same small molecule to 
obtain an intrinsically fluorescent probe to track a quantifiable biofunctional 
readout with combined features that brings additional benefits.  Furthermore, 
intent to increase signal to noise ratio and potentially eliminate concurrent use 
of pump inhibitors, as indispensable feature of Aldefluor kit, could provide an 
end-point detection by combining together DNA binding and cell retention 
capacity (refers to section I.7 features of the molecular probes design concept) . 
In light of the biological investigation of the cytotoxic profile, the DNA labelling 
affinity (see chapter IV) of the novel AAQ library of compounds (refer to chapter 
II for synthesis), the experimental objectives of this current chapter were to use 
the described cellular model to gain insights into: 
1. The excitation/emission profile of focussed library of AAQs in order to 
validate the quality of absorbance-fluorescence spectra; 
2. The use of novel probes in fluorescence imaging to investigate the ability 
of these molecules to penetrate fixed and live cellular systems and the 
stability of the fluorescence signal in the cellular environment over time; 
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3. To determine the spatial-temporal cellular localisation of the probe by 
using confocal laser scanning microscopy and time-lapse microscopy;  
4. To determine the ability of the AAQ derivatives (before/ after hydrolysis 
of the acetal moiety) to separate cells on the basis of ALDH activity by 
establishing a flow cytometric assay based on Aldefluor protocol; 
specifically, to validate the potential of finding an alternative assay kit and 
approach to quantify and/or separate cellular subpopulations by targeting 
ALDH activity. 
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V.2 Materials and Methods 
V.2.1 Probe stock solutions  
AAQs (see Table 5.2) were dissolved in DMSO (Sigma) to 20 mM stock 
concentration. DRAQ5 (Biostatus Ltd) was used as a control agent and 
dissolved in deionised water. Working solutions were prepared in PBS or 
HEPES (Sigma) at 20 or 40 µM. 
V.2.2 Determination of fluorescence excitation/emission peaks 
Probe solutions (20 µM), respectively in PBS or HEPES, were pipetted into a 1 
mL quartz cuvette (Thermo Fisher Scientific). After obtaining baseline spectra in 
PBS to zero the instrument, absorbance measurements were obtained using a 
Beckmann Coulter DU 800 UV/Visible spectrophotometer. The excitation 
wavelengths were scanned from 280 to 800 nm. Fluorescent spectral scans 
were performed using a Perkin Elmer LS-50B Luminescence 
spectrophotometer. For emission scans, the excitation wavelength was set 
accordingly to the recorded values for each probe and the emission wavelength 
were scanned from 400 nm to 900 nm in 1 nm increments. A Xenon flash lamp 
was used as the light source, with the lamp energy set to high. For each data 
point ten measurements were acquired with the photomultiplier tube sensitivity 
set at 125.  
V.2.3 Maintenance of mammalian cell lines 
Mammalian cell lines were cultured as outlined in Table 5.2. 
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Cell 
line 
Origin of cell 
line Culture Media 
Approx. frequency of 
subculture 
Dilution 
upon 
subculture 
A549 
Human lung 
adenocarcinoma  R10 
4 days 1:5-1:10 
U-2 OS 
Human 
osteosarcoma M10 
4-5 days 1:10 
 
_______________________________________________________________ 
Table 5.2 Culture of mammalian cell lines. See Appendix II for cell media composition. 
 
The cells were obtained from the American Type Culture Collection (ATCC) and 
were grown at 37 °C, 5% CO2 and 100% humidity. Cell culture plastics were 
from Corning. Cells were kept at subconfluent levels and were typically 
passaged when 70–80% confluent. Cell passaging, Determination of live cell 
number and cryopreservation were assessed as previously described on 
sections IV.3.1.2- IV.3.1.4. 
V.2.4 Cell seeding 
A549 and U-2 OS cells were counted (see section IV.3.1.3) and seeded at 4 x 
104 cells in 1 mL of the respective media per 24-well plate well for cells to be 
used in experiment after 24 h. Seeded cells were left to adhere and establish in 
a 37 °C humidified environment of 5% CO2 in air for overnight after seeding.   
V.2.5 Imaging 
All camera, shutter and stage were initially controlled by AQM 2000 software 
(Kinetic Imaging Ltd) before all systems were moved to MetaMorph version 7.5 
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(Molecular Devices). All image analyses were conducted using MetaMorph 
Offline version 7.5. Several microscopy platforms have been used: 
1. Fluorescence microscope CBS camera system (CBS Cardiff) consisting 
of an inverted Axiovert S100 TV microscope (Carl Zeiss Inc.) with 
Hamamatsu camera (model C4742-95-12, Hamamatsu Photonics), 
fluorescent lamp (model ebx75 isolated, Carl Zeiss Inc.) and shutter 
Lambda 10-2 (Kinetic Imaging Ltd). 
2. Confocal laser microscope consisting of Bio-Rad Radiance 2000MP 
system (Bio-Rad) linked to a Nikon TE300 inverted microscope (Nikon). 
Image capture and processing was primarily performed using Bio-Rad 
LaserSharp 2000 v4 software. Further image processing for cell 
localisation was performed using MetaMorph software. 
3. Time-lapse microscope system composed of a HAL100 microscope (Carl 
Zeiss Inc.) fitted with temperature (37 °C) regulating incubator system 
and CO2 (5%) supply (Solent Scientific). Illumination was controlled by a 
shutter (Prior Scientific) placed in front of the transmission lamp and a 
motorized xyz stage (Prior Scientific) permitted multi-field acquisition. 
Phase transmission images (x10 objective lens) were acquired with a 
cooled CCD (charge coupled device) camera (model 4920 COHU) every 
30 sec. 
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V.2.5.1 AAQs labelling of fixed cells 
Cells were plated in a 24 well plate as reported on section V.2.4. A 4% 
paraformaldehyde solution in PBS was made from a 16% stock solution 
(Thermo Fisher Scientific). Cells in 24 well plates were washed gently with 3x 2 
mL PBS per well. The PBS was removed and 0.5 mL of 4% paraformaldehyde 
solution was added in each well and cells were incubated for 30 min. The 
paraformaldehyde was removed and cells were washed 3x 2 mL PBS per well.  
1mL of PBS or HEPES was added to each well and the 24 well plates were 
treated respectively with 20 µM of AAQ probe or 20 µM of DRAQ5 as control. 
Before analysis, cells were incubated at 37 °C in the dark for 1 h and for 72 h. 
Samples were analysed directly without any further washing step. 
V.2.5.2 AAQs loading of live cells 
After seeding the cells in 24 well plates (see section V.2.4), 20 µM AAQ 
solutions or 20 µM of DRAQ5 solutions were added respectively in D10 media 
(see Appendix II). Prior to analysis, cells were incubated at 37 °C in the dark for 
30 min and for 18 h. Samples were analysed directly without any further 
washing step. 
V.2.5.3 Transmission imaging 
Bright field images from live cells in full culture media were captured on the 
CBS camera system. 
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V.2.5.4 Fluorescence imaging 
Images from fluorescently-stained slides were captured on the CBS camera 
system using the suitable filters block (Chroma Technology Corp) (see Table 
5.3). 
Dye Excitation (nm) DCLP (nm) Emission (nm) 
DRAQ5/AAQs ET620/60x T660LPXR ET700/75m 
 
_______________________________________________________________ 
Table 5.3 CBS camera filter block set-up. 
 
V.2.5.5 Confocal laser scanning microscopy (CLSM) 
CLSM was used in preference to a standard fluorescent widefield-microscopy 
system as it permitted the acquisition of volume limited optical sections through 
the cell and media.  This is perfect for the situations where the fluorescent 
probe gave high background fluorescence. Excitation (637 nm) and emission 
(>665 nm) values for the probe analysis were the optimal conditions for DRAQ5 
analysis. These data sets were then processed and assembled into a maximum 
projection image that represented all optical sections. The system enables both 
2D and 3D images to be generated encoding multiple parameters such as the 
fluorescent intensity, which were later analysed using either the supplied 
software (Bio-Rad) or exported into alternative programs such as the 
MetaMorph program for encoding or Adobe Photoshop for presentation.  
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V.2.5.6 Quantitation of confocal images using MetaMorph software 
All images were analysed using the MetaMorph software. Images were 
thresholded to remove background fluorescence, once set, the level of 
background threshold was maintained throughout the experiment. Fluorescence 
intensity was acquired in the nuclear area (pixels) and divided to the 
fluorescence intensity acquired in the cytoplasm. Results were sorted as 
nuclear against cytoplasm ratio in an Excel template sheet and plotted as 
histograms. 
 
V.2.5.7 Time-lapse imaging 
Time-lapse microscopy was used to monitor cells growing under normal culture 
conditions and also following treatment with various agents over a given time 
period, to monitor their morphological appearance and also to measure their 
mitotic properties. 
U-2 OS cell growth rates and plating densities were measured by plating serial 
cell densities on 24 well plates (refers to section V.2.4). Static phase contrast 
images were recorded for 48 h on a microscope mounted CCD camera (Nikon 
Eclipse TS120). Immediately following treatment (unless otherwise stated) cells 
set up in 24 well plates, were placed onto the time-lapse microscope (Zeiss 
Axiovert 200). The microscope and staging area of this microscope we 
enclosed in a transparent incubation chamber which maintained cell culture 
conditions of 37ºC at 5% CO2 (see Figure 5.6). Humidity was maintained by 
injecting CO2 through distilled water inside the 24 well plates.  
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_______________________________________________________________ 
Figure 5.6 Typical time-lapse setup for 6 well plates analysis. Example of a time-lapse 
microscope incorporating a surround incubator, image adapted from 
http://www.irp.oist.jp/g0/equipment.php. Cells were seeded in 6 well plates, with corresponding 
control and treated cells.  
 
The staging area (X, Y axis); focal plane (Z); shutter and illumination control 
were automated to permit unassisted image capture throughout the 
experiments (Prior Scientific). All images were captured as previously described 
by Errington et al. (Errington et al., 2005) and Marquez et al. (Marquez et al., 
2003). Following initial setup for region co-ordinates; interval time and duration 
the software was used to automatically cycle through the experiment. The time-
lapse microscope was set to capture images from one region per well (24 wells) 
containing colonies of cells at the correct confluency. Image capture of 
phase/contrast images was set to 5 min for cell cycle experiments. Image 
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capture was controlled through by MetaMorph software (Kinetic Imaging Ltd) 
Images from time-lapse capture were analysed using MetaMorph image 
analysis software (Universal Imaging Corp.).  
 
V.2.6 Flow cytometry 
FACS Vantage flow cytometer (Becton-Dickinson Systems) equipped with a 
Coherent Enterprise II laser (Coherent Inc.) simultaneously emitting at multiline 
UV (351–355 nm range) and 488 nm wavelength with the beams made 
noncolinear using dichroic separators. The laser power was regulated at 30 mW 
(monitored on the multiline UV output). Optics used for both systems are listed 
in Table 5.4.  
 Excitation (nm) Parameter & emission 
filter (nm) 
Aldefluor 488 FL1 530 / 30 
AAQs 488 FL3 695 LP 
DRAQ5 488 
637 
FL3 695 LP 
FL4 710 LP 
 
_______________________________________________________________ 
Table 5.4 FACS Vantage fluorescence optics specifics. LP: longpass filter. 
 
All parameters were collected using CellQuest software (Becton- Dickinson 
Systems). Forward and 90° light scatter were analyzed to exclude any cell 
debris. Unless otherwise stated data were collected for 1 x 104 cells using the 
FSC (forward scatter) parameter as the master signal.  
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V.2.6.1 Statistical analysis of functional capacity of selected AAQs 
The statistical analysis approach used for the current study was carried out 
using CellQuest software (Becton-Dickinson Systems). The Kolmogorov-
Smirnov (K-S) two-sample test was performed to determine if two overlaid 
histograms came from different populations (Young, 1977). The calculation 
computed the summation of the curves and obtained the greatest difference 
between the summation curves. The statistics, shown on Table 5.5, were 
reported for the portion of the histogram used in the analysis (1000 events). 
D/s(n)       Index of similarity for the two curves. If D/s(n) =0, the curves are identical 
D The K-S statistic or the greatest difference between the two curves 
P Value Probability of D being as large as it is, given that the two selected histograms are 
from the same population 
 
_______________________________________________________________ 
Table 5.5 K-S statistics to validate comparison between different histograms. 
 
V.2.6.2 Aldefluor assay  
The principle of Aldefluor has been extensively discussed in section I.5.6.  As 
reported in Figure 5.7, a vial of dry Aldefluor was solubilised in 25 µL of DMSO 
and incubated for 1 min at room temperature. After addition of one volume of 2 
M HCl, the mixture was incubated for 15 min at room temperature and, 
subsequently, 360 µL of Aldefluor buffer was added to quench the reaction. 
A549 cells were harvested and live cell number was calculated as already 
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reported on section V.2.3. 1x 106 cells were resuspended on 1 mL of Aldefluor 
buffer or cell media, according to the experiment. Recommended amount of 
DEAB solution (in 95% ethanol) was added to the “control” tube. Subsequently, 
activated Aldefluor solution (5 µl per mL of sample) was added to the “test” tube 
and immediately after mixing 0.5 mL of the mixture were transferred to the 
DEAB “control” tube. Samples were incubated at 37°C for 30 and 60 min, 30 
and 45 min respectively, before analysis. After incubation, cells were 
centrifuged at 250 g for 5 min and cell pellet was resuspended either in 
Aldefluor buffer or cell media and kept on ice.  Flow cytometry analysis was 
performed as reported on section V.2.5.7 set up and data acquisition followed 
the manufacturer recommendations (StemCell Technologies). 
 
_______________________________________________________________ 
Figure 5.7 Activation methodology for Aldefluor kit. Figure adapted from StemCell Technologies 
protocol. 
V.3 Results 
Chapter V                                                                                                   - 164 - 
_______________________________________________________________________ 
 
 
V.3.1 UV–Vis spectral studies 
UV–Vis absorbance and emission spectra were determined for LC- and HA- 
libraries of novel AAQs in PBS and HEPES buffer at pH 7.4. In this section only 
spectra in PBS are reported, but Supplementary Information V.5.A (see end of 
this chapter) refers to absorbance values summary in PBS and HEPES. 
As already presented in section IV.3.2, the tested probes presented three key-
sites for chemical modifications playing a role in absorbance-fluorescence 
properties (see Figure 5.8). 
 
_______________________________________________________________ 
Figure 5.8 Structural diversities in LC-AAQ probes. The coloured panels show the key-sites 
for chemical modifications. Blue box represents DRAQ5-like side-chain, added in the non-
symmetrical derivatives. These three modification points have a significant relevance on DNA 
binding and cytotoxic effect (see Chapter IV). 
 
As shown in Figure 5.9, the absorbance spectra of the LC-103 compound, a 
symmetrical derivative containing a carbon sidechain and no OH-groups in 5,8-
positions, gave maxima at 610 and 660 nm. Its congener LC-055, OH-
substituted in 5,8-positions (5,8-OH), showed a single absorbance peak at 585 
nm and a slight reduction on intensity was detected, due to OH insertion. 
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Interestingly, as reported for LC-110, addition of DRAQ5-like sidechain (see 
Figure 5.8, blue box) translated into increased peak intensity, compared to the 
symmetrical LC-103. Moreover, LC-110 absorption spectrum was observed to 
shift slightly to shorter wavelength, with maxima occurring at 586 and 630 nm. 
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Figure 5.9 Absorbance spectra analysis of LC-103, LC-055 and LC-110 derivatives. LC-
103 (black line) with LC-055 (dotted grey line, left plot) and LC-110 (dotted grey line, right plot) 
[all plots are normalised to DRAQ5 peak absorbance]. The red dotted line represents an 
arbitrary threshold for comparing peak intensity across the panels. 
 
Chemical insertion of an amide bond within the carbon sidechain (see Figure 
5.8, red box) translated into an increased absorbance as reported for the 
symmetrical LC-106 (containing no 5,8-OH) with maxima at 586 and 630 nm. 
As shown in Figure 5.10, insertion of DRAQ5-like sidechain in non-symmetrical 
LC-112 led into loss of peak intensity, however, no peak shift was observed. 
Differently, symmetrical LC-108 and non-symmetrical LC-111 containing both 
5,8-OH, had very similar spectral profile. Dramatic loss in peak intensity was 
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recorded in LC-108, compared to LC-106, its derivative without OH, remarking 
once again the role of OH in reducing the intensity of the peak. 
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_______________________________________________________________ 
Figure 5.10 Absorbance spectra analysis of LC-106, LC-112, LC-108 and LC-111. LC-106 
(black line, left plot) with LC-112 (dotted grey line, left plot) and LC-108 (black line, right plot) 
with LC-112 (dotted grey line, right plot) normalised to DRAQ5 maximum absorbance. The red 
dotted line represents an arbitrary threshold for evaluating peak intensity. 
 
Analysis of LC-111 (5,8-OH) and LC-112 (no 5,8-OH) in Figure 5.11 (top left) 
showed a red shifted spectra on LC-112. Furthermore, the absorbance ratio at 
peaks (see Supplementary Information V.A.1 for Abs1/Abs2 values) was >1 in 
LC-111, OH-substituted, and <1 in LC-112, no-OH substituted, suggesting a 
key role of this group on determining the spectral shape. Same spectral 
behaviour was reported in the derivatives containing reverse amide bond within 
the side chain skeleton. As reported in Figure 5.11 (top right), LC-114 (no 5,8-
OH) spectra was red shifted compared to LC-113 (5,8-OH) and peak ratio was 
>1 in LC-114 and <1 in LC-113.  
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_______________________________________________________________ 
Figure 5.11 Absorbance spectra analysis of LC-111, LC-112, LC-113 and LC-114. Left 
plots: absorbance spectra of LC-111 (black line) with LC-112 or LC-114 (dotted grey line). Right 
plots: absorbance spectra of LC-113 (black line) with LC-114 or LC-112 (dotted grey line). Plots 
are normalised to DRAQ5 maximum absorbance. Red dotted line represents an arbitrary 
threshold for evaluating peak intensity. 
 
Other interesting observation was the increased absorbance in LC-113 and 114 
compared to LC-111 and 112, suggesting that reverse amide bond substitution 
had a positive effect on the peak intensity (see Figure 5.11 bottom plots). 
However, no spectral shift was related to this structural variation. Thus overall 
for the LC compounds the rules of absorbance of the chromophore were 
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addition of DRAQ5-like sidechain, together with addition of the amide bond 
within the second sidechain. 
 
 
_______________________________________________________________ 
Figure 5.12 Structural diversities in HA-AAQ probes. The coloured panels show the key-sites 
for chemical modifications.  
 
Diverse structural modifications characterised HA-AAQs as reported in Figure 
5.12. Investigation of the symmetrical HA-AAQs established HA-218 as a 
greater absorber compared to its counterparts (see Figure 5.13).   
Indeed, substitution on the secondary amine of the sidechain with a methyl- 
(HA-222) or a benzyl- (HA-236) led into loss of peak intensity and shape. 
Moreover, no remarkable spectral differences were achieved on HA-252, 
containing a secondary amine directly attached to the chromophore and non-
symmetrical structure. 
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_______________________________________________________________ 
Figure 5.13 Absorbance spectra analysis of HA-AAQs. Fluorescence spectra of HA-218 and 
its derivatives normalised to DRAQ5 maximum absorbance. HA-218 spectrum is reported in 
black on the top left plot and with a dotted grey line in the other plots. Red dotted line represents 
an arbitrary threshold for evaluating peak intensity. 
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V.3.2 Fluorescence spectral studies 
Emission spectra were determined for LC- and HA- libraries of novel AAQs in 
PBS and HEPES buffer at pH 7.4, but only spectra in PBS are reported in this 
section. For fluorescence values summary in PBS and HEPES refers to 
Supplementary Information V.5.A. Fluorescence emission were obtained at 540 
nm and at the peak 1 absorbance value (see dotted lines on the plots) for each 
molecule. 
As observed in Figure 5.14, symmetrical LC-AAQs containing a carbon 
sidechain were very weak fluorophores. LC-055, containing 5,8-OH 
modification, revealed an enhanced fluorescence profile compared to its 
congener LC-103. Interestingly, the insertion of DRAQ5-like moiety on LC-110 
dramatically improved the absorbance and fluorescence properties of the 
fluorophore. However, LC-110 had an incomplete spectrum above 710 nm. 
Insertion of amide bond in the sidechain is showed on Figure 5.15. Spectral 
analysis of non-symmetrical LC-112 and symmetrical LC-106 showed similar 
fluorescence intensity, revealing no difference in fluorescence by DRAQ5-like 
sidechain insertion.  
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_______________________________________________________________ 
Figure 5.14 Fluorescence spectra of carbon chain substituted LC-AAQs. Compounds were 
excited at 540 nm (red line) and at excitation peak 1 (blue line) normalised to peak value. The 
excitation wavelengths are represented by red (540) and blue (peak1, PK1) dotted line. Grey 
line represents the given absorbance spectra. 
 
Signal was maintained either at 540 or at peak excitation. Same comparison 
between LC-111 and LC-108, respectively non-symmetrical and symmetrical 
AAQ-derivatives, but containing 5,8-OH, showed a reduced fluorescence on 
LC-108 at 540 nm, compared to LC-111.  
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Figure 5.15 Fluorescence spectra of LC-AAQs containing an amide bond in the 
sidechain. Compounds were excited at 540 nm (red line) and at excitation peak 1 (blue line) 
normalised to peak value. The excitation wavelengths are represented by red (540) and blue 
(peak1, PK1) dotted line. Grey line represents the absorbance spectra. 
 
Moreover, 5,8-OH substitution in LC-112 and LC-108 translated into an 
incomplete fluorescence emission above 710 nm. Non-symmetrical LC-AAQs 
(see Figure 5.16) containing amide and reverse amide bond in the sidechain 
showed a good profile on fluorescence emission. 
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Figure 5.16 Fluorescence spectra of non-symmetrical LC-AAQs containing amide and 
reverse amide bond in the sidechain. Compounds were excited at 540 nm (red line) and at 
excitation peak 1 (blue line) normalised to peak value. The excitation wavelengths are 
represented by red (540) and blue (peak1, PK1) dotted line. Grey line represents the 
absorbance spectra. 
 
However, 5,8-OH substitution in LC-111 and LC-114 gave incomplete emission 
spectra above 710 nm and a noisier profile at 540 nm compared to the no 5,8-
substituted LC-112 and LC-113. Ultimately, symmetrical HA-AAQs fluorescence 
emission analysis revealed very different spectral profile, depending on the 
degree of substitution on the secondary amine (see Figure 5.12 for structural 
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modifications). HA-218 revealed the brightest fluorescence signal compared to 
its derivatives (see Figure 5.17).  
 
 
_______________________________________________________________ 
Figure 5.17 Fluorescence spectra of HA-AAQs containing a secondary amine on the 
sidechain. Compounds were excited at 540 nm (red line) and at excitation peak 1 (blue line) 
normalised to peak value. The excitation wavelength is represented by red (540) and blue 
(peak1, PK1) dotted line. Grey line represents the absorbance spectra. 
 
Indeed, insertion of methyl group on the sidechain skeleton led to loss 
absorption and consequently to a very little fluorescence, whereas benzyl group 
addition led to no fluorescence. Non-symmetrical HA-252, containing a 
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secondary amine on the sidechain directly linked to the chromophore, 
demonstrated not enhanced fluorescence properties compared to HA-218. 
 
V.3.3 Screening of AAQs labelling in fixed U-2 OS cells  
Wide-field fluorescence microscopy was used to evaluate the cell labelling in 
fixed U-2 OS cell model, this essentially evaluated the ability of the fluorescent 
agent to label cellular compartments without active uptake or efflux prohibiting 
delivery into the given cells. First image collection was performed after 1 h of 
exposure to probes in PBS, as reported in Supplementary Information V.B.1 at 
the end of the chapter. The structural counterparts LC-055, LC-103 and LC-110, 
featuring a carbon sidechain, showed diverse staining when put into cells. LC-
055 gave a very dim cytoplasmic fluorescence, whereas LC-103 and LC-110, 
both not containing 5,8-OH substitution, had a diffuse cytoplasmic staining, with 
some perinuclear and nucleoli labelling. Moreover, very bright background was 
observed in LC-110 compared to LC-103. 
The second group of LC-derivatives, with amide functionality inserted in the side 
chain scaffold, included LC-106, LC-108 (symmetrical) and LC-111, LC-112 
(non-symmetrical). Both LC-106 and LC-108 revealed high background 
fluorescence and very little contrast; LC-108 showed some precipitation, as little 
dark spots. The non symmetric derivatives LC-111 and LC-112, containing a 
DRAQ5-like sidechain, showed heterogeneity in cytoplasmic staining and 
positive spots in the nuclei, probably due to DNA binding. LC-112 had better 
contrast than LC-111. Moreover, LC-113 and LC-114, containing the reverse 
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amide feature on the sidechain, showed very high background fluorescence, 
especially in LC-113, with cytoplasmic staining and heterogeneity on labelling of 
mitotic figures. 
Analysis of the HA-AAQ derivatives reported a very bright fluorescence on HA-
218 with cytoplasmic staining, good object recognition, and some heterogeneity 
on nuclear staining. On the other hand, HA-222 and HA-252 had a perinuclear 
staining and the majority of the cells had no DNA label, whereas HA-236 had 
gave a very dim staining almost no detectable also with longer exposure time. 
After 72 h of incubation with the probes, images were recollected to assess the 
fluorescence stability in PBS and the degree of labelling over time, as reported 
in Supplementary Information V.B.2. LC-103 and LC-110 revealed loss of 
fluorescence, but some labelling was still detectable, whereas LC-055, LC-106 
and LC-108 showed no detectable fluorescence.  Addition of DRAQ5-like 
sidechain rescued LC-111, LC-112 and LC-114 cytoplasmic signal, 
characterised by diffused background fluorescence. However, enhanced 
nuclear staining was detected in LC-113 compared to 1 h labelling and the high 
background fluorescence was maintained. HA-AAQs had stable fluorescence, 
with loss of signal for HA-218, but perinuclear and cytoplasmic labelling was 
revealed for the other derivatives. Better staining was observed in HA-236 
compared to 1 h incubation, whereas HA-222 and HA-252 had the same 
staining intensity detected after 1 h. 
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V.3.4 Screening of AAQs loading in U-2 OS live cells  
In order to understand whether AAQs were subjected to cellular uptake and 
possible compartmentalisation, cells were initially incubated with the respective 
probes for 30 min. All images were collected at the same exposure time (30 ms) 
to ensure good comparison; these images are shown in Supplementary 
Information V.B.3.  
The counterparts LC-055, LC-103 and LC-110 showed high background and 
low contrast. In particular, LC-055 had some precipitation, probably due to low 
solubility in media, whereas LC-103 and LC-110 had cytoplasmic staining with 
labelling of some mitotic figures and bright perinuclei.  LC-106 and LC-108 had 
no live cell access with bright background fluorescence. LC-108 presented 
some precipitate in solution. Counterparts with DRAQ5-like sidechain, LC-111 
and LC-112 had a similar staining pattern, with heterogeneous staining in 
nucleus and cytoplasm and background fluorescence, however LC-111 had 
brighter signal than LC-112. Comparing LC-113 and LC-114 analogues, both 
revealed high background and nuclear staining, but LC-114 had some 
precipitate. The HA-derivatives showed less cell loading and predominant 
cytoplasmic staining compared to LC-AAQs. HA-222 had really bright 
background fluorescence, no observed for the other HA-probes. 
After 18 h the images were recollected to determine whether cell viability was 
affected by probe loading (bright-field microscopy) and to measure penetration 
properties over time. The screenings at 18 h are reported in Supplementary 
Information V.B.4-5.  
Chapter V                                                                                                   - 178 - 
_______________________________________________________________________ 
 
 
Image collection in transmission showed healthy and flat cells after exposure to 
LC-055 and LC-103, however no fluorescence staining was detected on LC-055 
but a relative good load was maintained on LC-103. Cells exposed to LC-110 
were very rounded and dense, suggesting loss of viability, but stable 
cytoplasmic staining was still detectable. LC-106 and LC-108 did not affect cell 
viability because of no live cell penetration, indeed no loading was observed 
over time. After 18 h staining with LC-111, LC-112, LC-113 and LC-114 cells 
were no viable and therefore retain of fluorescence was really low. Complete 
loss was observed in LC-112 together with HA-222, HA-236 and HA-252, as 
consequence of cell death. HA-218 reported intracellular accumulation and 
stacking over time, however cells appeared no viable. 
 
V.3.5 Screening of AAQs loading in A549 live cells  
A549 cell line was used as a different cell model to understand whether 
presence of SP cell fraction led heterogeneity on cell penetration and to a 
consequent variation of the probe loading and localisation.  
Cells were incubated for 30 min with the respective probe and then images 
were collected at 30 ms exposure time (see Supplementary Information V.B.6). 
LC-055, LC-106 and LC-108 showed no cell penetration and no intracellular 
fluorescence signal was detected. LC-103 and LC-110 had high background 
and heterogeneous cytoplasmic staining. The LC-111, LC-112 and LC-113 
analogues revealed very bright background fluorescence, whereas LC-114 had 
a greater contrast and diffuse cellular staining. The HA-derivatives showed 
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heterogeneity on cytoplasmic load on HA-218, with bright fluorescence signal 
and staining of mitotic figures, whereas HA-222 had perinuclear accumulation 
and much dimmer signal intensity. HA-236 had no cell loading and very low 
loading was detected on HA-252. 
After 18 h of continuous incubation with the probes A549 were screened again 
to ask for cellular viability and retain of fluorescence signal, as reported in 
Supplementary Information V.B.7-8.  Cells, incubated with LC-055, LC-106 and 
LC-108, were healthy and monolayered as no uptake was shown; furthermore, 
LC-108 showed lots of precipitation. LC-103 exposure gave healthy and flat 
cells retaining perinuclear fluorescence over time, whereas cells exposed to LC-
110 were almost all dead but fluorescent signal was still retained. LC-111, LC-
112, LC-113 and LC-114 produced high toxicity and therefore very rounded and 
granular cells; however perinuclear accumulation was maintained on LC-112 
and LC-113, whereas most of the fluorescence signal was not retained in LC-
111 and LC-114. HA-236 exposure showed healthy cells as the dye was no 
loaded, whereas high cytotoxicity was observed on the HA-218, HA-222 and 
HA-252 with retain of perinuclear fluorescence. 
 
V.3.6 Confocal laser microscopy analysis in the U-2 OS cell line 
Confocal laser scanning microscopy was used to collect novel probe signals 
after 30 min incubation at different z depth and eliminating the solution 
background. Nucleus/cytoplasm ratio was calculated to quantify the localisation 
of the probe per cell.  
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As reported in Figure 5.18, confocality allowed detection of low levels of probe 
in the perinuclear region, with probable overload in Golgi body and large 
vesicles for LC-055 and LC-103.  The accumulation area appeared similarly to 
the MTOC (microtubule organising centre), however LC110, containing DRAQ5-
like sidechain, gave additional nuclear signal.  
Analysis of the counterparts LC-106 and LC-108 confirmed a very low uptake 
and intense background fluorescence, as already observed in the live cell 
screening, whereas its derivatives containing a DRAQ5-like sidechain had a 
greater nuclear localisation, with some vesicular perinuclear staining (see 
Figure 5.19). As reported on the nucleus/cytoplasm graph, the localisation was 
predominantly nuclear and this caused high cellular toxicity, as already shown 
on the 18 h incubation screening (see Supplementary Information V.B.4-5). 
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Figure 5.18 LC-055, LC-103 and LC-110 fluorescence analysis via direct confocal 
imaging. Analysis was performed using excitation (637 nm) and emission (>615 nm) 
wavelength. Plot reports the nucleus/cytoplasm index to determine DNA binding in live cells. 
Calibration bar represents 10 µm. 
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Figure 5.19 LC-112, LC-106, LC-111 and LC-108 fluorescence analysis via direct confocal 
imaging. Analysis was performed using excitation (637 nm) and emission (>615 nm) 
wavelength. Plot reports the nucleus/cytoplasm index to determine DNA binding in live cells. 
Calibration bar represents 10 µm. 
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As reported in Figure 5.20, LC-derivatives containing amide bond on the 
sidechain skeleton revealed a strong nuclear uptake and perinuclear staining, 
with possible ER accumulation. A whole cell staining was a specific feature of 
LC-113 and LC-112, whereas LC-114 was mainly loaded in the nuclear 
compartment. Black spots were detected on nuclei after LC-111 staining, due to 
probe accumulation.  
The HA-series, as shown in Figure 5.21, appeared to have a predominant 
cytoplasmic localisation. However, HA-218 had a nuclear signal and a reticular 
perinuclear pattern, probably with ER compartimentalisation. As already 
observed for LC-055 and LC-103, HA222 and HA236 revealed large vesicular 
accumulation and no nuclear staining. HA218 had a characteristic quenching of 
signal due to accumulation of the probe, as demonstrated by detection of black 
perinuclear spots in transmission.  
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Figure 5.20 LC-111, LC-112, LC-113 and LC-114 fluorescence analysis via direct confocal 
imaging. Analysis was performed using excitation (637 nm) and emission (>615 nm) 
wavelength. Plot reports the nucleus/cytoplasm index to determine DNA binding in live cells. 
Calibration bar represents 10 µm. 
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Figure 5.21 HA-AAQs fluorescence analysis via direct confocal imaging. Analysis was 
performed using excitation (637 nm) and emission (>615 nm) wavelength. Plot reports the 
nucleus/cytoplasm index to determine DNA binding in live cells. HA-218 in transmission reports 
the same field analysed in fluorescence, black spots represent probe accumulation. Calibration 
bar represents 10 µm. 
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V.3.7 Uptake of AAQs in A549 cell model and ABCG2-dependent efflux  
A549 uptake profile was investigated for selected AAQs and cells were 
incubated for 30 min with 20 µM of the selected probe before performing flow 
cytometry detection of the single cell signal.  
 
 
* 50% of total cell number 
_______________________________________________________________ 
Figure 5.22 Flow cytometry setup for LC- and HA-AAQs analysis. Dynamic range was set 
on DRAQ5 (red curve) parameters. The inset represents DRAQ5 dot plot distribution, used as 
positive control. Light blue line represents empty cells and dark blue line represents LC-111 
uptake, taken as AAQ exemplar. The dotted back line is the median of the distribution and 
represents 50% of the total cell population.  
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As shown in Figure 5.22, DRAQ5 was used as to set the dynamic range and for 
flow cytometry detection setup for anthraquinone-based fluorophores (FL-3, see 
section V.2.5.7 for parameters details). However, DRAQ5 and AAQs distribution 
plot were not comparable because of cellular DNA content-related histogram of 
DRAQ5 (Smith et al., 2000). Forward- and side-scattered signal was collected 
for 10,000 cells and were analyzed to exclude any cell debris. Analysis was 
conducted using the viable and intact fraction of cells, corresponding to ~95% of 
the total amount under investigation.  
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_______________________________________________________________ 
Figure 5.23 Uptake of selected AAQs on A549 cell line by flow cytometry analysis. 
Histograms represent the geometric mean of fluorescence intensity ± SD. Dynamic range was 
set on DRAQ5 parameters.  
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As shown in Figure 5.23, the population cellular uptake was obtained for all the 
selected probes with a median fluorescence between 36.93 and 72.93 (see 
Supplementary Information V.C.1 for detailed analysis). Uptake above 
background comparison revealed a median fluorescence for empty cells of 
19.27 versus an average of 50 for the cells pre-incubated with the probe. Within 
selected LC-derivatives, LC-111 showed a lower uptake than its derivatives LC-
110 and LC-114 (median fluorescence of 36 vs. 50-70). The low loader sub-
fraction of cells was explored and heterogeneity on the probe loading was 
reported (see 25%ile data on Supplementary Information V.C.1) probably 
dependent on the size of the cells. Moreover, the scatter properties before/after 
exposure to the AAQ probes were maintained even if highly dense particles 
were introduced to the system.  
As reported in Figure 5.24, functional profiling of ABCG2 activity was performed 
in ABCG2-expressing A549 cell line using flow cytometry detection of the 
uptake/exclusion of the selected AAQs with or without the presence of the 
ABCG2 inhibitor, fumitremorgin C (FTC, Sigma). During this time the SP 
experiments were performed with Hoechst 33342 that showed significant shifts 
in uptake with these cells and FTC batch. In the tested compounds, uptake of 
LC-110 was higher in cells without FTC compared to the FTC-treated cells 
(median fluorescence of 72.01 vs. 55.95), revealing that the uptake was less 
sensitive to FTC addition, suggesting a potential non-ABCG2 mediated efflux. 
LC-111, instead, had a better cell loading in cells treated with FTC compared to 
the non-treated cells (median fluorescence of 36.93 vs. 41.32) consistent with 
blocking the ABCG2-dependent exclusion. K-S statistical analysis was used to 
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validate the dissimilarity between the paired histograms (refers to V.2.5.7 for 
details).  
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Figure 5.24 AAQ uptake profiles in the A549 cell line +/- FTC pre-treatment. The cells were 
pre-incubated for 1 h with 10 µM FTC or DMSO, before incubation with 20 µM of the respective 
AAQ (30 min). The results represent an average of three replicates ± SD. P values represent 
the significance of the difference between the paired histograms. 
 
V.3.8 Hydrolysis effect on cellular uptake of LC-AAQ derivatives 
Flow cytometry analysis was performed to evaluate the effect of pre-treatment 
with HCl to generate an active aldehyde (refers to section III.3.1 for further 
details on the chemical hydrolysis) on the cell uptake properties. A549 cells 
Chapter V                                                                                                   - 190 - 
_______________________________________________________________________ 
 
 
were incubated for 30 min with selected parental/hydrolysed LC-AAQ (20 µM) 
prior to analysis. Furthermore, the rate of uptake was tested in A549 cell media 
(see section V.2.3 for cell media details) and in Aldefluor buffer, containing the 
pan MDR-blocker verapamil (Pearce and Bonnet, 2007), to evaluate the effect 
in uptake with/without the Aldefluor assay system. Analysis was conducted in 
the viable subset of cells, corresponding to ~95% of the total amount under 
investigation.    
As reported in Figure 5.25, no difference in cellular uptake was observed for the 
parental AAQs with or without addition of verapamil. However, there did seem 
to be some enhanced efflux of hydrolysed AAQs (HAAQs) in the absence of the 
ABC pump inhibitor verapamil. Hydrolysed LC-110 and LC-111 showed a 
statistically significant greater uptake in Aldefluor buffer than in media (median 
fluorescence of 102.97 vs. 64.9 for LC-110 and 51.51 vs. 61.44 for LC-111) 
whereas LC-114 had similar uptake level in both conditions (refer to 
Supplementary Informations V.C.2 for detailed analysis).  
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Figure 5.25 Parental/hydrolysed AAQ uptake profiles in the A549 cell line in media vs. 
Aldefluor buffer. Aldefluor buffer contained verapamil vs. cell media. The cells were incubated 
with 20 µM of the respective AAQ/HAAQs (30 min) before analysis. The results represent an 
average of three replicates ± SD. P values represent the significance of the difference between 
the paired histograms. 
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V.3.9 ALDH Activity by Aldefluor flow cytometry assay in A549 cells 
The amount of Aldefluor positive cells (%) was determined by placing the gate 
in the region based on the shift of fluorescent cells seen after DEAB (inhibitor of 
ALDH activity) treatment.  As shown in Figure 5.26A-B, high ALDH activity in 
A549 cells was observed after 30 min of incubation with Aldefluor before 
analysis (10.71% in Figure 5.26A, 5.99% in Figure 5.26B).  
Fluorescence shifting with DEAB addition was maintained and appeared to be 
more prominent at 30 min (0.47%), compared to 45 and 60 min incubation with 
Aldefluor reagent. Indeed, shoulder on the histogram without DEAB started 
disappearing after 45 min (6.4%) and it was almost cleared after 60 min (2.77%) 
of exposure to Aldefluor.  
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Figure 5.26 Histograms of Aldefluor uptake +/- DEAB. Plots represents uptake analysis with 
(grey curves) or without DEAB (black curves) for A549 cells, after incubation with the reagent for 
30 and 45 min (A) and 30 and 60 min (B) before flow cytometry analysis. 
 
The low activity was considered as an artefact of very high ALDH expression 
level in A549, as already reported by Moreb et al. (Moreb et al., 2007). Same 
experiment was performed using cell media instead of Aldefluor buffer to 
assess whether the presence of verapamil was crucial for Aldefluor retention 
within the cells and no fluorescence was detected. 
 
 
 
Chapter V                                                                                                   - 194 - 
_______________________________________________________________________ 
 
 
V.4 Discussion 
In summary, novel AAQs have been explored as functional probes in order to 
investigate potential targets within selected cell models.  Here, the study 
focused on determining the structural related rules of the AAQ library previously 
developed to their respective absorbance/fluorescence properties, the labelling 
properties in permeabilised/live cellular models, the probe loading in two 
different cell models with/without active pump, the possible 
compartimentalisation in specific subcellular locations and the single cell 
uptake.   
Similar studies, conducted on the development of DRAQ5 as functional assay 
(Smith et al., 2000), revealed that an anthraquinone-based fluorophore had a 
characteristic absorbance spectrum with a double peak shape and peak ratio 
(Abs1/Abs2>1 in OH-derivatives and Abs1/Abs2<1 in H-derivatives) depending 
on the intramolecular hydrogen bonding of the 5,8- OH substitution (Marasinghe 
and Gillispie, 1989). This chapter elucidated how minimal variations on the 
molecular skeleton were translated into a consistent alteration of the 
absorbance profile, as a red-shift due to the 5,8- OH insertion, probably 
depending on the strength of the hydrogen bond between the hydroxyl groups 
and the carbonyl groups of AAQs and the solvent molecules (Inoue et al., 1982; 
Yoshida and Takabayashi, 1968). Interestingly, increased peak intensity was 
obtained by addition of DRAQ5-like features or amide bond within the 
sidechain, whereas 5,8- OH substitution reduced the absorbance intensity. 
These features were crucial to obtain a significant fluorescent emission. 
Spectral studies on DRAQ5 acknowledged this probe as a “weak” far-red 
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fluorophore with a low quantum yield (Smith et al., 1999) and comparison with 
the novel AAQs showed comparable fluorescent emission profile between 650 
and >800 nm when excited at the corresponding absorbance peak. However, 
comparison of the emission spectra revealed that LC-106, LC-112 and LC-113 
probes had a quite intense fluorescent signal compared to the other derivatives. 
Same analysis on HA-AAQ family, containing diverse substitution patterns on 
the secondary amine of the sidechain, revealed an intense absorbance 
spectrum only for HA-218, however the fluorescence spectra were quite noisy 
for all the HA-AAQ counterparts, suggesting that HA-AAQs were less emitting 
compared to the LC-AAQs. No significant spectral differences were observed by 
using HEPES as a working buffer instead of PBS, confirming no effect of the 
interaction with phosphates on the AAQ stability (Jeon et al., 2004). 
Furthermore, fluorescence measurement of the tested AAQs after 15 months in 
DMSO solution showed the same intensity of the signal, suggesting a stable 
shelflife (data not shown; personal communication Sally Chappell) and therefore 
a good potential as fluorophore. 
The chapter reported the screening of the AAQs ability to stain fixed and thus 
permeabilised cells and to show affinity for a specific cellular compartment at 
different timepoints. DRAQ5 acted as the benchmark agent. We found that 
AAQs containing a carbon sidechain produced a localised cytoplasmic staining, 
and, as elucidated in the spectral studies, greater cellular signal was observed 
in LC-110 with addition of DRAQ5-like sidechain, revealing once again the 
“rescuer” role of this modification for the fluorescence signal. These data 
confirmed the poor affinity for the CT-DNA showed on DNA binding analysis 
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(Rahban et al., 2010), suggesting a preferred perinuclear 
compartimentalisation. Moreover, insertion of an amide bond in the symmetrical 
derivatives produced heterogeneity in the staining and high background, i.e. in 
LC-106. The high background could have been removed by washing out the 
dye after incubation; however potential loss of fluorescence signal could be a 
side effect of a washing step. Combination of amide bond in the sidechain and 
DRAQ5-like modification (i.e. LC-111 or LC-112) showed a probe that located to 
the nucleus while maintaining some perinuclear labelling, with heterogeneity on 
cell compartimentalisation. The structural modifications on HA-AAQs derivatives 
led to a cytoplasmic labelling; however, DNA-binding data showed that HA-
AAQs had a greater affinity for the CT-DNA than some nuclear binders LC-
AAQs, suggesting a substantial difference in affinity between highly purified CT-
DNA and chromosomal DNA, associated with several different positively 
charged proteins (histones) (Faulds et al., 1991), and therefore less accessible 
to the HA-AAQ probes binding. This study demonstrated a stable fluorescence 
over time for most of the probes tested, however solubility issues occurred with 
LC-108 and precipitation of unbound dye increased after 72 h incubation in 
PBS.  
It has been well established that observing a biological event as it unfolds in the 
living cell offers an unique insight into the nature of the phenomenon under 
study (Tsien, 1998). We found that in live U-2 OS and A549 cell models to 
evaluate cell penetration and potential loading levels depending on the 
expression of membrane pumps. In general, as reported in Figure 5.27, several 
of the fluorescent probes were successful in the labelling of cellular 
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compartments and this  could vary with our chosen two cell-types (Chen H, 
2010). U-2 OS cell line uptake revealed a complete exclusion from the cells of 
some probes, which consequently were not taken forward for further live cell 
imaging studies, as LC-106 and LC-108. 
 
 
_______________________________________________________________ 
Figure 5.27 Overview of the general principle for live cell imaging. Probes are constructed 
to label specific targets; the overall loading and localisation of fluorescence can be detected 
using fluorescence microscopy (Chen H, 2010). 
 
Less background fluorescence was found in A549 cell line, suggesting that the 
high expression of membrane transporter (Scharenberg et al., 2002) was 
helping the probe loading, therefore the cell model needed to be chosen 
carefully as membrane effluxers could play an important role on the final 
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biodistribution of the probe (Chen H, 2010). Intrinsic differences on cell 
morphology between the selected cell models needed to be bared in mind when 
wide-field screening was performed. Indeed, U-2 OS are typically flat cells, 
whereas A549 cells are characterised by protruding nuclei and very rounded 
shape (Hermanns et al., 2004).  
The study suggested that nuclear localisation affected cell viability after 18 h for 
LC-AAQs, as already assessed via cytotoxicity studies. Indeed exposure of 
A549 to LC-111 showed low µM IC50 value after 72 h (refers to Chapter IV) and 
in the present study it was confirmed that cell shape was affected already at 18 
h indicating an alteration on cell viability.  
We have determined the spatial-temporal cellular localisation of the probe by 
using confocal laser scanning microscopy and time lapse microscopy and we 
quantified the ratio of the mean nucleus/cytoplasmic fluorescence ratio to rank 
the compounds with the localisation. LC-111,112,113 and 114 reported a 
nuclear affinity, suggesting a DNA affinity, together with some perinuclear 
staining, which reflected the high cytotoxic effect on cell viability assessment.  
Different affinity has been found in live cell tracking of HA-AAQ derivatives; 
these molecules confirmed the same cytoplasmic affinity shown in fixed cells 
and a reticular labelling, suggested Golgi compartmentalisation. Intriguingly, we 
demonstrated on HA-218 analysis how stacking of the probe after cell loading 
translated into fluorescence signal quenching and interaction with cell viability.  
Moreover, we proved how cytoplasmic and Golgi affinity of LC-110 led to 
comparably high cytotoxicity, suggesting once again that also cytoplasmic 
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compartimentalisation could be crucial for cell viability. Using time-lapse 
microscopy, (Dailey M.E. , 2006), we analysed the probe redistribution in U-2 
OS cell line after mitotic event at 48 h and we confirmed a redistribution and 
probe segregation to the two daughter cells, even if the probe was highly 
segregated in subcellular organelle, possibly in endoplasmic reticulum, Golgi or 
endosomes (Bergeland et al., 2001).  Observation of the cell shape obtained 
using time-lapse microscopy, confirmed the data obtained in section IV.3.2, 
regarding the AAQs effect on cell health status.  
Interestingly, LC-103, a symmetrical derivative with carbon chains, had no 
detrimental effect on cell viability, as proved by imaging analysis, timelapse 
detection at 48 h and, already discussed, MTT assessment after 72 h (see 
Chapter IV). This probe revealed a consistent and unique accumulation in 
endoplasmic reticulum (ER), suggesting this compound as a potential candidate 
as ER-tracker.  
On the basis of the data collected on the imaging and spectral analysis, we 
selected five AAQ-derivatives characterised by bright fluorescence, good cell 
loading and unique cell localisation patterns to explore the single cell loading on 
A549 cells via flow cytometry analysis. After assessing a positive loading for the 
panel of AAQs, our studies were directed to better understanding the implication 
of ABCG2 transporters on the probe uptake, on the basis of the high affinity 
between BCG2 and anthraquinones (Doyle and Ross, 2003). Fumitremorgin C 
(FTC), a potent inhibitor of the ABCG2 transporter (Rabindran et al., 2000), 
provided a selective tool for evaluating the influence of the transporter in AAQs 
uptake. Experiment limitations were not ideal since the collection conditions 
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could have been improved to extend the dynamic range giving a more sensitive 
assay for the effect of ABCG2 inhibition. Similar or slightly increased uptake 
was demonstrated after addition of FTC, suggesting a potential ABCG2-
dependent efflux for the investigated compounds. Surprisingly, LC-110 revealed 
reduced uptake with FTC addition suggesting the potential prevailing of efflux 
mediated by different pumps. Indeed, its unique uptake profile was cleared by 
using verapamil. In this chapter we evaluate the potential to identify unique 
populations of A549 cells, possibly related to the SP subfraction, using the 
novel LC-AAQs (before/ after hydrolysis of the acetal moiety) on the basis of 
ALDH activity - by establishing a flow cytometric assay based on Aldefluor 
protocol. HA-derivatives were not considered because previous hydrolysis 
studies revealed resistance to the proposed hydrolysis conditions (refers to 
section III.2.1.2). The proposed study wanted to specifically validate the 
potential of finding an alternative assay kit and approach to quantify and/or 
separate cellular sub-populations by targeting ALDH activity. Our findings 
revealed no difference in uptake +/- verapamil, a general pump blocker (Pearce 
and Bonnet, 2007),  whereas after hydrolysis the role of the concurrent use of 
verapamil became crucial for enhancing intensity signal on LC-110 and LC-111. 
However, no significant difference was reported for LC-114 suggesting less 
affinity for the exporters for LC-114 or possibly less aldehyde formation after 
hydrolysis. Although ABCG2-driven SP functionality was not proved, here we 
demonstrate a potential substrate specificity of the tested AAQs thanks to a 
greater signal in Aldefluor-like conditions rather than normal cell media. 
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We have not yet demonstrated a specific affinity for ALDH family; however this 
study led to the characterisation of interesting novel AAQs, pointing out probe-
like features in these molecules (i.e. LC-103, LC-111 and LC-114).  
Overall this study provided a solid screening of the potential of these novel 
compounds and interesting features were reported in selected ones as high 
cellular penetration, discrete and adjustable compartimentalisation, and ability 
to maintain cell viability after loading. These molecules allowed the 
simultaneous or differential labelling of both nuclear and cytoplasmic 
compartments in live and fixed cells to clearly render the precise location of cell 
boundaries which may be beneficial for quantitative expression measurements, 
cell-cell interactions, and most recently compound in vitro toxicology testing 
(Edward, 2012).  
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Supplementary Information V.A 
AAQs UV-Vis absorbance (1) and fluorescent emission (2) values 
Peak 1 (λ1) and peak 2 (λ2) were measured. The molecules were excited at the 
measured UV-absorbance wavelength (Pk1, Pk2) and correspondent emitted 
fluorescence values were recorded (Pk1, Pk2). DRAQ5 was used as control. 
1) 
 UV-absorbance  in PBS (nm) UV-absorbance in HEPES (nm) 
- OH in 5,8 position  
Compound λ1 (nm) λ2 (nm) Abs1/Abs2 λ1 (nm) λ2 (nm) Abs1/Abs2 
LC-055 585 - NA 587 634 1.36 
LC-108 610 665 1.11 574 610 1.09 
LC-111 610 665 1.12 610 660 1.14 
LC-114 610 664 1.2 610 664 1.1 
HA-218 610 670 1.43 607 663 1.38 
HA-222 610 660 1.08 610 664 1.23 
HA-236 650 - NA 610 - NA 
HA-252 550 - 1.5 564 606 1.33 
DRAQ5 600 647 1.2 600 647 1.2 
- H in 5,8 position  
Compound λ1 (nm) λ2 (nm) Abs1/Abs2 λ1 (nm) λ2 (nm) Abs1/Abs2 
LC-103 610 660 0.98 600 650 0.95 
LC-106 586 630 0.81 585 630 0.85 
LC-110 586 630 0.92 586 630 0.94 
LC-112 584 628 0.87 583 627 0.88 
LC-113 583 627 0.92 583 628 0.90 
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2) 
 
Fluorescence Emission  (nm) in PBS 
- OH in 5,8 position 
 in PBS in HEPES 
Compound λ1 Ex 540 Ex λ1 Ex 540 Ex 
LC-055 747.5 - 740  
LC-108 684 712 726 NA 
LC-111 685 692 684 - 
LC-114 684 684 684 - 
HA-218 688 690 684 - 
HA-222 690.5 684 684 - 
HA-236 - - 680 - 
HA-252 678 690 696 - 
DRAQ5 >665  635 >665 - 
- H in 5,8 position 
 in PBS in HEPES 
Compound λ1 Ex 540 Ex λ1 Ex 540 Ex 
LC-103 - 712 - - 
LC-106 661 670 663 - 
LC-110 660 670 664 - 
LC-112 666 660 660 - 
LC-113 665.5 662 660 - 
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Supplementary Information V.B 
Screening of LC- and HA-AAQs in fixed and in live U-2 OS and A549 cell 
models 
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Supplementary Information V.C 
V.C.1 Statistical analysis of A549 uptake +/- Fumitremorgin C (FTC). Data 
were processed using FlowJo software (Tree Star). DRAQ5 was used to set the 
dynamic range and as control dye and empty cells were used to determine 
auto-fluorescence. 
 
A549 sample Median Covariance SD % ile (25) * 
Empty 19.27 31.07 31.07 16.3 
DRAQ5 192.79 35.73 35.73 162.03 
LC-110 72.01 41.06 41.06 60.2 
LC-110 + FTC 55.95 45.07 45.07 47.27 
LC-111 36.93 30.12 30.12 31.99 
LC-111 + FTC 41.32 31.48 31.48 36.03 
HA-218 54.05 35.94 35.94 46.3 
HA-218 + FTC 52.68 38.16 38.16 45.07 
HA-222 50.43 45.53 45.53 42.35 
HA-222 + FTC 50.76 52.10 52.10 42.18 
  
* Low loader cell population (representative of SP) 
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V.C.2 Statistical analysis of A549 uptake before/after hydrolysis. 
Experiments were performed in cell media vs. Aldefluor buffer. Data were 
processed using FlowJo software (Tree Star). DRAQ5 was used to set the 
dynamic range and as control dye and empty cells were used to determine 
auto-fluorescence.  
 
A549 sample Solution Median Covariance SD % ile (25) 
Empty media 15.94 31.29 31.29 13.48 
DRAQ5 media 217.4 31.61 31.61 191.27 
media 101.48 34.58 34.58 84.64 LC-110 
parental 
buffer 96.13 32.87 32.87 81.66 
media 64.9 35.28 35.28 55.56 LC-110 
hydrolysed 
buffer 102.97 31.38 31.38 86.76 
media 75.48 28.15 28.15 65.32 LC-111 
parental 
buffer 67.08 32.09 32.09 57.65 
media 51.51 33.5 33.5 44.66 LC-111 
hydrolysed 
buffer 61.44 38.88 38.88 51.25 
media 72.42 26.78 26.78 62.72 LC-114   
parental 
buffer 74.94 28.85 28.85 64.64 
media 59.33 32.6 32.6 49.93 LC-114 
hydrolysed 
buffer 57.89 35.36 35.36 48.48 
 
* Low loader cell population (representative of SP)  
  
 
 
Chapter VI 
 
Epigenetic regulation of ALDHs and 
ABC transporters 
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VI.1 Introduction and Aims 
Extensive studies have shown that aberrant methylation of CpG islands (CGIs) 
in promoter regions is associated with transcriptional inactivation of genes 
involved in all aspects of tumour development (Teodoridis et al., 2004). 
Furthermore, identification of epigenetic control in maintaining SC fate has been 
well characterised in hematopoietic and neural SCs, demonstrating that genes 
active in earlier progenitors are gradually silenced at later stages of 
development whereas other subsets of cell type-specific genes are activated 
(Lunyak and Rosenfeld, 2008). Transcription factors that are involved in 
regulating epigenetic information and particularly those that are necessary in 
reprogramming epigenetic marks in SCs are under intense study.  
However, less is known about the aberrant methylation of enzymes associated 
with drug resistance. Consequently, this study is aimed at exploring the 
expression of ALDH and ABCs, two different families of proteins that are 
connected through the metabolism and removal of xenobiotics from the 
intracellular pool such as Aldefluor and potentially also the novel anthraquinone 
probe molecules described in this thesis. Specifically, focus is on the expression 
of isoforms from the ALDH 1-3 sub-families (ALDH1A1, ALDH2, and ALDH3A1) 
and the major ATP-binding transporter proteins ABCB1 and ABCG2. In line with 
previous Chapters in this thesis, A549 and MCF7 cell lines will be examined. In 
addition, HT29 and HeLa, two other cell lines derived from different cancer 
tissue will be examined  in order to explore more broadly if the expression of 
ALDH and ABC proteins are cell-type specific and under epigenetic control.  
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A wide variety of methodologies can be applied to obtain DNA methylation data. 
The detection of this epigenetic alteration of the genome is based on the ability 
to differentiate between cytosine and 5-methylcytosine in the DNA sequence.  
There are three principal approaches to detect this difference in methylation: (1) 
the use of the chemical modification of DNA with sodium bisulfite (see Figure 
6.1), (2) digestion of DNA with either a methylation-sensitive or insensitive 
restriction enzyme, or (3) immunoprecipitation of 5-methylcytosine to distinguish 
any methylated fractions.   
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_______________________________________________________________ 
Figure 6.1 Chemical reaction of bisulfite conversion of cytosine to uracil. Step 1: 
sulfonation; Step 2: hydrolytic deamination; Step 3: alkali-desulfonation. Bisulfite conversion is 
performed under acidic conditions and preferentially deaminates cytosine in a nucleophilic 
attack whilst the methyl group on 5-methylcytosine is protecting the amino group from the 
deamination. Cytosine reacts with bisulfite, but not 5-methylcytosine. 
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Sodium bisulfite conversion relies on the differential deamination of cytosine to 
uracil without affecting 5-methylcytosine content. This conversion will produce a 
difference in DNA sequence, which depends on its original methylation status.  
Established methods using the bisulfite conversion of DNA described above 
include methylation-specific PCR (Herman et al., 1996), bisulfite sequencing 
(Frommer et al., 1992), combined bisulfite restriction analysis (COBRA) (Xiong 
and Laird, 1997) and, more recently, pyrosequencing (Ronaghi et al., 1998). 
Pyrosequencing can quantitate CpG methylation at individual sites following 
bisulfite treatment. As explained in Figure 6.2, the sequencing by synthesis 
based techniques involves the luminometric detection of pyrophosphate 
following sequential single nucleotide incorporation (Ronaghi, 2001).  
 
_______________________________________________________________ 
Figure 6.2 Schematic representation of the progress of the enzyme reaction in liquid-
phase pyrosequencing. Primed DNA template and four enzymes involved in liquid-phase 
pyrosequencing are placed in a well of a microtiter plate. The four different nucleotides are 
added stepwise and incorporation is followed using ATP sulfurylase and luciferase. The 
nucleotides are continuously degraded by nucleotide-degrading enzyme allowing addition of 
subsequent nucleotide. (d)XMP indicates one of the four nucleotides (Ronaghi, 2001). 
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Pyrosequencing allows the detection of 10 successive CpGs in a single 
sequencing reaction spanning up to 80 nucleotides (Tost and Gut, 2007). The 
main advantages of this technique over traditional sequencing methods are that 
it is a fast and an efficient quantitative method; it uses a PCR product to directly 
obtain information without the requirement of multiple sequencing reactions.  
In this study pyrosequencing technology will be used, together with quantitative 
RT-PCR gene expression profiling to understand whether there is a link 
between methylation status and gene expression of the ALDH and ABC target 
genes. Analysis of untreated samples will be compared with decitabine (DAC) 
treated samples or samples treated concurrently with DAC and TSA 
(trichostatin A) (refers to sections I.4.4-6 for epigenetic therapy details). 
Therefore, the specific aims of this study are: 
1. To investigate the methylation level of ALDH1A1, ALDH2, ALDH3A1, 
ABCB1 and ABCG2 in the four human cancer cell lines A549, MCF7, 
HeLa and HT29 before and after DAC exposure; 
2. To investigate if concurrent use of DAC and TSA alters the DNA 
methylation pattern compared with DAC alone; 
3. To investigate the gene expression of the selected ALDH and ABCs using 
qRT-PCR and to correlate findings with the methylation status;  
4. To quantify protein expression by western blotting and to establish if there 
is a connection between the methylation status of the selected genes and 
their gene and protein expression by use of DAC alone or in combination 
with TSA. 
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VI.2 Materials and Methods 
VI.2.1 Mammalian cell lines culture and drug treatments 
VI.2.1.1 Maintenance of mammalian cell lines 
Cells were obtained from the American Type Culture Collection (ATCC) and 
were grown as outlined in Table 6.1 at 37 °C, 5% CO2 at 100% humidity. Cell 
culture plastics were from Corning. Cells were kept at subconfluent levels and 
were typically passaged when 70–80% confluent. 
 
_______________________________________________________________ 
Table 6.1 Culture of mammalian cell lines. See Appendix II for cell media composition. 
 
VI.2.1.2 Mammalian cell passaging 
The old media was aspirated carefully and discarded from each 75 cm2 flask. 
The cells were washed with 10 mL Hank’s Balanced Salt solution (Sigma), 
which was then aspirated and discarded. To break down cellular attachments to 
the flask, 2 mL trypsin in EDTA (Sigma) (1:10 dilution) was added to cover all 
Cell line Origin of cell 
line 
Culture Medium Approx. frequency 
of subculture 
Dilution 
upon 
subculture 
A549 Human lung 
adenocarcinoma 
R10 4 days 1:5-1:10 
MCF7 Human breast 
adenocarcinoma 
R10 4-5 days 1:10 
HT29 Human colon 
adenocarcinoma 
R10 3-4 days 1:10 
HeLa Human cervical 
carcinoma 
R10 3 days 1:20 
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cells. The flasks were incubated for 3-5 min, and the contents of the flask were 
checked under light microscope to ensure that the cells were mobile and not 
clumped. The trypsin was quenched with 8 mL of medium, which was added 
slowly to avoid the formation of bubbles. The cells were then centrifuged at 
1,000 rpm for 5 min. The supernatant was discarded and cells were 
resuspended in culture medium to the appropriate volume. 
VI.2.1.3 Determination of live cell number  
To determine live cell counts, 0.5 mL 0.4% Trypan Blue Stain (Sigma), 0.3 mL 
Hank’s balanced salt solution and 0.1 mL cell suspension were assembled in a 
tube, mixed vigorously by vortexing and incubated at room temperature for 5 
min. Total cell number (non-stained cells and blue cells) and live cell number 
(non-stained cells) were then determined using a haemocytometer. 
VI.2.1.4 Cryopreservation of mammalian cells  
For storage in liquid nitrogen, mammalian cells were trypsinised, sedimented by 
centrifugation and suspended in ice-cold standard freezing medium. 
VI.2.1.5 Drug stock solution 
Drug stock solutions were prepared by dissolving the target compound (DAC or 
TSA) in DMSO (Sigma) to 30 mM concentration and kept at -20 °C till required. 
Working solutions were prepared in cell media immediately before use. Equal 
amount of DMSO was used to treat the cell control to establish the effect of the 
carrier on the cell activity. 
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VI.2.1.6 Treatment with decitabine  
Cells were seeded at a concentration of 1x105 cells in 75 cm2 flasks. The next 
day, treatment of cells with 0, 100 nM, 1µM decitabine (DAC, 5-aza-2'-
deoxycytidine) (Sigma) was started, and DAC was removed by changing 
medium 24 h later. The cells were harvested 6 days after removal of DAC for 
DNA and RNA extraction. For comparison, two more MCF7 samples which 
were treated with DMSO or 1 µM DAC every other day, for 7 days were kindly 
donated by Dr. Flanagan (Imperial College, London). 
VI.2.1.7 Combination treatment: decitabine and trichostatin A  
Cells were seeded at a concentration of 1x105 cells in 75 cm2 flasks. The next 
day, treatment of cells with 0 or 100 nM DAC (Sigma) was started, and DAC 
was removed by changing medium 24 h later. Cells were harvested after 5 days 
in standard conditions. On day 5, treatment of cells with 100 nM TSA (TCI) was 
carried out for 24 h. Cells were collected after removal of TSA for DNA-RNA 
extraction. 
 
VI.2.2 Methylation analysis 
VI.2.2.1 Isolation of genomic DNA and quantification 
After removing the media, cells were washed twice with Hanks’ Balanced Salt 
solution (Sigma) and detached from the flask using a cell scraper. 3x106 cells 
were collected in a 1.5 mL microcentrifuge tube and centrifuged for 5 min at 
maximum speed. The supernatant was removed and the cell pellet was 
Chapter VI                                                                                                   - 222 -
_______________________________________________________________________ 
 
 
resuspended in 200 µL PBS (Sigma). No proteinase K was added and total 
DNA was isolated from cultured cells with QIAamp DNA Mini Kit (QIAGEN) 
following the manufacturer's protocol. Briefly, 200 µL of buffer AL was added to 
the sample and mixed by pulse vortexing for 15 sec. Samples were heated at 
56°C for 10 min and centrifuged to remove drops from the inside of the lid. In 
order to lysate the samples, 200 µL of 100% ethanol was added and mixed by 
vortexing. The mixture was carefully transferred in a QIAamp Mini spin column 
and centrifuged at 8000 rpm for 1 min. The filtrate was discarded and 500 µL of 
buffer AW1 (provided with the kit) was added to wash the spin column. After 
repeating the centrifugation step and discarding the supernatant, 500 µL of 
buffer AW2 (provided with the kit) was added to wash the spin column and 
centrifuged at full speed for 3 min and 1 min. The collection tube containing the 
filtrate was discarded and total DNA eluted adding 200 µL of RNase-free water. 
The samples were incubated for 1 min at room temperature (25°C) and then 
centrifuged at 8000 rpm for 1 min. To determine the concentration and purity of 
the total DNA samples, the absorbance of UV light was quantified using 
NanoDrop™ 2000 (Thermo Fisher Scientific) and 260/280 ratio was calculated. 
Samples were stored at -70°C until required. 
VI.2.2.2 Bisulfite conversion 
A total of 1 µg of genomic DNA (gDNA) for each sample was bisulfite treated 
using Epitect Bisulfite kit (QIAGEN). According with the measured DNA 
concentration, the DNA solution was mixed in a PCR tube with 85 µL of bisulfite 
mix (previously dissolved according with manufacturer’s protocol) and 35 µL of 
DNA protect buffer, adjusting the final reaction volume with RNase-free water to 
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140 µL. The reaction mixture was mixed thoroughly and the bisulfite DNA 
conversion was performed using a MJ Research PTC-200 Peltier thermal cycler 
using the following conditions in Table 6.2. 
Step Time Temperature 
Denaturation 5 min 95°C 
Incubation 25 min 60°C 
Denaturation 5 min 95°C 
Incubation 85 min 60°C 
Denaturation 5 min 95°C 
Incubation 175 min 60°C 
Hold Indefinite (overnight) 20°C 
 
_______________________________________________________________ 
Table 6.2 Optimised PCR conditions for bisulfite conversion step. 
 
After bisulfite conversion, the PCR tubes containing the bisulfite reactions were 
briefly centrifuged and then each mixture was transferred into clean 
microcentrifuge tube. 560 µL of freshly prepared BL buffer (provided with the kit) 
containing 10 µg/mL of carrier RNA were added to each sample. The mixture 
was vortexed and transferred into an Epitect spin column (QIAGEN). The 
column was centrifuged at full speed for 1 min and the supernatant was 
discarded. 500 µL of washing buffer BW (provided with the kit) was added to 
each spin column and centrifuged at full speed for 1 min. The supernatant was 
discarded and the procedure was repeated by adding 500 µL of buffer BD and 
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incubating for 15 min at room temperature (25°C). The mixture was washed 
twice with 500 µL of buffer BW and centrifuged at maximum speed to discard 
the flow-through. The spin columns were heated at 56 °C for 5 min to enable 
the evaporation of any of any remaining liquid. The purified DNA was eluted by 
centrifugation for 1 min at 12000 rpm. The DNA samples were stored at -20°C 
until needed. 
VI.2.2.3 Control samples 
Positive CpG Universal Methylated Control DNA (Millipore), also known as in 
vitro methylated DNA (IVM) and human male gDNA (Promega) were bisulfite 
treated as standards. Negative unmethylated control DNA was amplified from 
any gDNA sample using whole genome amplification GenomiPhi V2 DNA 
amplification kit (GE Healthcare) and bisulfite converted with the target 
samples. Moreover, three additional serial dilutions of 25%, 50%, 75% of IVM 
and male gDNA were mixed and prepared prior to bisulfite treatment. Water 
control (WC) was included to detect eventual contaminations.  
VI.2.2.4 Calponin quantification 
The sequence of modified calponin-specific primers was obtained from 
(Sriraksa et al., 2009) and used to check bisulfite modified DNA with 333 bp 
product size. Modified calponin-specific primer sequences were: 
5′-GGAAGGTAGTTGAGGTTGTG-3′ (forward primer)  
5′-CCCAAACTCAAAACTCTAACCTAAC-3′ (reverse primer) 
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VI.2.2.5 Polymerase chain reaction (PCR) 
PCR samples were prepared with a 25 µL final volume using: 1× PCR buffer 
(16.6 mM ammonium sulfate and 67 mM Tris, pH 8.8), 3 mM MgCl2, 200 µM of 
dNTPs, 5 pmol of each primer, 150 ng of bisulfite-treated DNA and 1.5 U of Taq 
polymerase. The PCR was performed using a MJ Research PTC-200 peltier 
thermal cycler using the conditions in Table 6.3 for 35 cycles. 3 µL of PCR 
products was separated by 2% agarose gel electrophoresis and visualized 
under UV illuminator after ethidium bromide staining. 
 
Step Time Temperature 
Initial denaturation 5 min 95°C 
Denaturation 30 sec 95°C 
Annealing  30 sec 63°C 
Elongation 30 sec 72°C 
 Repeat 34 times from step 2  
Final elongation  10 min 72°C 
 
_______________________________________________________________ 
Table 6.3 Optimised PCR conditions for calponin amplification. 
 
VI.2.2.6 LINE1 analysis: PCR and pyrosequencing 
Methylation analysis of LINE-1 (long interspersed nucleotide element-1, or L1) 
promoter (GenBank accession number X58075) was investigated using a 
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pyrosequencing-based methylation analysis. PCR and pyrosequencing of LINE-
1 were performed using the PyroMark Q96 CpG LINE-1 kit (QIAGEN). 
The LINE-1 specific primer sequences were: 
5′-TTTTTTGAGTTAGGTGTGGG-3′ (forward primer) 
5′-BIO-TCTCACTAAAAAATACCAAACAA-3′ (reverse-biotinylated primer)  
5′-GGGTGGGAGTGAT-3′ (sequencing primer) 
 
Primer stocks were all prepared in RNA-free water at the concentration of 1 
µg/µL for forward/reverse and 10 µM for the sequencing primer. Each PCR 
mixture contained the forward and reverse primer (each 0.2 µmol/L), 0.8 µmol/L 
of dNTPs, 1.5 mmol/L of MgCl2, 1x PCR buffer (QIAGEN), 0.64 U of HotStar 
Taq polymerase (QIAGEN), and 1 µL of bisulfite-converted template DNA in a 
total volume of 25 µL reaction. The PCR was performed using a MJ Research 
PTC-200 Peltier thermal cycler and the conditions were as follows: 
 
Step Time Temperature 
Initial denaturation 15 min 95°C 
Denaturation 20 sec 95°C 
Annealing  20 sec 50°C 
Elongation 20 sec 72°C 
 Repeat 44 times from step 2  
Final elongation 10 min 72°C 
 
_______________________________________________________________ 
Table 6.4 Optimised PCR conditions for LINE-1 amplification. 
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After amplification of a 146 kb fragment, samples were stored overnight at 2-8 
°C or at -20 °C for longer storage. 3 µL of PCR products was separated by 2% 
agarose gel electrophoresis and visualized under UV illuminator after ethidium 
bromide staining to ensure no contamination on the negative control.   
A simplex Entry for the PyroMark CpG LINE-1 assay was assessed in PyroMark 
CpG Software using the following parameters: 
TTYGTGGTGYGTYGTTTTTTAAGTYGGTTT (Sequence to Analyze) 
ATCAGTGTGTCAGTCAGTTAGTCTG (Dispensation Order)  
The biotinylated PCR product (10 µL) was purified and made single-stranded to 
act as a template in a pyrosequencing reaction as recommended by the 
manufacturer using the PyroMark Q96 Vacuum Workstation (QIAGEN).  
The DNA immobilization component (80 µL per well) was prepared in a PCR 
plate with the following volumes: 
 
Master mix component Volume per sample (µL) 
Streptavidin Sepharose HP beads 2 
PyroMark Binding Buffer 38 
RNase-free water 30 
PCR product 10 
Total volume 80 
 
_______________________________________________________________ 
Table 6.5 Reagent volumes for pyrosequencing analysis. 
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Briefly, the PCR product that was bound to streptavidin sepharose HP 
(horseradish peroxidise) and sepharose beads (QIAGEN) containing the 
immobilized PCR product were purified, washed, denatured using a 0.2 M 
NaOH solution, and washed again (Estecio et al., 2007). The sequencing primer 
was diluted in Annealing buffer (QIAGEN) to a final concentration of 0.3 µM and 
12 µL of the prepared solution was added to the PyroMark Q96 H sequencing 
plate.  The PCR plate were agitated constantly for 5-10 min at room 
temperature (15-25°C) using a mixer. The reagents were respectively added in 
the PyroMark Q96 Vacuum Workstation (QIAGEN) as illustrated in Figure 6.3. 
 
 
_______________________________________________________________ 
Figure 6.3 PyroMark Q96 Vacuum Workstation. The marked positions contain 110 mL 70% 
ethanol, (1), 90 mL PyroMark Denaturation Solution (2), 110 mL PyroMark Wash Buffer (3), and 
110 mL high-purity water (4) (adapted from PyroMark Q96 handbook). 
 
After applying vacuum to the vacuum handset tool (see Figure 6.3), the beads 
containing immobilised DNA were captured onto the filter probes. The handset 
tool (P, see Figure 6.3) was transferred first to the trough containing 70% 
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ethanol (purification), secondarily to the trough containing PyroMark 
Denaturation Solution (denaturation), and finally to the trough containing Wash 
Buffer (washing). After the vacuum was switched off, the beads were released 
into the wells containing sequencing primer by gently shaking the tool in the 
wells. The PyroMark Q96 H Plate with the samples was heated at 80 °C for 2 
min using a heating block. The samples were cooled down to room temperature 
and PyroMark Q96 H Plate was loaded into the PSQ96 H System (QIAGEN).  
After the LINE-1 assay was set up in the PSQ96 H System, the reagent tips and 
capillary tips were loaded in the tip holder with the appropriate volumes of 
PyroMark Gold Q96 Reagents (QIAGEN), as shown in Figure 6.4. 
 
_______________________________________________________________ 
Figure 6.4 Order of tips in the capillary tip holder. E: Enzyme Mixture; S: Substrate Mixture; 
G: dGTP; C: dCTP; T: dTTP; A: dATP (adapted from PyroMark Q96 handbook). 
 
After the tip holder and the PyroMark Q96 H Plate were respectively loaded in 
the dispensing unit the run was performed. The analysis results (methylation 
level) and quality control were assessed using PyroMark Q96 MD Software and 
methylation values were calculated as an average of all CpG sites within the 
assay as determined by the Pyro Q-CpG Software. PyroMark CpG LINE-1 
Capillary tips 
Reagent tips 
Chapter VI                                                                                                   - 230 -
_______________________________________________________________________ 
 
 
assay was repeated in two independent biological replicates to assess the 
reproducibility of the methylation analysis via pyrosequencing.  
VI.2.2.7 Assay design for target genes 
Gene sequence, transcription start site, CpG island loci and any additional 
information were established using UCSC genome browser 
(http://genome.ucsc.edu/). Primer design was performed by PyroMark Assay 
Design software using the in silico bisulfite converted DNA sequence. After the 
target region was selected and the desired sequence length was set, the 
automatic assay design was run to generate the primer sets. A biotin tag was 
placed on either the forward or reverse primer (depending on the strand to be 
sequenced). The utility indicated if there were repeated bases in the region of 
interests, potential mispriming and if the pyrosequencing template (bisulfite- 
treated PCR product) could form 3' template loops.  Mispriming and template 
loops caused background in the pyrosequencing reaction that could render an 
assay unusable.  These problems could be solved by moving one or both of the 
PCR products to exclude the offending sequence.  The utility assigned a score 
and quality for each sequencing primer that it designed, penalizing a primer for 
any of the above problems and also for length more than 15 bases. The primer 
set (forward, reverse and sequencing) with the highest quality and no warnings 
was selected as final set and saved to be imported and used in other 
pyrosequencing software. All the final assays for the studied genes are reported 
at the end of the present chapter in Supplementary Information VI.A. 
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VI.2.2.8 PCR Conditions for designed assay 
VI.2.2.8.1 Primers 
The sequence of bisulfite converted specific primers was obtained for every 
target gene as explained on section VI.2.2.7.  
VI.2.2.8.2 Primers Polymerase chain reaction (PCR) 
The sequence PCR samples contained a final volume of 25 µL and were 
prepared using: 1× PCR buffer (16.6 mM ammonium sulfate and 67 mM Tris, 
pH 8.8), 3 mM MgCl2, 200 µM of dNTPs, 5 pmol of each primer, 150 ng of 
bisulfite-treated DNA and 1.5 U of Taq polymerase. The PCR was performed 
using a MJ Research PTC-200 Peltier thermal cycler using the conditions listed 
on the Table 6.6.  
Step Time Temperature 
Initial denaturation 5 min 95 °C 
Denaturation 30 sec 95 °C 
Annealing 30 sec see table below  
Elongation 30 sec 72 °C 
 Repeat 34 times from step 2  
Final elongation  10 min 72 °C 
 
_______________________________________________________________ 
Table 6.6 PCR conditions for amplification of target genes. 
 
Chapter VI                                                                                                   - 232 -
_______________________________________________________________________ 
 
 
Primer-template annealing temperatures were optimised for every assay using 
a temperature gradient between 53 and 62°C to avoid PCR dimers by annealing 
of their 3'-termini or non-specific amplification, which cause the appearance of 
multiple bands on agarose gels (Rychlik et al., 1990). The final annealing 
temperature values are listed in Table 6.7. 
After the reaction, 3 µL of PCR product was separated by 2% agarose gel 
electrophoresis and visualized under UV illuminator after ethidium bromide 
staining. Negative control was added to detect DNA contamination. 
 
Target gene Annealing Temperature (°C) 
ALDH1A1 59 
ALDH2 56 
ALDH3A1 59 
ABCB1 62 
ABCG2 59 
 
_______________________________________________________________ 
Table 6.7 Optimised annealing temperature for PCR amplification of target genes. 
 
VI.2.2.9 Pyrosequencing 
A simplex Entry for the PyroMark CpG assay was assessed in PyroMark CpG 
Software using the gene-specific parameters listed in Supplementary 
Information VI.A. The pyrosequencing procedure was performed as already 
described for the LINE-1 assay (refer to “LINE-1 analysis” section for details). 
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PyroMark CpG assay was repeated in two PCR replicates to assess the 
reproducibility of the methylation analysis.  
VI.2.2.10 Statistical analysis 
Each treatment of the cell lines was performed in duplicate. The two values 
were then averaged to obtain one value for each culture. From these data, the 
mean value ± standard error of the mean (SEM) was calculated for each 
experimental condition. An analysis of variance was carried out on the data for 
testing the treatment effect. For comparison of two means, Student’s t-test was 
used for unpaired samples. A difference was considered significant when the P 
value was <0.05. 
 
VI.2.3 Gene expression analysis using quantitative RT-PCR (qRT-PCR) 
before and after epigenetic treatment 
VI.2.3.1 RNA extraction and quantification 
The cell monolayer was washed twice with Hanks’ Balanced Salt solution 
(Sigma) and detached from the flasks using a cell scraper. 2x106 cells were 
collected in a 1.5 mL microcentrifuge tube and centrifuged for 5 min at 
maximum speed. The supernatant was removed and the cell pellets were 
resuspended in 200 µL PBS (Sigma). No DNase treatment was performed and 
RNA was extracted from the cell pellets using an RNeasy RNA extraction kit 
(QIAGEN) according to the manufacturer’s instructions.  Briefly, cells were 
disrupted in the lysis buffer and homogenized using a QIA spin shredder 
column (QIAGEN) or a blunt 20-gauge needle fitted to an RNase-free syringe. 
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70% ethanol was added to homogenate the lysate and mixed well by pipetting. 
Supernatant was transferred in a spin column (QIAGEN) and the spin column 
membrane was washed multiple times to avoid carryover of ethanol. Finally the 
RNA was eluted by adding 40 µL of RNase-free water and centrifuging for 1 min 
at maximum speed. Quality and quantity of extracted RNA was analysed by 
measuring the absorbance of UV light using NanoDrop™ 2000 (Thermo Fisher 
Scientific) and calculating the 260/280 ratio. Samples were stored at -70°C until 
required. 
VI.2.3.2 Complementary DNA synthesis 
Complementary DNA (cDNA) single stranded was generated from total RNA in 
20 µL reactions using Multiscribe Reverse Transcriptase kit (Applied 
Biosystems) as follows: 10x reverse transcription buffer, 5.5 mM MgCl2, 500 
µM/dNTP, 2.5 mM random hexamers, 0.5 U/µL RNase inhibitor, 1.25 U/µL 
multiscribe reverse transcriptase and RNase free water.  
 
Step Time Temperature 
Incubation 10 min 25 °C 
Synthesis 30 min 48 °C 
Enzyme inactivation 5 min 95 °C 
 
_______________________________________________________________ 
Table 6.8 Optimised conditions for cDNA synthesis. 
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2 µL of specimen RNA was added to each reaction. Reactions were carried out 
in a MJ Research PTC-200 Peltier thermal cycler using the conditions listed on 
Table 6.8. 
VI.2.3.3 Universal Probe Library technology 
PCR primers were designed using Roche Universal Probe Library (UPL) 
(Roche Diagnostic Corporation), containing 90 short hydrolysis probes (8-9 
nucleotides), labelled at the 5' end with fluorescein (5’-FAM, Ex/Em: 494/522 
nm) and at the 3' end with a dark quencher dye. In order to maintain the 
specificity and melting temperature that hybridizing qRT-PCR probes requires, 
Locked Nucleic Acids (LNA) were incorporated into the sequence of each UPL 
probe. These LNAs had the ribose ring “locked” with a methylene bridge by 
connecting the 2’-O atom with the 4’-C atom. This modification conferred base 
stacking and increased thermal stability compared to normal DNA nucleotides. 
VI.2.3.4 QRT-PCR primers design 
The Probe Finder software (Roche Diagnostic Corporation) allowed a rapid 
design of qRT-PCR assays for the targets of choice in three steps: organism 
selection, gene name or gene accession number insertion, and sequence paste 
into the appropriate field. The software created a specific qRT-PCR assay by 
combining a suitable UPL probe with a set of target specific PCR primer pairs. 
Multiple primer pair options were available and the system ranked them to 
favour intron spanning amplicons to remove false signals from contaminating 
gDNA together with a small amplicon size for reproducible and robust assays. 
Three best ranked assays were chosen for each target gene and the one giving 
the best amplification profile was kept as definitive. Detailed informations 
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regarding the final assays are listed in Supplementary Information VI.B at the 
end of the present chapter. 
VI.2.3.5 QRT-PCR method 
QRT-PCR was set up in a 96 well plate in triplicates in a UV-irradiated hood on 
a Stratagene Mx3005P QPCR System (Agilent Technologies). The assay was 
performed using 25 µL reactions consisting of 1 µL of cDNA, 12.5 µL of 2x 
TaqMan Universal PCR master mix (Roche Applied Biosystems), 400 nM 
forward and reverse primers for the target genes and 400 nM forward and 
reverse primers and for housekeeping genes GAPDH and PPIA. TaqMan 
probes were used at a concentration of 50 nM for all genes. Optimal primers 
and probe concentrations were deduced through optimisation reactions for each 
gene, and amplification efficiencies were obtained using standard curves for 
each gene primer and probe combination. For each assay, no-template controls 
were included.  
Step Time Temperature 
Enzyme activation 10 min 95 °C 
Denaturation 15 sec 95 °C 
Annealing/Extension 60 sec 60 °C 
 Repeat 39 times from step 2  
 
_______________________________________________________________ 
Table 6.9 Primer sequences and assay details for qPCR analysis of target genes. 
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A commercial kit containing primers and TaqMan probes for the housekeeping 
genes GAPDH and PPIA respectively (Human Endogenous Control (FAM / 
MGB Probe, Non-Primer Limited), Roche Applied Biosystems) was used for the 
normalisation of the reaction.  Cycling conditions are listed in Table 6.9.  
VI.2.3.6 QRT-PCR efficiency validation 
To validate the qRT-PCR efficiency (E) of target gene primers, standard curves 
were generated from a dilution series of target cDNA (example shown in Figure 
6.5). The PCR efficiency was calculated from the slope of the standard curve 
using the following equation: 
E= (10-1/slope) -1 
For example, a slope of -3.32 represents a PCR efficiency of 1 (100%). The 
PCR efficiency (E) values of the target genes were ranged between 50-85%, as 
listed in Table 6.10. 
 
Target gene Efficiency (%) 
ALDH1A1 73 
ALDH2 64 
ALDH3A1 80 
ABCB1 50 
ABCG2 67 
 
_______________________________________________________________ 
Table 6.10 PCR efficiency value calculated using the equation reported above. 
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_______________________________________________________________ 
Figure 6.5 Standard Curves of PPIA, ALDH3A1, and ABCG2 derived from a dilution series 
of A549 cDNA using quantitative real-time PCR (TaqMan Assays). The Ct values correlated 
to the copy number of the gene (R2 = 0.992, Y = -4.959*LOG(X) + 21.55, PPIA; R2 = 0.991, Y = 
-4.171*LOG(X) + 25.26, ALDH3A1; R2 = 0.962, Y = -4.526*LOG(X) + 26.37, ABCG2). 
 
VI.2.3.7 Data analysis  
This assay was based on measuring fluorescence using fluorescent chemistries 
such as TaqMan probes (see “Universal Probe Library technology” section for 
details). The fluorescence intensity detected during each cycle was 
proportionally correlated to the amount of amplicon produced.  
MxPro QPCR Software (Agilent Technologies) was used to perform all data 
analysis. The baseline for the amplification plot was determined above the small 
changes in fluorescence signals produced by the initial cycles of PCR. As the 
PCR products accumulates during PCR amplification, the fluorescence intensity 
increased above the baseline. Consequently, a cycle threshold (Ct or Cts) was 
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fixed and set above the baseline. The Ct of each PCR cycle represented the 
time point where fluorescent signals of target amplicons were first determined 
and then crossed to the fixed threshold (Stewart et al., 2006). 
Cts < 29 were strong positive reactions indicative of abundant target nucleic 
acid in the sample. Cts of 30-37 were positive reactions indicative of moderate 
amounts of target nucleic acid. Cts of 38-40 were weak reactions indicative of 
minimal amounts of target nucleic acid (Hunt, 2010). 
Relative quantification was used to estimate the ratio between a target mRNA 
expression and an endogenous reference gene. These ratios were compared 
between samples being assayed. The endogenous references were 
housekeeping or maintenance genes whose expressions were relatively 
constant and not affected by experimental conditions. In this study, GAPDH 
(Glyceraldehyde 3-phosphate dehydrogenase) or PPIA (peptidylprolyl 
isomerase A or Cyclophilin A) were used as validated housekeeping genes in 
the selected cell lines. 
2-∆Ct method was used to calculate the relative expression of target gene (Livak 
and Schmittgen, 2001). This method was mainly based on Ct values. ∆Ct was 
firstly calculated for each sample using the following equation: 
∆Ct (sample) = Ct target gene- Ct reference gene 
2-∆∆Ct method was used to compare the fold change of gene expression 
between chemically treated and untreated samples. The fold changes were 
obtained by applying the following equation:  
∆Ct (calibrator or untreated cells) = Ct target gene- Ct reference gene 
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Then, ∆∆Ct value for each sample was calculated by subtracting the ∆Ct value 
of the calibrator from the ∆Ct value of the sample: 
∆∆Ct= ∆Ct (sample) - ∆Ct (calibrator or untreated cells) 
Finally, the ∆∆Ct formula was used to estimate the normalized fold differences 
between treated and untreated cells 2-∆∆Ct. 
VI.2.3.8 Statistical Analysis 
The significance of results was assessed through a comparison of means using 
a paired two-tailed t-test with two way ANOVA (analysis of variance) followed by 
Bonferroni correction for multiple testing (Bonferroni, 1936). All statistical 
analysis was performed using GraphPad Prism version 4.00 (GraphPad 
Software, www.graphpad.com). Results were expressed as the mean ± 
standard error of the mean unless otherwise stated. P values were calculated to 
determine statistical significance of the results obtained as outlined in Table 
6.11. 
P value Wording Summary 
<0.001 Extremely significant *** 
0.001 to 0.01 Very Significant ** 
0.01 to 0.05 Significant * 
>0.05 Not Significant n 
 
_______________________________________________________________ 
Table 6.11 P values summary and significance. 
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VI.2.4 Western blot analysis 
DAC was demonstrated to reflect its ability to reactivate methylation-silenced 
genes in a cell dependent manner. To establish protein expression of the target 
families of enzymes western blotting analysis was performed in the samples 
that showed positive correlation between DAC treatment and gene reactivation. 
VI.2.4.1 Sample preparation 
Mammalian cell lines were cultured and treated as outlined in section VI.2.1. 
After treatment the cells were harvested and centrifuged at 1000 rpm for 5 min 
at 4°C. The supernatant was removed and pellets were resuspended in RIPA 
lysis buffer (see Appendix II for buffers and solutions). Cell suspensions were 
maintained in constant agitation for 30 min at 4°C. Samples were centrifuged at 
12000 rpm for 10 min at 4°C and the supernatant was transferred to a fresh 
eppendorf tube. The concentration of protein in the supernatant was determined 
using the Bradford assay. 
VI.2.4.2 Determination of protein concentration 
Protein standards ranging from 0 mg/mL to 1 mg/mL were prepared by serial 
dilutions of a bovine serum albumin (BSA) (Sigma) standard in deionised water. 
The cell lysates were diluted 1:5 in a new 1.5 mL eppendorf tube. Bradford 
reagent (Bio-Rad) was prepared by diluting one part of dye with four parts of 
deionised water. The diluted reagent was filtered through Whatman paper to 
remove particulates. 20 µL of sample or standard dilution were added to 1 mL of 
diluted dye reagent in a 1.5 mL eppendorf tube in duplicate. The mixture was 
vortexed and incubated at room temperature for 5 min. The absorbance of 
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standards and samples was measured at 595 nm using a spectrophotometer 
and the water blank was subtracted. To allow quantification of sample protein 
concentration, a standard curve was created using the protein standards. To 
normalise the protein loading in each well, the volume of sample containing 10 
µg of protein was calculated. This volume was transferred to a new eppendorf 
tube and 1x SDS loading buffer (see Appendix II) was added to give a total 
volume of 20 µL. Samples were subsequently denaturated at 95°C for 5 min.  
VI.2.4.3 Polyacrylamide gel preparation 
The gel loading assembly (Bio-Rad) was cleaned with 70% ethanol and 
assembled as directed in the manufacturer instructions. A 10% resolving gel 
(see Appendix II) was prepared and pipetted into the assembled apparatus. The 
gel was allowed to set at room temperature for 20 min. A 4% stacking gel (see 
Appendix II) was prepared and pipetted over the running gel. A gel comb was 
inserted and the gel let to set for 20 min. The comb was removed and the gel 
apparatus was transferred to an electrophoresis buffer tank (Bio-Rad) filled with 
1x TBS-Tween20 running buffer. The denaturated samples containing 10 µg of 
protein were loaded in the gel wells along with 10 µL of pre-stained molecular 
weight marker (Full range rainbow marker 10-250 kDa, Amersham 
Biosciensces). The gel was run at 3W for 1 h.  
VI.2.4.4 Protein transfer to PVDF membrane  
Following electrophoresis, wet blotting was carried out using a PVDF 
(polyvinylidene fluoride) membrane soaked up in transfer buffer. Transfer was 
carried out at 100V for 1 h.  
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VI.2.4.5 Immunodetection of electrophoresed proteins after transfer to 
nitrocellulose membrane 
The cassette was dismantled and the blotted PVDF membrane was placed in a 
Petri dish and rinsed with deionised water. The membrane was placed in 10 mL 
of 4% blocking solution (see Appendix II for solutions) for 30 min on a rocker. 
The blocking solution was removed and replaced with 10 mL of 2% blocking 
solution containing one of the unconjugated primary antibodies listed on Table 
6.12. 
Specificity Host species Molecular weight (kD) Dilution Manufacturer 
ALDH1A1 Rabbit polyclonal 54.9 1:1000 Prestige Antibodies, 
Sigma 
ALDH2 Mouse monoclonal 50 1:500 Calbiochem 
ALDH3A1 Mouse polyclonal 50 1:500 Abnova 
ABCB1 Mouse monoclonal 36 1:500 Sigma 
ABCG2 Mouse monoclonal 72 1:500 Chemicon,Millipore 
 
_______________________________________________________________ 
Table 6.12 List of used primary antibodies and working dilutions. 
 
This was incubated at 4°C on a rocker for overnight. The membrane was then 
washed in 1x TBS-Tween20 for 4 x 15 min.  The membrane was subsequently 
incubated for 1 h with 10 mL of secondary antibody (see Table 6.13) solution in 
2% blocking solution (see Appendix II). The membrane was washed in 
TBS/Tween20 for 4 x 15 min and then prepared for detection of the bands. 
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Specificity Host species Dilution Manufacturer 
Anti-Mouse Polyclonal goat  1:4000 Bio-Rad 
Anti-Rabbit  Polyclonal goat 1:4000 Southern Biotech  
 
_______________________________________________________________ 
Table 6.13 List of used secondary antibodies and working dilutions. 
 
VI.2.4.6 Enhanced chemiluminescent detection 
Membranes were developed using the enhanced chemiluminescence system 
(ECL Plus™ detection kit, GE Healthcare). The detection solutions were 
prepared according to the manufacturer instructions. The excess washing buffer 
was drained off and the prepared detection solution pipetted onto the 
membrane surface protein side up. This was incubated at room temperature for 
5 min on a clean filter paper. The excess of detection reagent was removed and 
the membrane was placed in a Bio-Rad 170-8126 Universal Hood (Bio-Rad) 
under epi-white illumination using ChemiDoc XRS Gel documentation system. 
The exposure time and configurations were adjusted using Quantity One 
analysis software (Bio-Rad). Band intensity was determined using densitometry 
and Quantity One analysis software (Bio-Rad).  
VI.2.4.7 Stripping western blots for reprobing with loading control  
After chemiluminescence detection, the membrane was washed in 
TBS/Tween20 for 2 x 10 min. Excess of washing buffer was drained off and the 
membrane was stripped using 10 M urea in 100 mM Tris-HCl pH 6.8. The blot 
was incubated in hybaid oven at 55 °C for 1 h with shaking. After stripping, the 
membrane was washed with TBS-Tween20 for 2 x 10 min. The blocking step 
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with 4% skimmed milk was repeated for 30 min. Anti-GAPDH monoclonal 
antibody produce in mouse (Calbiochem) or anti-αtubulin monoclonal antibody 
produce in mouse (Bio-Rad) was used as control, diluted 1:2000 in 2% blocking 
solution (see Appendix II) and incubated for 1 h at RT on a rocker. Incubation 
with secondary antibody was carried out as previously described on section 
VI.2.4.5. 
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VI.3 Results 
VI.3.1 Pyrosequencing analysis of the promoter region in LINE-1 
DNA methylation measured in LINE-1 has been correlated with global DNA 
methylation (Irahara et al.). Several studies have demonstrated that LINE-1 
retrotransposable elements made up about 15% of human genome and DNA 
methylation played a fundamental role within the promoter region of human 
LINE-1 elements for maintaining transcriptional inactivation and for inhibiting 
transposition (Singer, 1982).  
In the analysed samples, methylation levels of the LINE-1 repetitive elements 
were used as a surrogate marker of genome-wide methylation changes (Estecio 
et al., 2007). Given the abundance of LINE-1 elements in the genome, minimum 
amounts of DNA were required for their amplification and analysis. Therefore 
the technique was validated by investigating the methylation level of LINE-1 
promoter together with methylated and unmethylated controls. Methylation 
analysis of LINE-1 promoter was used to evaluate the reproducibility of the data 
generated via pyrosequencing (see Supplementary Information VI.C at the end 
of the present chapter for LINE-1 methylation analysis plots).  
Prior to pyrosequencing analysis, successful bisulfite modification of the DNA 
sample was verified using a region of the calponin promoter as described in 
section VI.2.2. This sequence could only be amplified if the cytosines in the 
template sequence were converted to uracils (Sriraksa et al., 2009). Samples 
which did not give a band of similar intensity were considered unmodified or 
incompletely modified and the modification experiment was repeated for these, 
as illustrated in Figure 6.6. 
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← 333 bp
NC    1    2     3     4     5     6     7     8     9    10   11   12   13   14   15   16   17   18    M
 
_______________________________________________________________ 
Figure 6.6 Examples of successful sodium bisulfite modifications. Calponin amplification 
product appeared at 333 bp.  NC, reaction without template (negative control); 1-5:  IVM, in vitro 
methylated DNA and DNA from whole male blood (0-100% matrix); 6-18 successfully modified 
DNA from tumour samples. 
 
Reproducibility of the methodology was assessed for the entire set of samples 
by repeating the experimental procedure in two independent pyrosequencing 
runs with LINE-1 assay (see Figure 6.7).  In the analysed cell lines, the DMSO 
treated controls showed a LINE-1 methylation status of 50-70% and 
consistency of the values between the two replicates was obtained. 
Reproducibility was then assessed after treatment with DAC at 100 nM (D100) 
or 1 µM (D1) and in combination with TSA (D+T). After a 24 h treatment with 
100 nM DAC, average LINE-1 methylation in the analysed cancer cell DNA 
decreased by 10-20%, showing a generalised effect. No evident difference was 
shown with higher dose of DAC or the combination with TSA. 
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_______________________________________________________________ 
Figure 6.7 Reproducibility of LINE-1 promoter methylation analysis using 
pyrosequencing. The four graphs show data from two independent experiments before/after 
treatment with DAC or DAC and TSA. Control samples showed higher methylation level 
compared to treatment with DAC (D100: DAC 100nM; D1: DAC 1µM) or DAC/TSA (D+T: DAC 
100nM+ TSA 100nM). 
 
A previous study of reproducibility and calibration of pyrosequencing 
demonstrated that experimental errors, classified as insertions, deletions, 
mismatches (substitutions) and ambiguous base calls were estimated between 
2 and 4% of the measured methylation value (Huse et al., 2007). On this basis, 
the accuracy of the pyrosequencing method was maintained on heterogeneous 
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DNA templates suggesting that the higher error with experimental data was 
derived from the experimental manipulation of the sequences prior to 
pyrosequencing.  
 
VI.3.2 Promoter methylation status of ALDH and ABC genes in selected 
cancer cell lines 
The amplification regions were primarily designed to cover CpG islands (CGIs) 
overlapping with the 5’ UTR of the target genes. When no CGI was annotated 
by the UCSC genome browser in close proximity of TSS, the sequence directly 
surrounding the 5’ UTR was used for primer design, containing a variable 
number of CG sites. The initial methylation data were filtered to exclude poor 
quality measurements and adjustment of the design assay was made to 
exclude any region responsible of pyrosequencing failure. For excluded regions, 
PCR was identified as the leading cause of reaction failure.  
The methylation status of three ALDH isoforms (ALDH1A1, 2 and 3A1) and two 
ABC transporters (ABCB1 and ABCG2) were examined in four different cell 
lines of the NCI-60 panel (A549, MCF7, HT29 and HeLa) before and after 
treatment with the demethylating agent decitabine (DAC) alone and in 
combination with histone deacetylation inhibitor trichostatin A (TSA). The 
pyrosequencing assays were designed for each gene as reported in 
Supplementary Information VI.A. According with the literature (Shaw et al., 
2006), promoter methylation value below 10% is considered “unmethylated” and 
above 10% were considered “methylated”. ALDH1A1 gene did not show 
annotated CGIs in the promoter region; hence the analysed amplicon 
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(containing three CpG sites) was selected around the TSS, in a portion of DNA 
including three CpG sites.  
 
_______________________________________________________________ 
Figure 6.8 ALDH1A1 promoter methylation analysis in HeLa cell line. Analysis was 
performed in three CpG sites selected around the TSS. Percentage methylation was reported 
above the respective sample as average value of the CpG sites under analysis. The graph 
shows the average data from two independent pyrosequencing runs before/after treatment with 
DAC (D100: DAC 100nM; D1: DAC 1µM) or DAC/TSA (D+T: DAC 100nM+ TSA 100nM). The 
first two samples (0, 100% Me) represented the DNA control.  
 
The percentage methylation of ALDH1A1 analysis of the control samples was 
very low (between 4-6%) in A549, MCF7 and HT29, revealing an unmethylated 
status of the CpG sites around the promoter region (<10%) (see Supplementary 
Information VI.D.1 for methylation plots). However, DNA from HeLa cells (see 
Figure 6.8) showed a methylation level of 49,5% whereas DNA from DAC-
treated HeLa cells was 29-33% methylated at each CpG site. As expected, a 
dose-dependent demethylation effect was revealed between 100 nM and 1 µM 
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24 h treatment with DAC. Furthermore, combination of DAC with TSA did not 
show a greater effect on demethylation than DAC alone. 
ALDH2 methylation status was investigated within a CGI of 481 bp. The 
analysed amplicon covered ten CpG sites. The promoter region was 
unmethylated in the analysed region for A549, HT29 and HeLa control with 
methylation status below 5 % for the three cell lines (see Supplementary 
Information VI.D.2 for methylation plots). Indeed, no variation was shown in the 
treated samples.  
 
* p< 0.05, *** p< 0.001 
______________________________________________________________ 
Figure 6.9 ALDH2 promoter methylation analysis using pyrosequencing in MCF7 cell line. 
Analysis was performed in six CpG sites selected from a CGI of 481 bp. Percentage methylation 
was reported above the respective sample as average value of the CpG sites under analysis. 
The graph shows the average data from two independent pyrosequencing runs before/after 
treatment with DAC (D100: DAC 100nM; D1: DAC 1µM) or DAC/TSA (D+T: DAC 100nM+ TSA 
100nM). The first two samples (0, 100% Me) represented the DNA control. In the MCF7 plot two 
additional samples showed the DMSO control and DAC treatment for 7 days, with new drug 
addition every 2 days. 
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In contrast, the MCF7 investigation (refers to Figure 6.9) showed a high 
methylated pattern in the control (84%) and a significant demethylation was 
determined after DAC treatment (60%), suggesting the efficacy of the drug in 
hypomethylating the analysed gene region. 
Demethylation did not appear to be dose-dependent and no greater results 
were shown via combination treatment with TSA. However, as shown in the last 
two samples of Figure 6.9, prolonged exposure of MCF7 with multiple doses of 
1 µM DAC for 7 days resulted into a further demethylation of around 47%. 
Ultimately, ALDH3A1 promoter analysis of eight CpG sites, within a selected 
CGI upstream of the TSS, revealed a very low percentage methylation of the 
control samples (between 2-5%) in HT29 and HeLa cells, suggesting that the 
ALDH3A1 gene promoter is unmethylated in these cancer cell lines (see 
Supplementary Information VI.D.3 for methylation plots). 
A549 (see Figure 6.10A) showed a methylation level above 10% (18%) and 
according to the pyrosequencing technology, a CGI with a methylation status 
above 10% is considered as methylated (Ronaghi, 2001). 
 DAC treatment of this cell line at 100 nM and 1 µM respectively led to 
demethylation of maximum 6%. A similar response was obtained after 
combination with TSA, suggesting that no further demethylation could be 
obtained after combination treatment.  
However, DNA from MCF7 cells (see Figure 6.10B) showed a very high 
methylated pattern (92%) whereas DNA from DAC-treated MCF7 cells was 
shown to contain 71% methylation after 100 nM DAC treatment, and further 
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demethylation was observed after 1 µM DAC exposure (60%). This data 
revealed an interesting dose-dependent demethylation mechanism. Moreover, 
combination of DAC and TSA (both at 100 nM concentration) showed greater 
effect (67%) than compared with DAC 100 nM alone (71%). A dramatic 
demethylation was observed in MCF7 by longer exposure (7 days) to DAC 100 
nM: methylation pattern changed from a highly methylated DMSO control (96%) 
to half of the original methylation level after treatment (45%). 
 
A) 
 
*** p< 0.001 
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B) 
 
*** p< 0.001 
_______________________________________________________________ 
Figure 6.10 ALDH3A1 promoter methylation analysis using pyrosequencing in A549 and 
MCF7 cell lines. Analysis was performed in eight CpG sites selected on a CGI of 353 bp. 
Percentage methylation was reported above the respective sample as average value of the 
CpG sites under analysis. The graph (A: A549, B: MCF7) show the average data from two 
independent pyrosequencing runs before/after treatment with DAC (D100: DAC 100nM; D1: 
DAC 1µM) or DAC/TSA (D+T: DAC 100nM+ TSA 100nM). The first two samples (0, 100% Me) 
represents control DNA. In the MCF7 plots two additional samples showed the DMSO control 
and DAC treatment for 7 days, with new drug addition every 2 days. 
 
The final assay for ABCB1 included the analysis of only two CpG sites due to 
failure of the pyrosequencing run and consequent shortening of the initial 
designed assay. As previously proven by Reed et al. (Reed et al., 2008), 
contribution of ABCB1 downstream promoter had a fundamental role in the 
expression of ABCB1 transcripts in the MCF7 cell line. Here, pyrosequencing 
analysis showed hypermethylation of the ABCB1 downstream promoter in 
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MCF7 control cells (46%) and a demethylation effect after DAC treatment 
(35%), with no greater effect at higher DAC dose or in combination with TSA 
(see Figure . 6.11A). 
Same analysis was performed in A549 and HeLa cells, but the control samples 
showed unmethylated status (<10%) in the promoter region of both genes (see 
Supplementary Information VI.D.4 for methylation plots). A different profile was 
found in the HT29 cell line (see Figure 6.11B). Indeed, the methylation pattern 
in the untreated control was above 10% (13%) and the percentage methylation 
was slightly reduced via DAC treatment, however, perhaps due to the borderline 
results with an unmethylated pattern, the statistic analysis classified the results 
as no significant (p>0.05).  
 
A) 
 
* p< 0.05 
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B) 
 
_______________________________________________________________ 
Figure 6.11 ABCB1 downstream promoter methylation analysis using pyrosequencing. 
Analysis is performed in two CpG sites selected on a CGI of 950 bp. Percentage methylation 
was reported above the respective sample as average value of the CpG sites under analysis. 
The graph (A: MCF7, B: HT29) show the average data from two independent pyrosequencing 
runs before/after treatment with DAC (D100: DAC 100nM; D1: DAC 1µM) or DAC/TSA (D+T: 
DAC 100nM+ TSA 100nM). The first two samples (0, 100% Me) represents control DNA. In the 
MCF7 plot two additional samples show the DMSO control and DAC treatment for 7 days, with 
new drug addition every 2 days. 
 
The second isoenzyme explored from the ABC family was ABCG2. The assay 
for ABCG2 was designed within a CGI of 698 bp and revealed an unmethylated 
status as a common feature in the four cell lines under analysis.  
As shown in Table 6.14, the percentages of methylation were always comprised 
between 1-2% before and after treatment without cell-to-cell variation (see 
Supplementary Information VI.D.5 for methylation plots).  
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Cell line Cntr (% Met) D100 (% Met) D1 (% Met) D+T (% Met) 
A549 2,5                      2,2                      3,0                          2,7 
MCF7 2,6                 2,3                 2,4                  2,4               
HT29 1,6                        2,1                       2,8                          2,1 
HeLa 1,6                        2,0                       1,8                          2,0 
 
_______________________________________________________________ 
Table 6.14 ABCG2 downstream promoter methylation analysis in selected cell lines. 
Average of four CpG sites methylation status is reported. Experiment was repeated in duplicate, 
before/after treatment with DAC (D100: DAC 100nM; D1: DAC 1µM) or DAC/TSA (D+T: DAC 
100nM+ TSA 100nM).  
 
VI.3.3 Gene expression profiling of ALDH and ABC target genes 
CGI methylation within promoter regions of genes have shown an association 
with transcriptional repression of the reciprocal gene (Bird and Wolffe, 1999). 
Here, the RNA expression levels of ALDH1A1, ALDH2 and ALDH3A1 together 
with ABCB1 and ABCG2 were quantified in the panel of selected cell lines 
A549, MCF7, HT29 and HeLa using qRT-PCR. PPIA or GAPDH housekeeping 
gene were, respectively, used to normalise the target gene expression and 
allow for differences in initial RNA concentration. These genes have been 
widely used as control genes for relative-quantification RT-PCR reactions, and 
optimisation showed that the selected housekeeping gene displayed consistent 
levels of expression over the established cell lines.  
QRT-PCR was used to quantitatively examine the expression levels by 
measuring mRNA levels in the four cell lines for both ALDH and ABC selected 
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isoforms before and after treatment with DAC. Gene profiling was also analysed 
after combination of DAC with trichostatin A, TSA. 
The expression was calculated successively in three individual experiments to 
verify values obtained, as shown in the graphs represented in Figures 6.12-14. 
Statistical analysis was performed as referred to in section VI.2.3. 
In Figure 6.11, the A549 cell line showed high expression of ALDH1A1, 2 and 
3A1 as revealed by the low number of cycles to achieve gene amplifications (Ct 
values around 25 cycles). No variation after DAC treatment with or without TSA 
was observed in the expression level of these genes.  
 
* p< 0.05, ** p< 0.01, *** p< 0.001 
_______________________________________________________________ 
Figure 6.12 A549 qRT-PCR plot. PPIA was used for normalisation. Analysis was repeated in 
triplicate before/after treatments and values represent an average of the three independent 
experiments. P values summary and significance are reported in Table 6.17. 
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However, ABCB1 and ABCG2 expression in A549 showed no variation after 
DAC treatment.  
The same analysis was performed in MCF7 cells (see Figure 6.13) and the 
expression level revealed a very pronounced reactivation of all genes after 
epigenetic treatment. High dose of DAC (1 µM) and the combination experiment 
with TSA showed a greater effect in gene reactivation (up to 75 fold change for 
ALDH3A1), revealing a trend in all the performed analysis. Statistical analysis 
showed high significance (p<0.001) for the majority of the expression values.  
* p< 0.05, ** p< 0.01, *** p< 0.001 
 
_______________________________________________________________ 
Figure 6.13 MCF7 qRT-PCR plot. PPIA was used for normalisation. Analysis was repeated in 
triplicate before/after treatments and values represent an average of the three independent 
experiments. P values summary and significance are reported in Table 6.17. 
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The highly pronounced reactivation after DAC treatment suggests that in some 
genes, such as ALDH3A1 or ABCB1, that methylation of the promoter region is 
associated with reduced mRNA expression. 
In the HT29 profiling (see Figure 6.14), only ABCB1 showed gene reactivation 
after epigenetic treatment, perhaps due to the endogenous expression level of 
the whole panel of analysed genes within this cell model.  
* p< 0.05, ** p< 0.01, *** p< 0.001 
_______________________________________________________________ 
Figure 6.14 HT29 qRT-PCR plot. PPIA was used for normalisation. Analysis was repeated in 
triplicate before/after treatments and values represent an average of the three independent 
experiments. P values summary and significance are reported in Table 6.17. 
 
Indeed, no variation was observed in the ALDH isoforms expression, but up to 
two fold increased expression was observed on ABCG2. 
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As shown in Figure 6.15, different results were obtained in analysis of HeLa 
cells, where ALDH1A1 mRNA level increased up to 8 folds after exposure to 
DAC at 100 nM, and up to 1000 folds when treated in combination with TSA 
100 nM.  
* p< 0.05, ** p< 0.01, *** p< 0.001 
_______________________________________________________________ 
Figure 6.15 HeLa qRT-PCR plot. GAPDH was used for normalisation. Analysis was repeated 
in triplicate before/after treatments and values represent an average of the three independent 
experiments. P values summary and significance are reported in Table 6.17. 
 
Gene reactivation after DAC/TSA combination treatment was shown also for 
ALDH2, ABCB1 and ABCG2 genes, but not for ALDH3A1. 
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VI.3.4 Western analysis of total protein extracts from selected cell lines 
Immunoblotting detection was performed on the protein extract from the 
harvested cell lines before and after DAC treatment alone or in combination with 
TSA. Protein extract from A549 contained a high level of ALDH1A1 (see Figure 
6.16A), which is in accordance with previous published data (Ucar et al., 2009) 
and detectable levels of ALDH2 (see Figure 6.16). However, no difference in 
the expression was obtained after epigenetic treatment.  
ALDH3A1 protein level revealed a slight augmentation (up to 6 fold) after DAC 
treatment (see Figure 6.16), demonstrating a potential correlation between gene 
activation and protein translation. The ABCG2 protein was detected but no 
change was observed after DAC treatment. In contrast, the ABCB1 protein was 
downregulated after DAC treatment, which may be a result of an indirect “turn-
off” signal activated via DAC and DAC/TSA exposure. 
 As shown in Figure 6.17A, protein extract from untreated MCF7 revealed no 
expression of ALDH1A1 and ALDH3A1, as already reported in past studies 
(Marcato et al., 2011; Sreerama and Sladek, 2001). No variation in the 
ALDH1A1and 3A1 protein levels were observed after epigenetic treatment. 
However, DAC treatment led to ALDH2 protein induction and greater signal was 
detected after combination treatment with TSA (see Figure 6.17).  
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_______________________________________________________________ 
Figure 6.16 Western blot analysis ALDH and ABC proteins in A549 cell line. Untreated 
control and expression profiles following treatment for 24 h with DAC alone (100 nM) or in 
combination with TSA (100 nM) for a further 24 h. 
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Figure 6.17 Western blot analysis of ALDH and ABC proteins in MCF7 cell line. 
Untreated control and expression profiles following treatment for 24 h with DAC alone (100 
nM) or in combination with TSA (100 nM) for a further 24 h. 
 
The ABCB1 protein (see Figure 6.17) showed a silent status in the control 
sample, but after epigenetic treatment protein augmentation >2000 folds was 
observed, as shown by densitometry analysis of the signal intensity (refers to 
Table 6.15).  
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Gene Area/GAPDH Normalised to untreated control 
MCF7 Control 3 x 10-5 1,00 
MCF7 DAC 0,07 2216,36 
MCF7 DAC+TSA 0,08 2701,60 
 
_______________________________________________________________ 
Table 6.15 Densitometry analysis of ABCB1 protein expression in MCF7 cell line. All the 
bands were normalised to GAPDH. Quantification was performed by calculating the ratio 
between the number of pixels in the treated samples and the untreated control.  
 
 As already widely demonstrated, analysis of ABCG2 in the MCF7 cell lysate 
showed high protein expression in the untreated sample (Kim et al., 2002), but 
exposure to DAC alone or with TSA led to a loss of protein signal. 
The protein levels were also investigated in HT29 and HeLa cell lines (see 
Figure 6.18). As already proven in previous studies, western blotting analysis in 
HeLa-control cells did not show expression of ABCB1 (Lazo et al., 2010) or 
ABCG2 (Seamon et al., 2006). Furthermore, no expression of ALDH isoforms 
was observed in HeLa before or after drug exposure. In HT29, the only relevant 
protein level was reported for ALDH1A1 (see Figure 6.18B), where the protein 
level was downregulated after DAC treatment alone but re-established after 
combination of DAC/TSA, suggesting a role of TSA in the activation of the 
protein translation. 
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_______________________________________________________________ 
Figure 6.18 Western blot analysis of HT29 and HeLa cell lines. Untreated control and 
expression profiles, following treatment for 24 h with DAC alone (100 nM) or in combination with 
TSA (100 nM) for further 24 h. 
 
No other endogenous target protein expression was detected in HT29 which is 
in agreement with the literature on ABCB1- and ABCG2-negative (Oh et al., 
2011; Takakura et al., 2010).  
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VI.4 Discussion 
The acquisition of aberrant CGI methylation is a now a widely accepted 
hallmark of cancer (Plass and Smiraglia, 2006; Strathdee and Brown, 2002). It 
is evident therefore that defined groups of genes can become concordantly 
methylated in specific cancers which supports the concept of the "CpG island 
methylator phenotype" (CIMP) and that epigenetic gene silencing in the drug 
resistance field has recently been defined as polygenic (Glasspool et al., 2006; 
Segura-Pacheco et al., 2006). Indeed, previous studies showed that concordant 
promoter hypermethylation of multiple genes, which is known as the CIMP, may 
exist in gastric and colorectal carcinomas (An et al., 2005; Toyota et al., 2000), 
in ovarian cancer (Wei et al., 2006) and in neuroblastoma (Abe et al., 2005).  
The recent surge of interest in epigenetic studies has created high demand for 
reliable techniques to quantify DNA methylation in cells and tissues. In many 
instances, DNA methylation is not uniform, meaning that individual CpG sites 
are not 100% methylated or unmethylated within a cell population or even within 
individual cells. We selected pyrosequencing technique (Reed et al., 2009; 
Ronaghi, 2001) to gain insight in the epigenetic regulation of the promoter 
regions of a selected panel of genes and we combined the qRT-PCR gene 
profiling to establish relationship between promoter methylation and mRNA 
expression. 
In this “pilot” study, we investigated the methylation status relative to the 
promoter regions of ALDH1A1, ALDH2 and ALDH3A1 in a heterogeneous panel 
of cell lines, demonstrating that these ALDH isoforms are controlled via 
promoter methylation in a tissue-specific manner and that the methylation 
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pattern of these genes may be important in transcriptional regulation. Till date, 
very little is known regarding the potential epigenetic control of ALDH enzymes 
and their susceptibility for reactivation by DAC exposure. The data generated in 
this study can contribute towards a better understanding of ALDH biology.   
The promoter region of ALDH3A1 was demonstrated to be heavily methylated 
in MCF7 and A549 cell lines, and exposure of these cell lines to DAC led to 
demethylation and increased mRNA levels. Analysis of the protein status prior 
and post epigenetic treatment revealed ALDH3A1 protein augmentation in A549 
but not in MCF7 cells, suggesting either a (i) a tissue-specific related response 
or (ii) a difference in post-translational pathways. Combination treatment with 
DAC and TSA also translated into ALDH3A1 protein augmentation, but only in 
A549 and not in MCF7, indicating synergistic interplay between DNA 
methylation and histone acetylation. This result is consistent with a previous 
report that gene silencing conferred by methylated DNA can be also influenced 
by inhibition of HDAC, facilitating the remodelling of chromatin and 
transcriptional activation (Irvine et al., 2002; Lee et al., 2008).  
It was demonstrated that no CGI within the promoter region of ALDH1A1 
existed, therefore investigations in the ALDH1A1 methylation status was carried 
out in proximity to the transcription start site. The data showed only significant 
hypermethylation in HeLa cells, which could be modulated by DAC-treatment. A 
dramatic 1000-fold gene reactivation was observed when low dose DAC (100 
nM) was combined with non-toxic dose of TSA (100 nM). This result suggests 
ALDH1A1 gene silencing can be reactivated via modulation of both the 
ALDH1A1 gene and histone acetylation. DAC and TSA have been discussed as 
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synergistic therapies (Esteller, 2009), but as TSA is considered a pan HDAC 
inhibitor it is at present difficult to assess how this synergy is achieved.  
The ALDH2 gene was hypomethylated in all the analysed cell lines with 
exception of MCF7 cells. An inverse relationship between expression and DNA 
demethylation after DAC treatment was observed. However, no protein 
augmentation was detected after gene reactivation of ALDH1A1 and ALDH2, 
implying that other mechanisms are required for post transcriptional control.  
In attempt to understand the regulation of ALDHs and their potential role as 
relevant biomarkers, this study has concerned epigenetic regulation of isoforms 
from ALDH1-3 sub-families. Moreover, due to the affinity of many 
anthraquinones for ABC drug transporters (Doyle and Ross, 2003) it was also 
desirable to understand whether the principal efflux pump proteins ABCB1 and 
ABCG2 were affected by epigenetic mechanisms. Increased ABCB1 expression 
upon DAC-mediated demethylation of its downstream promoter was observed 
in MCF7 cells. This is at large in agreement with a recent study examining the 
role of methylation in the ABCB1 promoter region  where  correlation was made 
between ABCB1 promoter hypermethylation and acquisition of docetaxel 
resistance in MCF7 cells (Reed et al., 2008).  
Data presented in this chapter revealed that significantly increased ABCB1 
gene expression after DAC treatment was also correlated with protein 
augmentation. In contrast, the ABCG2 gene was not silenced via methylation of 
the gene promoter in any of the four cell lines investigated.  
These findings are in line with other studies on established cancer cell lines 
from other tissues including pancreatic (Chen et al., 2012), gastric (Hiraki et al., 
2010) and renal (To et al., 2006). This could suggest lack of ABCG2 promoter 
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methylation as a cancer specific phenotype (Hiraki et al., 2010). However,  
ABCG2 promoter  methylation has been observed in multiple myeloma (Turner 
et al., 2006) and in leukaemia (Bram et al., 2009), resulting in epigenetic 
silencing.  Interestingly,  drug selection with topotecan or mitoxantrone has 
been shown to induce complete demethylation of the ABCG2 promoter in both 
leukaemia and ovarian carcinoma model cell lines (Bram et al., 2009), 
suggesting that ABCG2 expression is controlled in part by methylation of its 
promoter.  
In summary, this study provides some insight into how selected ALDH isoforms 
and ABC transporters may be under epigenetic control and how their 
expression can be modulated with epigenetic drugs such as DAC and TSA, 
either alone or in combination. The data may also suggest tissue-specific 
silencing of both ALDH and ABC proteins, but further studies are needed to 
support preliminary investigations presented in this chapter. Indeed, the concept 
of the potential epigenetic control of ALDH family could negatively impact the 
use of i.e. ALDH1A1 as a biomarker for SCs as well as complicating molecular 
fluorescent probe design and development. In contrast, this study demonstrates 
that ABCG2 transporter appears at large not to be under epigenetic control, 
hence supporting it as valid marker of MDR cancer cells or CSCs.  
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Supplementary Information VI.A 
Final assays for target genes 
 
1. Assay for ALDH1A1 
The ALDH1A1 gene was transcribed from the antisense strand. The position of the gene on 
chromosome 9 according to UCSC was 74705407-74757789. No CGIs were found according to 
UCSC genome browser. The sequence chosen for the DNA-methylation analysis for primer set   
was on the antisense strand of the genomic DNA near the transcription start site (TSS). The 
final assay was designed as shown in the sequence and Table VI.A.I. 
Genomic sequence searched: 
AGGGCCTTTCTTCCCCAAACAGCACCTTGATTTTCTGGGAGATGGACTG
ATTTCCTGAAAGCCTTGTCCTGAAGACACCTGGCCAGCTTCTACTGAGA
ACAAGTGCCCTTTTAGACTCTTTTCAATCCTCAAATTCTCTGATTCCAA
GTCTGTCAGAGAACAGAAAGTTACATAGTAGCATTAAAAAGCATGAGAA
GTCAAAAAAATAATAACTGGCCTTAGTGGCCAGAGCAGCTGCTGCATAC
ACTTATCACAGGTTTCGGCTTTGTAAATTAATTCATCTGCAAATAGTGC
ACTGTCTCCAGGTACAAATTCGATGCTGGAGCACTGGTTTCTTAAGGAT 
TTAAGTTTAAAGTCAAAGGCTTCCTGCCCTAGGTGTTACAAATAAGTAG
TGTCGTTTTCTTTTTTTGCTCTGAGTTTGTTCATCCAATCGTATCCGAG
TATGCAAATAAACTTTAGCCCGTGCAGATAAAAAAGGAACAAATAAAGC
CAAGTGCTCTATCAGAACCAAATTGCTGAGCCAGTCACCTGTGTTCCAG    
GAGCCGAATCAGAAATGTCATCCTCAGGCACGCCAGACTTACCTGTCCT
ACTCACCGATTTGAAGATTCAATATACTAAGGTGAGTAAAACTTCTATT 
TTCTGCTTTGACTCGGGTTTGCAAAAACTGCATTTATGTAAAGCATTAA
AGGTCAATTTAAGT 
Bisulfite converted sequence: 
AGGGTTTTTTTTTTTTAAATAGTATTTTGATTTTTTGGGAGATGGATT
GATTTTTTGAAAGTTTTGTTTTGAAGATATTTGGTTAGTTTTTATTGA
GAATAAGTGTTTTTTTAGATTTTTTTTAATTTTTAAATTTTTTGATTT
TAAGTTTGTTAGAGAATAGAAAGTTATATAGTAGTATTAAAAAGTATG
AGAAGTTAAAAAAATAATAATTGGTTTTAGTGGTTAGAGTAGTTGTTG
TATATATTTATTATAGGTTTCGGTTTTGTAAATTAATTTATTTGTAAA
TAGTGTATTGTTTTTAGGTATAAATTCGATGTTGGAGTATTGGTTTTT
TAAGGATTTAAGTTTAAAGTTAAAGGTTTTTTGTTTTAGGTGTTATAA
ATAAGTAGTGTCGTTTTTTTTTTTTGTTTTGAGTTTGTTTATTTAATC
GTATTCGAGTATGTAAATAAATTTTAGTTCGTGTAGATAAAAAAGGAA
TAAATAAAGTTAAGTGTTTTATTAGAATTAAATTGTTGAGTTAGTTAT
TTGTGTTTTAGGAGTCGAATTAGAAATGTTATTTTTAGGTACGTTAGA
TTTATTTGTTTTATTTATCGATTTGAAGATTTAATATATTAAGGTGAG
TAAAATTTTTATTTTTTGTTTTGATTCGGGTTTGTAAAAATTGTATTT
ATGTAAAGTATTAAAGGTTAATTTAAG 
 
 
 
The biotin-modification was made on the reverse primer. The position of the TSS according to 
UCSC on the (-) strand was 74757787 (highlighted with red in the sequence above). The 
Forward Primer 
Sequencing Primer 
Analyzed sequence 
Reverse primer TSS 
Illumina CpG site 
Forward Primer 
Sequencing Primer 
Analyzed sequence 
Reverse primer TSS 
Illumina CpG site 
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amplicon length was 208 bp and the assay covered three CpG sites, including one CpG site 
analysed by Illumina (Illumina cg16601861, highlighted in yellow in the sequence above) 
(Illumina, CA, USA). 
 
_______________________________________________________________ 
Table VI.A.1 Primers and sequence to analyse (highlighted in the genomic and bisulfite 
converted sequences) for ALDH1A1 gene. 
 
2. Assay for ALDH2 
The ALDH2 gene was transcribed from the sense strand and was positioned on chromosome 
12. A CGI with 481 bp was positioned between 112204499-112204979 loci on the gene 
according to the UCSC, covering 58 CpG counts. The selected CGI included the final assay as 
shown in the sequence and Table VI.A.II. 
Genomic sequence searched: 
CGAGCTGCGTTCGCGGGGCCGGGTCTTTCCGCACAGGCGGAGGGCGGTGG 
CGGGCGCGGAGGCGTCGCGCGAGCCAGGGGGCAGCCACGGGCCGGGGGTA 
CCTAGCGCCACCCGCTTCGCTTGCATCAGCTGCGCGCCCCATCCCGAGGA Forward primer 
ATGGTAGAGGCAGCCCCGCCCCCGGCCCGCCCCCGCCTTTCCATTGGCTG Seq primer  
CCGCGCGGGGCGGGGAGCGGGGTCGGCTCAGTGGCCCTGAGACCCTAGCT  TSS 
CTGCTCTCGGTCCGCTCGCTGTCCGCTAGCCCGCTGCGATGTTGCGCGCT Reverse primer 
GCCGCCCGCTTCGGGCCCCGCCTGGGCCGCCGCCTCTTGTCAGCCGCCGC Seq Analyzed 
CACCCAGGCCGTGCCTGCCCCCAACCAGCAGCCCGAGGTCTTCTGCAACC 
AGGTGAGCCCACCGGCCGGGCTCGCGCTTTGTTTTCCGGCCCGAGTCCCC  
CGCAGGCCCCTAGGAAGGCCCCGCGCCGCCGTGGGCCTTAGTG  
        
 
 Sequence Legend Length 
(nb) 
Forward 
primer 
5’- GGTTTTTTAAGGATTTAAGTTTAAAGT -
3’ 
Highlighted in 
green 
27 
Reverse 
primer 
5’-Biotin- 
AAAACACAAATAACTAACTCAACAATT -3’ 
Highlighted in 
pink 
27 
Sequencing 
primer 
5’- TTGTTTTGAGTTTGTTTATTTAAT -3’ Highlighted in 
blue 
24 
Sequence to 
analyze 
CGTATCCGAGTATGCAAATAAA 
CTTTAGCCCGTGCAGA 
Underlined 38 
Converted 
sequence to 
analyze 
CGTATTCGAGTATGTAAATA 
AATTTTAGTTCGTGTAGA 
Underlined 38 
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Bisulfite converted sequence: 
CGAGTTGCGTTCGCGGGGTCGGGTTTTTTCGTATAGGCGGAGGGCGGTGG 
CGGGCGCGGAGGCGTCGCGCGAGTTAGGGGGTAGTTACGGGTCGGGGGTA 
TTTAGCGTTATTCGTTTCGTTTGTATTAGTTGCGCGTTTTATTTCGAGGA Forward primer 
ATGGTAGAGGTAGTTTCGTTTTCGGTTCGTTTTCGTTTTTTTATTGGTTG Seq primer 
TCGCGCGGGGCGGGGAGCGGGGTCGGTTTAGTGGTTTTGAGATTTTAGTT TSS 
TTGTTTTCGGTTCGTTCGTTGTTCGTTAGTTCGTTGCGATGTTGCGCGTT Reverse primer 
GTCGTTCGTTTCGGGTTTCGTTTGGGTCGTCGTTTTTTGTTAGTCGTCGT Seq Analyzed 
TATTTAGGTCGTGTTTGTTTTTAATTAGTAGTTCGAGGTTTTTTGTAATT 
AGGTGAGTTTATCGGTCGGGTTCGCGTTTTGTTTTTCGGTTCGAGTTTTT  
CGTAGGTTTTTAGGAAGGTTTCGCGTCGTCGTGGGTTTTAGTG 
 
 
_______________________________________________________________ 
Table VI.A.II Primers and sequence to analyse (highlighted in the genomic and bisulfite 
converted sequences) for ALDH2 gene. The biotin-modification was made on the reverse 
primer. The position of the TSS according to UCSC on (+) strand was 89079780 (highlighted in 
red in the sequence above) and the amplicon length was 109 bp and the assay covered ten 
CpG sites.  
 
3. Assay for ALDH3A1 
The ALDH3A1 gene, located on chromosome 17 was transcribed from the antisense strand. A 
CGI with 353 bp was positioned between 19648140-19648492 loci on the gene according to the 
 Sequence Legend Length 
(nb) 
Forward 
primer 
5’-AGGAATGGTAGAGGTAGT-3’ Highlighted in 
green 
18 
Reverse 
primer 
5’-Biotin-
AACAAAACTAAAATCTCAAAACCACTA-3’ 
Highlighted in 
pink 
27 
Sequencing 
primer 
5’-GAATGGTAGAGGTAGTT-3’ Highlighted in 
blue 
17 
Sequence to 
analyze 
CCGCCCCCGGCCCGCCCCCGCCTTTCCA
TTGGCTGCCGCGCGGGGCGGGGAGCGG
GGTCGGCT 
Underlined 63 
Converted 
sequence to 
analyze 
TCGTTTTCGGTTCGTTTTCGTTTTTTTATT
GGTTGTCGCGCGGGGCGGGGAGCGGGG
TCGGTT 
Underlined 63 
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UCSC, covering 30 CpG counts. The selected CGI included the final assay as shown in the 
sequence and Table VI.A.III. 
Genomic sequence searched: 
GCCGAGCCCAGGGAAGTCCCTTCCTATAGAATTCAGGCAGGGTGGGAGGC Forward primer  
AGGGCGCGCTCGTGCCCCTCAGCCAGCTGCAGGTGCTCTCTGTCCCCAGG Sequencing primer  
CGCCATGAGCAAGATCAGCGAGGCCGTGAAGCGCGCCCGCGCCGCCTTCA Seq Analyzed 
GCTCGGGCAGGACCCGTCCGCTGCAGTTCCGGATCCAGCAGCTGGAGGCG 
CTGCAGCGCCTGATCCAGGAGCAGGAGCAGGAGCTGGTGGGCGCGCTGGC  
CGCAGACCTGCACAAGGTGCTCAGGCTGGGCGGCCGCCTTCTGCCAGTGT Reverse primer  
CGGGGCCATGCGATGGGGCGTGGGGGGAGGGGCTGGGGAGAGTGCGACCC 
AGAGAGGTTCAGGAAGGACTTGGGGCCACCTGGCCCCTCGGTCGCGGAGA 
CTGGGCGCACCGCCCTCCCCTCCGCCGCGCCCCGCGCGCCCCCGCCGCCT  
CTTCCGCCCTCTGGCCTTTTCCTCCTGGCCCGGCCTCCGCGTCCCGCCCG  
CAGCGTCCCCCATTTCAACTTCCTGCTGCCCCGACACCCTGAACTTCTGG 
 
Bisulfite converted sequence: 
GTCGAGTTTAGGGAAGTTTTTTTTTATAGAATTTAGGTAGGGTGGGAGGT Forward primer  
AGGGCGCGTTCGTGTTTTTTAGTTAGTTGTAGGTGTTTTTTGTTTTTAGG Sequencing primer 
CGTTATGAGTAAGATTAGCGAGGTCGTGAAGCGCGTTCGCGTCGTTTTTA 
GTTCGGGTAGGATTCGTTCGTTGTAGTTTCGGATTTAGTAGTTGGAGGCG Seq Analyzed 
TTGTAGCGTTTGATTTAGGAGTAGGAGTAGGAGTTGGTGGGCGCGTTGGT  
CGTAGATTTGTATAAGGTGTTTAGGTTGGGCGGTCGTTTTTTGTTAGTGT Reverse primer 
CGGGGTTATGCGATGGGGCGTGGGGGGAGGGGTTGGGGAGAGTGCGATTT 
AGAGAGGTTTAGGAAGGATTTGGGGTTATTTGGTTTTTCGGTCGCGGAGA 
TTGGGCGTATCGTTTTTTTTTTCGTCGCGTTTCGCGCGTTTTCGTCGTTT  
TTTTCGTTTTTTGGTTTTTTTTTTTTGGTTCGGTTTTCGCGTTTCGTTCG  
 
 
 
 
The biotin-modification was made on the reverse primer. The position of the TSS according to 
UCSC was on (-) strand 19651621 (highlighted in red in the sequence above), the amplicon 
length was 256 bp and the assay covered 11 CpG sites. Due to failure of the pyrosequencing 
run, the last three CpG sites were deleted from the assay. 
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Table VI.A.III Primers and sequence to analyse (highlighted in the genomic and bisulfite 
converted sequences) for ALDH3A1 gene. 
 
4. Assay for ABCB1  
The ABCB1 gene, located on chromosome 7 (position 86970884-87180500) was transcribed 
from the antisense strand. ABCB1 downstream gene promoter sequences were based on Reed 
et al. study (Reed et al., 2008). The same study described also ABCB1 upstream promoter, but 
in the analysed samples the upstream assay failed after multiple attempts, so it was excluded 
from the analysis. A CGI with 950 bp was positioned between 87256959-87258444 loci on the 
gene according to the UCSC, covering 51 CpG counts. The selected CGI included the final 
assay as shown in the sequence and Table VI.A.IV. 
Genomic sequence searched: 
TTTCATTCCATTTATCATCAAATAAAGGATGAACAGATGTAACTCAGAAA 
CTGTCAAGCATGCTGAAGAAAGACCACTGCAGAAAAATTTCTCCTAGCCT 
TTTCAAAGGTGTTAGGAAGCAGAAAGGTGATACAGAATTGGAGAGGTCGG Forward primer 
AGTTTTTGTATTAACTGTATTAAATGCGAATCCCGAGAAAATTTCCCTTA 
ACTACGTCCTGTAGTTATATGGATATGAAGACTTATGTGAACTTTGAAAG 
ACGTGTCTACATAAGTTGAAATGTCCCCAATGATTCAGCTGATGCGCGTT 
TCTCTACTTGCCCTTTCTAGAGAGGTGCAACGGAAGCCAGAACATTCCTC 
CTGGAAATTCAACCTGTTTCGCAGTTTCTCGAGGAATCAGCATTCAGTCA Seq Analyzed 
ATCCGGGCCGGGAGCAGTCATCTGTGGTGAGGCTGATTGGCTGGGCAGGA Reverse primer  
ACAGCGCCGGGGCGTGGGCTGAGCACAGCCGCTTCGCTCTCTTTGCCACA Sequencing primer 
 Sequence Legend Length 
(nb) 
Forward 
primer 
5’-TTTATAGAATTTAGGTAGGGTGGGAGGTA-
3’ 
Please note: Sequence outside CGI (grey colour 
on illustration) 
Highlighted in 
green 
29 
Reverse 
primer 
5’_Biotin_CAACCTAAACACCTTATACAAATCT
AC-3’ 
Highlighted in 
pink 
27 
Sequencing 
primer 
5’-TTTTTAGGAGTTATGAGTAAGATTA-3’ Highlighted in 
blue 
25 
Sequence 
to analyze 
GCGAGGCCGTGAAGCGCGCCCGCGCCGCC
TTCAGCTCGGGCAGGACCCGTCCGCTGCAG
TTCCGGATC 
 
Underlined 68 
Converted 
sequence to 
analyze 
GCGAGGTCGTGAAGCGCGTTCGCGTCGTTT
TTAGTTCGGGTAGGATTCGTTCGTTGTAGTT
TCGGATT 
 
Underlined 68 
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GGAAGCCTGAGCTCATTCGAGTAGCGGCTCTTCCAAGCTCAAAGAAGCAG 
AGGCCGCTGTTCGTTTCCTTTAGGTCTTTCCACTAAAGTCGGAGTATCTT 
CTTCCAAAATTTCACGTCTTGGTGGCCGTTCCAAGGAGCGCGAGGTAGGG 
GCACGCAAAGCTGGGAGCTACTATGGGACAGTTCCCAAGTGTCAGGCTTT 
CAGATTTCCTGAACTTGGTCTTCACGGGAGAAGGGCTTCTTGAGGCGTGG 
ATAGTGTGAAGTCCTCTGGCAAGTCCATGGGGACCAAGTGGGGTTAGATC 
TAGACTCAGGAGCTCCTGGAGCAGCGCCCAAACCGTAGTGGCACTGGACC 
ATGTTGCCCGGAGCGCGCACAGCCCGCGCGGTGCGGGGACCTGCTCTCTG 
AGCCCGCGGGCGGTGGGTGGGAGGAAGCATCGTCCGCGGCGACTGGAACC 
GGGAGGGAGAATCGCACTGGCGGCGGGCAAAGTCCAGAACGCGCTGCCAG 
Bisulfite converted sequence: 
TTTTATTTTATTTATTATTAAATAAAGGATGAATAGATGTAATTTAGAAA 
TTGTTAAGTATGTTGAAGAAAGATTATTGTAGAAAAATTTTTTTTAGTTT 
TTTTAAAGGTGTTAGGAAGTAGAAAGGTGATATAGAATTGGAGAGGTCGG Forward primer 
AGTTTTTGTATTAATTGTATTAAATGCGAATTTCGAGAAAATTTTTTTTA 
ATTACGTTTTGTAGTTATATGGATATGAAGATTTATGTGAATTTTGAAAG 
ACGTGTTTATATAAGTTGAAATGTTTTTAATGATTTAGTTGATGCGCGTT 
TTTTTATTTGTTTTTTTTAGAGAGGTGTAACGGAAGTTAGAATATTTTTT 
TTGGAAATTTAATTTGTTTCGTAGTTTTTCGAGGAATTAGTATTTAGTTA Seq Analyzed 
ATTCGGGTCGGGAGTAGTTATTTGTGGTGAGGTTGATTGGTTGGGTAGGA Reverse primer 
ATAGCGTCGGGGCGTGGGTTGAGTATAGTCGTTTCGTTTTTTTTGTTATA Sequencing primer 
GGAAGTTTGAGTTTATTCGAGTAGCGGTTTTTTTAAGTTTAAAGAAGTAG 
AGGTCGTTGTTCGTTTTTTTTAGGTTTTTTTATTAAAGTCGGAGTATTTT 
TTTTTAAAATTTTACGTTTTGGTGGTCGTTTTAAGGAGCGCGAGGTAGGG 
GTACGTAAAGTTGGGAGTTATTATGGGATAGTTTTTAAGTGTTAGGTTTT 
TAGATTTTTTGAATTTGGTTTTTACGGGAGAAGGGTTTTTTGAGGCGTGG 
ATAGTGTGAAGTTTTTTGGTAAGTTTATGGGGATTAAGTGGGGTTAGATT 
TAGATTTAGGAGTTTTTGGAGTAGCGTTTAAATCGTAGTGGTATTGGATT 
ATGTTGTTCGGAGCGCGTATAGTTCGCGCGGTGCGGGGATTTGTTTTTTG 
AGTTCGCGGGCGGTGGGTGGGAGGAAGTATCGTTCGCGGCGATTGGAATC 
GGGAGGGAGAATCGTATTGGCGGCGGGTAAAGTTTAGAACGCGTTGTTAG 
 
The biotin-modification was made on the forward primer. The position of the TSS according to 
UCSC was on (-) strand 87180530 (highlighted in red in the sequence above), the amplicon 
length was 348 bp and the final assay covered only 2 CpG sites, due to failing of the run with 
the original 6 CpG sites.  
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Table V.A.IV Primers and sequence to analyse (highlighted in the genomic and bisulfite 
converted sequences) for ABCB1 gene. 
 
5. Assay for ABCG2 
The ABCG2 gene was located on chromosome 4 and transcribed from the antisense strand. A 
CGI with 698 bp was positioned on between 89079757-89080454 loci on the gene according to 
the UCSC, covering 77 CpG sites. The selected CGI included the final assay as shown in the 
sequence and Table VI.A.V. 
Genomic sequence searched: 
CGAGCAGCGCTTGTGACTGGGCAACCTGTGCGTCAGCGTCCCCGGTGCTT Forward primer 
CGGCGCTCCGGCCAGTGACGGCGACCAAACCCAGCTAGGTCAGACGAGGT Sequencing primer 
ACTGATCAGCCCAATGAGCGCCTGGTGATTCTCGTAGTTAATCACTCTGG  
TTCATTCCGTTCGATCCCGGAGGCGGGAGTGTTTGGCTTGTCCCTGCGTG Analyzed sequence  
TCACGGCAGGGTGACCCTAGCCCCGAGGGAGGGCGGTGGTACCAGTCCTG Reverse primer 
CTGGCGGCTCAGCGCGGCAGGACACGTGTGCGCTTTCAGCCGGGTCGCAG 
GGCGCTTATCGCGGCCCGGCAGTCGGGGCCACGCCTCACCCCCGCCCGCG  
AACCCCGACCTGGGGAAACCCGGGGCGCTGGGGAGGGGCCACTGCGTTCA 
GCTCTGGCGGTCCACAGCCCGAAGCGCGGCTTAGGAAGTTCGTGTCAGCG 
CTGCCTGAGCTCGTCCCCTGGATGTCCGGGTCTCCCCAGGCGGCCACCCG 
CCGGCTCCCATCGTGACCTCCAGCCGCAGCGCCTCCCACGCCGGCCGCCG 
CGCGAGGGGAGCGCTCGGGCGCGCCGGGTGTGGTTGGGGGAAGGGGTTGT 
GCCGCGCGCGGGCTGCGTGCTGTGCCCACTCAAAAGGTTCCGGGCGCGCA 
GGAGGGAAGAGGCAGTGCCCGCCACTCCCACTGAGATTGAGAGACGCG TSS 
 
 Sequence Legend Length 
(nb) 
Forward 
primer 
5’_Biotin_ 
AGGTGTTAGGAAGTAGAAAGGTGATATA-3’ 
Highlighted in 
green 
28 
Reverse 
primer 
5’-CTATTCCTACCCAACCAATCAACCTCA-3’ Highlighted in 
pink 
27 
Sequencing 
primer 
5’-CAATCAACCTCACCACAAA-3’ Highlighted in 
blue 
19 
Sequence 
to analyze 
GAGGAATCAGCATTCAGTCAATCCGGGCCG
GGAGCAGTCA 
Underlined 40 
Converted 
sequence to 
analyze 
TAACTACTCCCRACCCRAATTAACTAAATA 
CTAATTCCTC 
Underlined 40 
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Bisulfite converted sequence: 
CGAGTAGCGTTTGTGATTGGGTAATTTGTGCGTTAGCGTTTTCGGTGTTT Forward primer 
CGGCGTTTCGGTTAGTGACGGCGATTAAATTTAGTTAGGTTAGACGAGGT  
ATTGATTAGTTTAATGAGCGTTTGGTGATTTTCGTAGTTAATTATTTTGG       Sequencing primer 
TTTATTTCGTTCGATTTCGGAGGCGGGAGTGTTTGGTTTGTTTTTGCGTG Analyzed sequence 
TTACGGTAGGGTGATTTTAGTTTCGAGGGAGGGCGGTGGTATTAGTTTTG    Reverse primer 
TTGGCGGTTTAGCGCGGTAGGATACGTGTGCGTTTTTAGTCGGGTCGTAG   
GGCGTTTATCGCGGTTCGGTAGTCGGGGTTACGTTTTATTTTCGTTCGCG 
AATTTCGATTTGGGGAAATTCGGGGCGTTGGGGAGGGGTTATTGCGTTTA 
GTTTTGGCGGTTTATAGTTCGAAGCGCGGTTTAGGAAGTTCGTGTTAGCG 
TTGTTTGAGTTCGTTTTTTGGATGTTCGGGTTTTTTTAGGCGGTTATTCG 
TCGGTTTTTATCGTGATTTTTAGTCGTAGCGTTTTTTACGTCGGTCGTCG 
CGCGAGGGGAGCGTTCGGGCGCGTCGGGTGTGGTTGGGGGAAGGGGTTGT 
GTCGCGCGCGGGTTGCGTGTTGTGTTTATTTAAAAGGTTTCGGGCGCGTA 
GGAGGGAAGAGGTAGTGTTCGTTATTTTTATTGAGATTGAGAGACGCG TSS 
 
 
 
_______________________________________________________________ 
Table VI.A.V Primers and sequence to analyse (highlighted in the genomic and bisulfite 
converted sequences) for ABCG2 gene.  
The biotin-modification was made on the reverse primer. The position of the TSS according to 
UCSC on (+)-strand was 89079780 (highlighted in red in the sequence above), the amplicon 
length was 216 bp and the assay covered 4 CpG sites.  
 
 
 
 Sequence Legend Length 
(nb) 
Forward primer 5’-GTTTGTGATTGGGTAATTTGTG-3’ Highlighted in 
green 
22 
Reverse primer 5’-Biotin-
CAAACTAAAATCACCCTACC-3’ 
Highlighted in 
pink 
20 
Sequencing 
primer 
5’-GTAGTTAATTATTTTGGTTTA-3’ Highlighted in 
blue 
21 
Sequence to 
analyze 
TTCCGTTCGATCCCGGAGGCGG 
GAGTGTTTGGCTTGTCCCTG 
Underlined 42 
Converted 
sequence to 
analyze 
TTTCGTTCGATTTCGGAGGCGG 
GAGTGTTTGGTTTGTTTTTG 
Underlined 42 
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Supplementary Information VI.B 
qRT-PCR oligonucleotides and cycling conditions 
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Chapter VII 
 
Epigenetic modulation of ALDH 
expression in prostate cancer 
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VII.1 Introduction and Aims 
VII.1.1 Background 
To date, the knowledge and understanding of the biochemical and molecular 
processes implicated in the pathogenesis of prostate cancer are rapidly 
growing. Clinical benign prostatic hyperplasia (BPH) has been described as a 
non premalignant condition with no correlation to prostatic cancer (PCa), 
however it may well give rise to a “transition cancer zone” (Maitland et al., 
2011). Furthermore, manifestation of symptomatic BPH is generally recognised 
in men over the age of 50 years and therefore the aging factor needs to be 
considered as a risk factor relating to the disease (Kirby et al., 2005).  The 
normal, mature human prostate consists of a high level of cellular organisation 
(Figures 7.1 and 7,2). 
 
 
_______________________________________________________________ 
Figure 7.1 Schematic representation of the architecture of the human normal prostate 
epithelium. The human prostate epithelium consists of a basal layer of relatively 
undifferentiated basal cells and a luminal layer of terminally differentiated secretory luminal 
cells. Figure adapted from Oldridge EE (Oldridge et al., 2011).    
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Briefly, three phenotypically and morphologically distinct cell types are included 
within a two-layered epithelium: columnar secretory, luminal cells, relatively 
undifferentiated basal cells and rare neuroendocrine cells (Oldridge et al., 2011; 
Tang et al., 2007).  
 
 
_______________________________________________________________ 
Figure 7.2 The hierarchical pathway of human prostate epithelium. SCs are mostly 
quiescent and generate rapidly proliferating transit-amplifying cells. These cells still maintain a 
degree of multipotency, but commit to differentiation giving rise to committed basal cells. 
Through the differentiation process, terminally differentiated secretory luminal cells are then 
formed. Figure from Oldridge EE (Oldridge et al., 2011). 
 
Importantly, it has been established that PCa is primarily a disease of the 
luminal secretory epithelium in the prostate gland (Maitland et al., 2011). 
Indeed, differentiated luminal cells (see Figure 7.2), which constitute the major 
component of normal and malignant prostate, are the ‘factory’ within the 
epithelium generating secretory products like prostate-specific antigen (PSA) 
Chapter VII                                                                                                  - 284 - 
_______________________________________________________________________ 
 
 
and prostatic acid phosphatase (PAP) and can be identified by the expression 
of androgen receptor (AR) (Maitland and Collins, 2008). 
There is a consistent body of evidence that SCs reside in the basal layer (Lang 
et al., 2009; Signoretti et al., 2000). Within this layer, SCs represent a small 
subpopulation of quiescent cells with high proliferative potential in vitro with 
potential for reconstructing functional prostate acinar structures in vivo (Oldridge 
et al., 2011; Richardson et al., 2004). 
 
VII.1.2 Prostate cancer and ALDH 
PCa is the most commonly diagnosed cancer in men and the second leading 
cause of death. Although PCa detected at an early stage can be successfully 
eradicated by radical prostatectomy and radiotherapy, there is a great need for 
novel therapies against castration-resistant PCa and metastatic disease (Jemal 
et al., 2009; van den Hoogen et al., 2010). Although it has been estimated that 
prostate tumours comprise only 0.1% of SCs, it is rationalised that such cells 
are crucial to the formation of drug-resistant tumours and metastasis, causing 
patients to relapse (Collins et al., 2005; Kelly and Yin, 2008).  
A study from Burger et al (Burger et al., 2009), demonstrated that murine 
prostate stem/progenitor cells expressed high levels of ALDH activity and that 
almost all of these cells co-expressed Sca-1 (stem cell antigen-1). Furthermore, 
the ALDHhi cells had higher in vitro and in vivo proliferative potential than cells 
expressing low levels of this enzyme, revealing the potential of ALDH as 
functional marker in these specific tumour cells. On this basis, van den Hoogen 
Chapter VII                                                                                                  - 285 - 
_______________________________________________________________________ 
 
 
et al. (van den Hoogen et al., 2010) showed that the ALDHhi subpopulation of 
human PCa cells had not only enhanced clonogenicity, migration, and 
tumorigenicity but also readily form metastases in vivo. It is important to note 
that the these observations were derived on the basis of the Aldefluor assay 
that is proposed to target ALDH1, but may not be selective for the 19 different 
isoforms identified to date (Marchitti et al., 2008) (refers to section I.5.1 for 
details). Indeed, in PCa, it has been demonstrated that higher expression of 
ALDH isoforms other than ALDH1A1 was found in Aldefluor-positive cells, 
including ALDH3A2, ALDH4A1, ALDH7A1, ALDH9A1 and ALDH18A1 (van den 
Hoogen et al., 2011). Notably, ALDH7A1 expression was at particularly high 
levels in cell lines, primary tissue and matched bone metastasis samples, 
suggesting that at least for PCa (van den Hoogen et al., 2011a) ALDH7A1 is 
contributing to the Aldefluor activity of these cells.  
Aberrant DNA methylation is known to be an early molecular event in PCa  
development (Baylin, 2005), but only two studies have described the epigenetic 
modulation of ALDHs in PCa (Ju et al., 2010; Kim et al., 2005). Importantly, one 
of the studies (Kim et al., 2005) demonstrated dense hypermethylation of the 
ALDH1A2 gene promoter and reported it as a candidate tumour suppressor 
gene in PCa. Given the importance of epigenetics in cancer (see section I.6.3), 
it is vital to understand how ALDH is expressed and regulated under such 
circumstances, and how such information can be translated into a clinical 
setting.  
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VII.1.3 ALDH investigation in human primary cells  
Preliminary studies by Prof. Norman Maitland’s group (data not published, but 
shown in Figure 7.3), using DNA microarray analysis of stem and progenitor cell 
types isolated from benign and PCa tissues revealed heterogeneity in ALDH 
expression within these cell populations.  
 
ALDH2
ALD3A2
ALD4A1
ALDH9A1
ALDH16A1
ALDH18A1
ALDH3B2
ALDH1A3
_______________________________________________________________ 
Figure 7.3 Microarray analysis of selected ALDH isoform expression levels in PCa 
primary cells. Analysis was performed within primitive SCs (S) and their more differentiated 
progeny (C) from both clinical PCa (P) and benign (N) samples. ALDH isoforms are shown at 
the bottom of the graph with the individual probes above. Coloured horizontal bars represent 
individual patient values with black bar indicating the mean of each data set. The shaded 
rectangles show the interquartile range (IQR, a measure of statistical spread) for the data. The 
lower solid red line highlights the background expression limit for the assay (data used with 
permission from Prof. Norman Maitland, University of York). 
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Gene expression analysis of all 19 ALDHs in 12 patient samples demonstrated 
high expression of ALDH2, 3A2, 4A1, 9A1, 16A1 and 18A1, but not  ALDH1A1. 
ALDH1A3 was observed to be the highest expressed isoform, which also has 
been shown to play an important role in breast cancer (Marcato et al., 2011).  
Analysis of the ALDH isoform expression levels between PCa SCs and their 
differentiated progeny revealed that only changes in expression of ALDH3B2 
and ALDH16A1 isoforms (highlighted in red on Figure 7.3) were statistically 
significant. 
Further proof of ALDH1A1 not being the key ALDH is evident from microarray 
analysis on ovarian cancer bioptic samples (data not published, but kindly 
provided for the purpose of this thesis by Dr. Phil Burns, Leeds Institute of 
Molecular Medicine) ALDH1A3 and ALDH9A1 were shown to be the 
predominant isoforms in the set of analysed samples whereas ALDH1A1 
expression was shown to be insignificant (see Figure 7.4). Moreover, ALDH2, 
as well as ALDH3A2, both revealed higher level than ALDH1A1 but no 
comparison with ALDH3A1 could be made as it was not present in the analysed 
chip.  
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Figure 7.4 Microarray analysis of selected ALDH isoform expression levels within ovarian 
cancer patients. P7, A136, T20, T25: unknown. A100, A111, T10, T15, T18: drug-naïve 
primary samples. P6, A60, A89, A90, A92, A96, A102, A109, A114, A129, A130, A175, A178: 
drug-treated primary samples. Data used with permission from Dr. Phil Burns, Leeds Institute of 
Molecular Medicine. 
 
As shown in Figure 7.5, clusterisation of the naïve samples versus the treated 
ones illustrated a higher expression of ALDH1A1 and ALDH2 isoforms after 
treatment, which is in agreement with a fundamental role of these enzymes in 
drug resistance acquisition (Moreb et al., 2000; Sladek et al., 2002). 
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Figure 7.5 ALDH1A1 and 2 expressions before/after chemotherapy. Clusterisation of 
microarray analysis showed on Figure 7.4 for ALDH1A1 and ALDH2 isoform in treated versus 
drug-naïve primary bioptic samples.  Y axes represent log2 expression. 
 
VII.1.4 Rationale and aims of the investigation  
As reported in section I.4, ALDH activity has emerged as an important 
identification and purification marker for cancer stem cells (CSCs). Despite the 
plethora of information on ALDH1 as a marker of cells with “stemness” 
properties (see section I.4.3), there is little literature with regard to the 
epigenetic control of ALDH (Kim et al., 2005). Given the importance of 
epigenetics in carcinogenesis and resistance, such information could have a 
profound impact on the understanding of cancer development and the 
identification and characterisation of CSCs. Accordingly, this study focussed on 
the expression and regulation of ALDH genes in cancer cells as well as in 
benign and malignant prostatic tissues derived from patients. In addition, 
decitabine (DAC), which modify epigenetic chemical tags  (see section I.4.4 for 
details),  was used to determine whether specific ALDH genes are under 
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epigenetic control, and if so, assess the consequences of modulating such 
epigenetic signatures. In summary, in order to understand the implications of 
ALDH regulation in PCa, the aim in this chapter was to use methodologies 
already optimised and established in Chapter VI to gain insights into: 
1. Gene expression level of selected ALDH isoforms (ALDH1A1,2 and 3A1) 
using qRT-PCR with already optimised primer sets (see section VI.3.3.4) 
in a wide panel of prostate cell lines and in primary prostate epithelial 
cultures (benign and malignant bioptic tissue);  
2. Pyrosequencing-based methylation analysis of selected ALDH promoter 
regions in prostate cell lines versus primary prostate epithelial cultures; 
3. ALDH gene status in the prostate epithelial hierarchy (benign and 
malignant) in order to investigate cancer specific features. The analysis 
was performed in three selected cell subtypes: committed basal (CB), 
transit amplifying (TA) and stem cells (SC) to explore the cell type-
dependent ALDH regulation; 
4. ALDH gene expression status before and after DAC treatment as well as 
potential methylation pattern alterations in cell lines versus primary 
cultures. 
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VII.2 Materials and Methods 
VII.2.1 Maintenance of mammalian prostate cell lines 
Mammalian prostate cell lines were cultured as outlined in table 7.1 and 
propagated as previously elucidated in section IV.3.1.2. Cells were 
cryopreserved as explained in section VI.3.1.4. 
 
Cell line Origin of cell line 
Culture 
Media 
Approx. 
frequency of 
subculture 
Dilution 
upon 
subculture 
PNT1A 
benign immortalized 
prostate epithelial cell 
 
R10 4 days 1:10 
PNT2C2 
benign immortalized 
prostate epithelial cell 
 
R10 4-5 days 1:10 
PC3 
Human prostatic 
adenocarcinoma metastatic 
site in bone 
 
H7 3-4 days 1:5-1:10 
P4E6 
Well-differentiated prostate 
cancer 
 
K2 3-4 days 1:2-1:4 
RC165 
benign immortalized 
epithelial prostate cell 
 
KSFM 4-5 days 1:10 
DU145 
androgen independent 
prostate cancer cell 
 
R10 3 days 1:10 
LNCaP 
Human prostatic 
adenocarcinoma metastatic 
site in supraclavicular 
lynphonode 
 
R10 3-4 days    1:5 
STO 
Mouse embryonic fibroblast 
 
D10 3-4 days  1:10-1:20 
 
_______________________________________________________________ 
Table 7.1 Cell culture conditions of prostate cell lines. For media compositions refer to 
Appendix II. 
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VII.2.2 Treatment with decitabine  
The listed cells were seeded at a concentration of 1x105 cells in 75cm2 flasks. 
The next day, treatment of cells with 1 µM decitabine (DAC) (Sigma) was 
started, and fresh drug was added every 24 h for 96 h (total exposure time) 
before the cells were harvested for DNA and RNA extraction.  
VII.2.3 Maintenance of primary cultures  
Primary prostate epithelial cells (see Supplementary Information VII.A at the 
end of the chapter) were cultured on BioCoat™ Collagen I cellware (BD 
Biosciences) in complete stem cell medium  (Chaproniere and McKeehan, 
1986; Hoshi and McKeehan, 1984). Primary cells were co-cultured with 
irradiated STO feeder cells where indicated and were typically sub cultured 1:2 
when approximately 80% confluent. Culture medium was typically replenished 
every second day or when cell debris was present in the culture supernatant.  
Primary prostate fibroblasts were cultured in R10 medium supplemented with 
100 U/mL of penicillin and 100 µg/mL of streptomycin. 
VII.2.4 Irradiation of mouse embryonic fibroblasts  
For mitotic inactivation by irradiation, STO embryonic fibroblasts (Sandoz inbred 
mouse, Thioguanine- and Ouabain-resistant) were trypsinised at approximately 
80-90% confluence and were sedimented by centrifugation. The cell pellet was 
washed in 10 mL PBS per 75 cm2 culture surface before cells were 
resuspended in 10 mL complete SC medium per 100 cm2 of culture surface and 
transferred into a centrifuge tube. Cells in centrifuge tubes were treated with a 
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radiation dose of 60 Gy. Following irradiation, cells were stored at 4 ºC for up to 
7 days before use. 
VII.2.5 Selection of sub-populations of primary prostatic cells 
As elucidated in Figure 7.6, sub-populations were selected from the prostate 
primary cultures by using CD133 and α2β1 integrin expression in a two step 
separation protocol (Collins et al., 2005; Collins et al., 2001).  
 
 
Subpopulation Selection 
marker 
Differentiation status 
Committed basal 
cells 
CD133-/ α2β1
lo Differentiated 
Transit amplifying 
cells  
CD133-/α2β1
hi
 Intermediate 
differentiation status 
Stem cells CD133+/ α2β1
hi
 Undifferentiated 
 
_______________________________________________________________ 
Figure 7.6 Selection markers and differentiation status of sub-population obtained from basal 
cells selection.  
Chapter VII                                                                                                  - 294 - 
_______________________________________________________________________ 
 
 
VII.2.6 Separation of α2β1 integrin high/low (α2 β1
hi/lo) prostate cancer cells 
from primary cultures  
Cultures were allowed to reach approximately 80% confluence before selection 
was performed. Prior to selection, BioCoat™ Collagen culture dishes were 
blocked with 2 mL BSA blocking buffer for 1 h at 37 ºC. Cells were washed 
twice in 10 mL PBS per 75 cm2 culture surface and trypsinised using 2 mL of 1x 
trypsin/EDTA for 5 min. 3 mL of R10 culture medium were added to the plate 
and cells were collected in a centrifuge tube. The trypsinisation was repeated by 
adding 1 mL of 10x trypsin/EDTA for 10 min. The cells were combined in the 
same centrifuge tube after addition of 3 mL of R10 culture medium to stop the 
trypsinisation step. Cells were centrifuged at 1500 rpm for 3 min and 
resuspended in 3 mL of complete stem cell medium.  The cells were counted 
(refer to section IV.3.1.3) and plated out in the BSA-blocked collagen dishes in 
triplicate. Cells in the BSA-blocked collagen dishes were incubated for 20 min at 
37 ºC in 5% CO2 atmosphere to allow the α2β1
hi cell sub-population to adhere. 
The medium containing α2β1
lo cells was collected and centrifuged at 1500 rpm 
for 10 min. The cell pellets were resuspended in 3 mL of complete stem cell 
medium and plated out in triplicate. 
VII.2.7 Isolation of CD133+/α2β1
hi prostate stem cells from primary samples 
Cells adhered to BSA-blocked collagen dishes were collected by adding 1 mL of 
1x trypsin/EDTA for 5 min. 3 mL of R10 culture medium were added to the 
plates and cells were collected in a centrifuge tube. The trypsinisation was 
repeated by adding 1 mL of 10x trypsin/EDTA for 10 min. The cell suspension 
was passed through a cell strainer (40 µm pore size, BD Biosciences) to 
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remove cell clumps and cells were counted before being collected in a 
centrifuge tube and sedimented at 1500 rpm for 10 min. 
After centrifugation, CD133 expressing prostate SCs were isolated from transit 
amplifying cells with a direct CD133 Cell Isolation Kit (Miltenyi Biotec). Up to 108 
cells were suspended in 300 µL (direct CD133 cell isolation kit) of MACS buffer 
and magnetic cell labelling solution. Cell separation on MACS MS columns 
were performed according to the manufacturer’s instructions. Following elution 
from the first column, cells were passed over a second column to increase 
purity of the selected population. One separation column was used for 
approximately 6 x 106 cells for the first round of selection and up to 4 mL eluate 
for the second round of selection. CD133+ cell fraction was eluted in a final 
volume of 0.5 mL MACS buffer. The eluate was transferred to a 15 mL 
centrifuge tube and combined with 14 mL of PBS. After inverting the tube 
several times, CD133-expressing cells were sedimented and the supernatant 
was carefully aspirated, leaving approximately 100 µL of liquid above the cells. 
The cells were resuspended in culture medium and 10 µL of this suspension 
were used to determine live cell number (for detailed information, see section 
VI.3.1.3). The remaining cell suspension was combined with an appropriate 
amount of complete SC media and then plated.  
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VII.2.8 Methylation analysis 
For methylation analysis protocols, see materials and methods section VI.3.2. 
Isolation of genomic DNA from prostate cell lines, committed basal and transit 
amplifying cells was performed as elucidated in section VI.3.2.1. DNA extraction 
from SC-selected population using QIAamp Micro Kit (QIAGEN) was carried out 
as described in the manufacturer's protocol. 
 
VII.2.9 Gene expression analysis using qRT-PCR prior and after epigenetic 
treatment 
For the qRT-PCR materials and methods refers to the sections VI.3.3.4-8. 
Isolation of total RNA from prostate cell lines, committed basal and transit 
amplifying cells was carried out as explained in detail in section VI.3.3.1. For 
total RNA extraction from SC-selected population total DNA was isolated from 
cultured cells with RNeasy Micro Kit (QIAGEN) following the manufacturer's 
protocol. Complementary DNA synthesis was performed as described in section 
VI.3.3.2. In this analysis, RPLP0 was used as the housekeeping gene as it was 
already optimised by Prof Norman Maitland’s group (University of York). 
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VII.3 Results 
VII.3.1 Expression profiling of ALDH genes in prostate cell lines 
Gene expression levels were analysed in three selected ALDH isoforms 
(ALDH1A1, 2 and 3A1) in 7 prostate cell lines. This panel comprised of 3 benign 
epithelial prostatic cell lines and 4 PCa cell lines. As reported in Figure 7.7, 
qRT-PCR (see section VI.3.3.4 for assay design) revealed no clear distinction 
between malignant and epithelial cell lines in the ALDH expression pattern. 
ALDH1A1 was expressed at variable levels in the PCa cell lines but also the 
benign PNT1A cell line was shown to express ALDH1A1 (Figure 7.6A).  ALDH2 
showed very high level of expression on PNT1A (up to 1000 folds) compared 
with the general trend of ALDH2 expression in both benign and cancerous cell 
lines. 
 
A) 
0
5
10
15
20
25
30
PNT1a PNT2C2 RC165 P4E6 PC3 Du145 LNCaP
F
o
ld
 C
h
a
n
g
e
Relative ALDH1A1 expression
Benign epithelial cell lines Prostate cancer cell lines
N.D.
 
 
Chapter VII                                                                                                  - 298 - 
_______________________________________________________________________ 
 
 
B) 
0
200
400
600
800
1000
1200
PNT1a PNT2C2 RC165 P4E6 PC3 Du145 LNCaP
F
o
ld
 C
h
a
n
g
e
Relative ALDH2 expression
Benign epithelial cell lines Prostate cancer cell lines
 
C) 
0
100
200
300
400
500
600
700
PNT1a PNT2C2 RC165 P4E6 PC3 Du145 LNCaP
F
o
ld
 C
h
a
n
g
e
Relative ALDH3A1 expression 
Benign epithelial cell lines Prostate cancer cell lines  
_______________________________________________________________ 
Figure 7.7 Relative ALDH gene expressions in PCa cell lines. (A) ALDH1A1, (B) ALDH2, (C) 
ALDH3A1 fold change plots. Each set of data is normalised to the smallest expression value. 
Data are represented as average of three experiments ±SD. RPLP0 was used as control gene 
(optimised by Prof. Maitland’s group, University of York). Note: difference scale of the y axis. 
 
The same analysis was performed on ALDH3A1 gene expression and PNT1A 
together with PC3 revealed very high endogenous levels of this gene (above 
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500 folds) compared to the set under analysis, suggesting once again no 
correlation between cell-type and expression pattern. 
 
VII.3.2 Effect of DAC on ALDH promoter methylation pattern and gene 
expression in prostate cell lines 
The potential epigenetic regulation of the ALDH target genes (ALDH1A1, 2 and 
3A1) in PCa was investigated by performing DNA methylation analysis of gene 
promoters, using already optimised assays in the previous chapter (section 
VI.3.2.7). Unfortunately, pyrosequencing analysis could not be repeated with 
ALDH2 due to lack of reproducibility of the pre-designed assay in the new set of 
cell samples.  
As reported in Figure 7.8A, ALDH1A1 promoter was methylated in PNT2C2 
control (65.7%) and DAC treatment induced reduction of the methylation level 
(44.35%). qRT-PCR analysis revealed that DAC exposure led to a 5-fold 
increase in ALDH1A1 gene expression when compared with the DMSO control 
(see Figure 7.8B). Similarly, ALDH1A1 was shown to be heavily methylated in 
benign PNT2C2 and malignant Du145 prostate cells. DAC exposure to these 
cell lines resulted in 44.35% and 51.40% demethylation of ALDH1A1 
respectively. 
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Figure 7.8 ALDH1A1 promoter methylation and gene expression analysis in prostate cell 
lines before and after DAC treatment. (A) ALDH1A1 promoter methylation analysis was 
performed at three CpG sites with average % methylation reported as a red line across the 
bars. The same experiment was repeated in duplicate. For assay design, see section VI.3.2.7. 
(B) Relative ALDH1A1 gene expressions. DMSO control samples are set at 1 for all the graphs. 
Data are represented as average of three experiments ±SD. RPLP0 was used as a control gene 
(optimised by Prof. Maitland’s group, University of York). DAC (1 µM) treatment was repeated 
every other day for 96 h before RNA extraction. 
 
Chapter VII                                                                                                  - 301 - 
_______________________________________________________________________ 
 
 
Only two of the three CpG sites under analysis seemed to have consistent high 
methylation levels in both cell lines and therefore were more affected by the 
DAC exposure. No significant ALDH1A1 methylation level was detected in the 
other cell lines under analysis, hence no difference was observed after 
epigenetic treatment in gaining demethylation. However, PNT1A and P4E6 cell 
lines, both expressing ALDH1A1 gene (see section VII.3.1 for relative gene 
expression data), showed an upregulation after DAC exposure, but not directly 
related to demethylation of the ALDH1A1 promoter.  
The same investigation was performed in the ALDH3A1 promoter and the 
overall methylation status was above 25% for the entire sample set under 
analysis with the exception of the P4E6 cell line (see Figure 7.8A). The benign 
RC165 cell line had a very heavily methylated promoter region (88.18%) with 
reduction of the methylation level of almost 30% after DAC exposure (61.59%). 
However, as evident from Figure 7.9B, this demethylating effect did not result in 
gene reactivation. In terms of DAC-dependent demethylation, a common trend 
was followed in all the prostate cell lines: small fluctuations in the methylation 
status after treatment did not led to significant re-expression of the ALDH3A1 
gene as revealed via qRT-PCR analysis (see Figure 7.9B). Moreover, the 
mRNA levels increased after DAC treatment on Du145 and LNCaP cell lines, 
but independently from demethylation of the ALDH3A1 gene promoter.  
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Figure 7.9 ALDH3A1 promoter methylation and gene expression analysis in prostate cell 
lines before and after DAC treatment. (A) ALDH3A1 promoter methylation analysis was 
performed in eight CpG sites The same experiment was repeated in duplicate. For assay 
design, see section VI.3.2.7. (B) Relative ALDH3A1 gene expressions. DMSO control samples 
are set at 1 for all the graphs. Data are represented as average of three experiments ±SD. 
RPLP0 was used as a control gene (optimised by Prof. Maitland’s group, University of York). 
DAC (1 µM) treatment was repeated every other day for 96 h before RNA extraction. 
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Finally, a direct comparison of the Ct values of ALDH1A1 versus the ALDH3A1 
gene revealed that ALDH1A1 mRNA levels were reduced compared with 
ALDH3A1 endogenous levels, suggesting a quite low abundance of the 
ALDH1A1 gene in the prostatic cell lines examined in this study. 
 
Sample  ALDH1A1 Ct  ALDH2 Ct  ALDH3A1 Ct  RPLP0 Ct  
PNT1A DMSO 37,92  28,39  29,91  19,18  
PNT1A DAC  34,01  28,82  30,58  19,09  
PNT2C2 DMSO  39,50  34,34  34,74  19,75  
PNT2C2 DAC  36,01  31,41  33,33  18,70  
RC165 DMSO N.D  33,61  34,23  21,36  
RC165 DAC  N.D  33,18  34,57  21,36  
P4E6 DMSO 36,98  35,86  31,64  22,30  
P4E6 DAC  30,72  29,93  27,79  20,06  
PC3 DMSO 39,51  32,91  28,77  19,77  
PC3 DAC  37,88  29,86  28,23  19,57  
Du145 DMSO 37,39  32,08  34,35  20,98  
Du145 DAC  35,15  30,03  30,62  20,64  
LNCaP DMSO 37,97  30,41  37,78  20,03  
LNCaP DAC  37,73  31,7  35,36  21,34  
 
_______________________________________________________________ 
Table 7.2 Ct values of ALDH gene expressions before and after DAC treatment in prostate 
cell lines. RPLP0 was used as control gene (optimised by Prof. Norman Maitland’s group, 
University of York). DAC (1 µM) treatment was repeated every other day for 96 h before RNA 
extraction. 
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VII.3.3 Expression profiling of ALDH genes in primary epithelial cultures 
from prostatic tissues 
Expression of the selected ALDH isoforms (ALDH1A1, 2 and 3A1) and 
methylation of their promoter (see Supplementary Information VI.A) were 
measured in primary epithelial cultures derived from clinical samples of BPH 
and PCa. The three isoforms were expressed in both BHP and PCa samples 
and no significant differences in mRNA level were seen between benign and 
malignant samples (see Figure 7.10).  Furthermore, primary cultures were 
shown to express ALDH isoforms in a comparable manner with established 
human PCa cell lines.  
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Figure 7.10 qRT-PCR analysis of ALDHs gene expression in prostate primary epithelial 
cultures. (A) ALDH1A1, (B) ALDH2, and (C) ALDH3A1 gene expression profiles. RPLP0 was 
used as normalising gene (optimised by Prof. Norman Maitland’s group, University of York). Cell 
cultures were generated from specimens of 4 human PCa and 4 non-malignant BPH control 
tissues. 
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Next, investigation of the methylation status of ALDH gene promoters was 
performed via pyrosequencing (see Figure 7.11).  
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Figure 7.11 ALDH1A1 and ALDH3A1 promoter methylation analysis in bioptic sample 
from benign hyperplasia (BPH) and prostate cancer (PCa). Cell cultures were generated 
from specimens of human prostate cancers (n = 4, red bars) and non-malignant BPH control 
tissues (n = 4, green bars). Analysis was performed at three CpG sites for (A) ALDH1A1 and 
eight CpG sites for (B) ALDH3A1. The average of % methylation is reported in red above the 
correspondent sample. For assay design, see section VI.3.2.7. 
 
The DNA methylation levels were shown to be low, with the average 
methylation less than 12%, in all the samples analysed. No significant 
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distinction was observed between BPH and PCa samples. In fact, none of the 
samples contained significantly hypermethylated DNA compared with control 
samples. Due to the lack of hypermethylation of ALDH gene promoters, it was 
not possible to epigenetically modulate ALDH gene levels in this small cohort of 
prostate primary epithelial cells. 
 
VII.3.4 Expression profiling of ALDH genes in the prostate epithelial 
hierarchy 
ALDH expression was next analysed by qRT-PCR in stem (SC, CD133+/ α2β1
hi), 
transit amplifying (TA, CD133-/α2β1
hi) and committed basal (CB, CD133-/ α2β1
lo) 
cell populations isolated from low passage (<10) primary prostate epithelial 
cultures. In ALDH1A1, the expression was consistent in unselected cultures 
(see section VII.3.4).  CB cells had the highest mRNA level compared with TA 
and SC and this trend was evident in both BPH and PCa cultures (see Figure 
7.12). The Ct values in Figure 7.9 revealed a consistent trend, where CB had 
the lowest Ct score compared with the other sub-populations in the all samples 
under investigation.  
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Figure 7.12 ALDH1A1 gene expression analysis in basal epithelial cells after sub-
population selection. SC: stem cells (CD133+/ α2β1
hi); TA: transit amplifying cells (CD133-
/α2β1
hi); CB: committed basal cells (CD133-/ α2β1
lo). 
 
The same analysis, performed for ALDH2 gene expression (see Figure 7.13), 
resulted in an inverted regulation pattern with high expression level in SCs 
population compared with the CB cells. This result was confirmed by Ct values 
as shown in Figure 7.11, which suggested an inverted, but still consistent, trend 
compared to ALDH1A1 Ct values. Once again no detectable difference was 
observed between BPH and PCa. 
 
BPH Sample ALDH1A1 Ct RPLP0 Ct PCa Sample ALDH1A1 Ct RPLP0 Ct 
01 CB 30,21 24,5 01 CB 31,03 24,2 
01 TA 31,75 21,27 01 TA 33,18 20,56 
01SC 35,38 24,89 01SC 34,2 22,35 
02 CB 31,13 24,82 02 CB 28,08 22,1 
02 TA 32,43 20,67 02 TA 32,32 22 
02 SC 32,71 22,15 02 SC 34,26 22,75 
03 CB 28,05 24,88 03 CB 28 24,02 
03 TA 29,75 25,03 03 TA 31,74 23,46 
03 SC 31,83 24,93 03 SC 34,12 24,69 
04 CB 31,05 23,42 04 CB 30,78 25,63 
04 TA 33,88 22,24 04 TA 32,81 25,36 
04 SC 32,71 22,55 
 
04 SC 33,61 25,69 
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Figure 7.13 ALDH2 gene expression analysis in basal epithelial cell after subpopulation 
selection. SC: stem cells (CD133+/ α2β1
hi); TA: transit amplifying cells (CD133-/α2β1
hi); CB: 
committed basal cells (CD133-/ α2β1
lo). 
 
 
Finally, the same qRT-PCR expression analysis for the ALDH3A1 gene was 
investigated and similar expression trend resulted in ALDH3A1 and ALDH1A1 
genes.  
 
BPH Sample ALDH2 Ct RPLP0 Ct PCa Sample ALDH2 Ct RPLP0 Ct 
01 CB 32,33  24,5  01 CB 32,27  24,2  
01 TA 29,51  21,27  01 TA 29,75  20,56  
01SC 31,36  24,89  01SC 29,97  22,35  
02 CB 33,12  24,82  02 CB 30,65  22,1  
02 TA 29,99  20,67  02 TA 30,52  22  
02 SC 30,19  22,15  02 SC 29,59  22,75  
03 CB 33,34  24,88  03 CB 31,57  24,02  
03 TA 31,43  25,03  03 TA 30,31  23,46  
03 SC 31,09  24,93  03 SC 30,03  24,69  
04 CB 30,79  23,42  04 CB 33,28  25,63  
04 TA 29,64  22,24  04 TA 30,9  25,36  
04 SC 29,41  22,55  
 
04 SC 31,52  25,69  
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Figure 7.14 ALDH3A1 gene expression analysis in basal epithelial cell after 
subpopulation selection. SC: stem cells (CD133+/ α2β1
hi); TA: transit amplifying cells (CD133-
/α2β1
hi); CB: committed basal cells (CD133-/ α2β1
lo). 
 
The very low expression of ALDH3A1 at the mRNA level (see Figure 7.14) 
seemed to be a common feature in the SC population, whereas higher levels 
were measured in TA and CB respectively.   
These results provided evidence that the investigated ALDH isoforms could be 
regulated at the transcriptional level during differentiation of prostate epithelia 
from clinical tissues. Accordingly, methylation analysis of the selected sub-
BPH Sample ALDH3A1 Ct RPLP0 Ct PCa Sample ALDH3A1 Ct RPLP0 Ct 
01 CB 31,45  24,5  01 CB 28,77  24,2  
01 TA 30,21  21,27  01 TA 28,65  20,56  
01SC 32,4  24,89  01SC 28,95  22,35  
02 CB 30,24  24,82  02 CB 27,58  22,1  
02 TA 30,87  20,67  02 TA 28,89  22  
02 SC 32,23  22,15  02 SC 30,21  22,75  
03 CB 32,23  24,88  03 CB 28,63  24,02  
03 TA 31,49  25,03  03 TA 28,8  23,46  
03 SC 34,31  24,93  03 SC 30,41  24,69  
04 CB 29,05  23,42  04 CB 29,81  25,63  
04 TA 27,68  22,24  04 TA 28,25  25,36  
04 SC 28,1  22,55  
 
04 SC 30,34  25,69  
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populations was needed to demonstrate whether this differential regulation was 
sustained by DNA methylation. Pyrosequencing analysis (section VI.3.2.7) was 
carried out on selected SC, TA and CB cells. However, very low levels of 
methylation (<12%) were found in all the populations without remarkable 
differences between BPH and PCa samples. 
 
VII.4 Discussion 
 
 
Prostate cancer (PCa) has been classified as a molecularly and phenotypically 
heterogeneous disease and its “chaos of phenotypes” has challenging clinical 
implications (Roudier et al., 2003), for example in regard to distinguishing and 
selecting PCa cells with tumour- and metastasis-initiating ability (van den 
Hoogen et al., 2010). As a consequence, the hypothetical model of hierarchical 
organization of PCa cells (see Figure 7.2) is crucial in helping to explain how 
the tremendous heterogeneity associated with PCa can be generated. 
Recent studies sustained that identification of cancer SC-like sub-populations in 
PCa cell lines, stained positive for ALDH, are capable of self-renewal and re-
establishment of parental cells (Hellsten et al., 2011). Furthermore, a high 
expression of ALDH in PCa SCs has been shown to be positively correlated 
with Gleason score (see Supplementary Information VII.A for Gleason sum 
definition), pathologic stage, and inversely correlated with overall survival in 
PCa patients (Li et al., 2009). Moreover, high ALDH activity has successfully 
been used to identify tumour initiating PCa cells and components of metastases 
(van den Hoogen et al., 2010).  
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The data presented in this study demonstrated that ALDH1A1, ALDH2 and 
ALDH3A1 are expressed in prostate cell lines but with no apparent distinction 
between benign or malignant cellular phenotype. Interestingly, findings in this 
study indicated that ALDH1A1 and ALDH3A1 expression in part is controlled via 
DNA methylation in prostate cell lines, where an inverse correlation between 
expression and DNA methylation was observed, together with upregulation of 
mRNA levels after gene demethylation by DAC treatment. 
Previous studies have strongly suggested that the basal cell layer of the adult 
human prostate contain highly undifferentiated progenitor cells (Lang et al., 
2009). It has been demonstrated that a high percentage of proliferating cells in 
the basal layer microenvironment may be important in maintaining fundamental 
properties of SCs strictly localized to this compartment (Tang et al., 2007).  
Therefore, it was desirable in the present study to investigate the ALDH 
expression level and gene promoter methylation status within primary epithelial 
cells from human prostatic biopsies. The data demonstrated that primary 
prostate cultures expressed similar mRNA levels of ALDH1A1 and ALDH3A1, 
whereas low expression levels were observed for ALDH2. Preliminary studies 
carried out by Prof. Maitland’s group suggested that in basal epithelial cultures 
ALDH2 is expressed at a higher level than ALDH1A1 and 3A1 and in particular 
that PCa samples had higher expression than BPH cultures (see Figure 7.3) 
Furthermore, DNA methylation profiling data obtained from the primary 
epithelial cultures were in contrast with data obtained from the prostate cell 
lines. The very low levels of promoter methylation found in these samples 
indicated that the lack of expression of ALDH1A1 and ALDH3A1 was 
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independent of promoter methylation, indicating that other mechanisms are 
important in controlling their expression in prostate tissues and primary cultures. 
For example, several ALDH isoforms (ALDH1A1, ALDH1A2, ALDH1A3 and 
ALDH8A1) have been shown to function in retinoic acid cell signalling via 
oxidation of all-trans-retinal and 9-cis-retinal, which has been linked to the 
“stemness” characteristics of CSCs (Gudas and Wagner, 2011). 
As reported in section VII.1.1, prostate epithelium is highly heterogeneous and 
formed by a variety of cell populations at different differentiation stages (Collins 
et al., 2001). When SC (CD133+/ α2β1
hi), TA (CD133-/α2β1
hi) and CB (CD133-/ 
α2β1
lo) populations from primary epithelial cultures were analysed separately, 
gene expression analysis revealed that ALDH1A1 and ALDH3A1 had higher 
mRNA levels in CB compared to SC sub-populations, whereas an inverted 
correlation was observed for the ALDH2 expression pattern. This preliminary 
investigation provided evidence that ALDH2 may be regulated at the 
transcriptional level during differentiation of prostate epithelia from basal 
tissues, which is in agreement with Prof. Maitland’s unpublished data (see 
Figure 7.3).  
A recent study identified and isolated ALDH1A1+ expressing cells from two 
human PCa cell lines (PC3 and LNCaP) on the basis of the Aldefluor assay. 
The study showed such cells to be highly clonogenic and with tumour forming 
potential in animal models (Li et al., 2009). The results in this chapter suggest 
that ALDH1A1 expression is not linked with the SC-like phenotype in selected 
cells from the primary prostate epithelium. Data provided by Dr. Phil Burns (see 
Figure 7.3) also suggest that ALDH1A1 is not the key enzyme in primary 
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ovarian samples although this contradicts findings from a recent study (Deng et 
al., 2010; Silva et al., 2010). Some doubts of using ALDH1A1 as a SC marker 
has been described in the literature (Ginestier et al., 2007; Moreb, 2008), which 
further emphasises the need to understand the expression and regulation of this 
class of enzymes in cancer. 
These results suggest differential ALDH expression pattern between cell lines 
and primary tissues. Furthermore, the results obtained showed no disparate 
methylation of the ALDH1A1 and ALDH3A1 promoter in individual populations. 
Regulation of ALDH1A1 and 3A1 gene expression appears to be independent 
of DNA methylation and may involve retinoid-dependent pathways as described 
above.  
In conclusion, ALDH1A1, ALDH2 and ALDH3A1 expression appears to be 
differentially expressed in prostate cell lines relative to the primary cultures. This 
expression is independent of gene promoter methylation, but it remains to be 
seen whether epigenetic marks on the histones have implications for ALDH 
regulation and expression. A larger number of clinical samples must also be 
analysed in order to fully provide conclusions to the possibility of epigenetic 
modulation of ALDHs not limited to just ALDH1A1, 2 and 3A1. Indeed, the data 
from Prof. Maitland’s group (see Figure 7.3) suggest that ALDH3B2 and 
ALDH16A1 isoform may be statistically important, but also showed that ALDH2, 
3A2, 4A1, 9A1, 16A1 and 18A1 could be important players in PCa. In addition 
to these preliminary studies, the recent published studies from van den Hoogen 
(van den Hoogen et al., 2010; van den Hoogen et al., 2011) suggest that 
ALDH7A1 is a key enzyme in tumourigenesis. The number of ALDH isoforms 
Chapter VII                                                                                                  - 315 - 
_______________________________________________________________________ 
 
 
that may be important as highlighted in this chapter suggests a complexity in 
their regulation and expression. A better understanding of the importance of 
ALDH in PCa can only be achieved by examining larger number of clinical 
samples and by carefully assessing their expression within the various cell 
layers of the prostate. The complexity of ALDH expression also complicates the 
potential of using a specific ALDH isoform as a biomarker for PCa and indeed 
the development of a specific molecular fluorescent chemical probe. 
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Supplementary Information VII.A 
Prostatic carcinoma primary samples list  
Identification 
code 
Sample 
name 
Origin of tissue 
BPH 01 
125/11 Benign Prostatic Hyperplasia 
PCa 01 
120/11 Ra** Prostate cancer (Gleason 6*) 
BPH 02 68/11 Benign Prostatic Hyperplasia 
PCa 02 
116/11 Ra** Prostate cancer (Gleason 7*) 
PCa 03 
116/11 Rb
†
 Prostate cancer (Gleason 7*) 
PCa 04 
50/11 Ra** Prostate cancer (Gleason 6*) 
BPH 03 
60/11 Benign Prostatic Hyperplasia 
BPH 04 
71/11 Benign Prostatic Hyperplasia 
 
**Ra: Right apex 
†Rb: Right base 
 
*The Gleason Grading System is used to ensure that physicians are aware of 
the prostate cancer’s stage and to help evaluate the tumour prognosis 
(Gleason, 1977). Cancers with a higher Gleason score are more aggressive 
and have a worse prognosis. The Gleason score may be between 2 to 10. 
Gleason grades are associated with the following features: 
 
• Scores from 2 to 4 are very low on the cancer aggression scale. 
• Scores from 5 to 6 are mildly aggressive. 
• A score of 7 indicates that the cancer is moderately aggressive. 
• Scores from 8 to 10 indicate that the cancer is highly aggressive. 
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Supplementary Information VII.B 
Relative quantification of ALDH gene expression in selected primary 
samples: (A) ALDH1A1, (B) ALDH2, (C) ALDH3A1. Histograms represent fold 
change of the respective ALDH target gene normalised to RPLP0 housekeeping 
gene. A full list and details of the primary samples under analysis are reported 
in Supplementary Information VII.A. 
A) 
 
B) 
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C) 
 
 
 
 
 
 
 
  
 
 
 
 
Chapter VIII 
 
Final Conclusions and Future 
Directions 
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New strategies for investigating SCs are required to fully understand the 
complex biology behind this cellular phenotype. Indeed, despite many years of 
intensive research, there is very little consensus about suitable markers to 
locate and isolate SCs from adult tissues. The focus in the recognition of CSCs 
by featuring high expression ALDHs has been a hot topic over the past decade 
(Moreb, 2008; Moreb et al., 2008). Currently, cells expressing high ALDH 
activity are identified by employing the Aldefluor assay with subsequent sorting 
of cells by FACS. This strategy has been successful in the isolation of SCs from 
many human tumours (Ginestier et al., 2007), notably breast cancer (Marcato et 
al., 2011), prostate (van den Hoogen et al., 2010; van den Hoogen et al., 2011), 
ovarian (Sun and Wang, 2011) and non-small cell lung cancer (Jiang et al., 
2009). However, new findings regarding the heterogeneity of tissue-specific 
ALDH isoforms underline complexity in identifying a unique SC population by 
measuring ALDH activity. Because of this limited knowledge, the approach of 
designing fluorescent small molecules selective for a specific ALDH isoform is a 
difficult challenge.  
The aim of the thesis was to develop a novel library of LC-AAQs focussed on 
the modification of the chemical functionalities in the β-position to the terminal 
acetal group. This LC-AAQ library, obtained in a three-five steps synthesis, was 
combined with a second library of HA-AAQ derivatives, featuring a β-positioned 
secondary or tertiary amine in proximity to the terminal acetal moiety. Therefore, 
12 compounds were synthesised (LC-AAQ library), another 4 compounds 
provided for this study for biological analysis (HA-AAQ library) and a total of 32 
compounds (16 AAQs and 16 hydrolysed counterparts, HAAQs) were 
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biologically investigated. AAQs were subjected to acidic hydrolysis (with 2M 
HCl) in order to generate active aldehyde moieties capable of targeting ALDHs. 
The results obtained in Chapter III demonstrated that LC-AAQ derivatives were 
prone to acidic hydrolysis, generating the target aldehydes (albeit not in 100% 
yield), whereas modifications in HA-AAQ library of compounds revealed intrinsic 
resistance to hydrolysis even at high temperature (70ºC). These results show 
unexpected differences in capacity of acetal moieties to undergo acidic 
hydrolysis, which at present is unexplainable.  
Metabolism studies, as discussed in Chapter III, were conducted using several 
enzyme sources to evaluate the potential ALDH-dependent conversion of the 
aldehyde-containing HAAQs into carboxylic acid products. Incubation with 
HAAQs showed activity in rat liver cytosolic fraction (Shum and Blair, 1972), but 
not in yeast or human recombinant ALDH. The results from the latter provided 
inconclusive results and hence it is still possible that ALDH1A1 metabolism did 
occur. Probable explanations for lack of yeast ALDH activity could be that (i) it 
mainly contains ALDH2 isoform (Bostian and Betts, 1978a, b; Devaraj et al., 
1997) which may not be able to accommodate AAQs in their active sites, or (ii) 
yeast ALDH only metabolise substrates in the high µM to mM range; as the 
anthraquinones are dark blue, such high concentrations are not compatible with 
measuring kinetic reactions due to absorbance interference. Furthermore, 
human recombinant ALDH1A1 was only preliminary investigated due to cost 
limitations. In order to investigate it in more detail, future works would include 
the purification of ALDH1A1 and ALDH3A1 from both human and rat liver and 
establish optimal conditions for setting up robust enzymatic assays (Lindahl and 
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Evces, 1984; Sidhu and Blair, 1975), which could be used to test the selectivity 
of AAQs. Interestingly, parental AAQs appeared to be metabolised when 
incubated with the cytosolic fractions from rat liver, which may suggest the 
acetal moieties are prone to oxidative metabolism by other enzymes than 
ALDHs present in the cytosol.  
Assessment of the DNA affinity of the novel AAQ compounds revealed a weak 
DNA interaction with CT-DNA and a general lack of cytotoxicity (Chapter IV), 
which is encouraging in regard to the generation of a live cell tracker to be used 
in a commercial setting. Furthermore, the chemosensitivity studies revealed that 
AAQs before and after hydrolysis had greater impact on cell viability in ALDH-
deficient MCF7 cell line compared to the ALDH-positive A549 cell line, 
suggesting that an interplay between ALDH level and cell survival may have 
occurred. Assessment of AAQs and HAAQs were carried out in the MCF7 and 
A549 cell lines derived from breast ang lung cancer tissue respectively. As 
such, meaningful data in regard to the involvement of ALDH is difficult. 
Therefore, future work should ideally include the establishment of isogenic cell 
lines expressing various ALDH isoforms so that more direct comparisons of the 
AAQ and HAAQ chemical probes can be made.  
A screening of the fluorescence properties of these novel AAQs was assessed 
in two fixed and live cell models, U-2 OS and A549, to gain insight into their 
potential ability of labelling cells with or without the involvement of membrane 
uptake systems (Chapter V). The data generated revealed that the tested AAQs 
were stable fluorophores with structure-dependent cellular localisation. 
Although, the affinity for ALDH-metabolism is unclear, the presented AAQs 
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showed potential as non-toxic fluorescent probes, with selective affinity for 
endoplasmic reticulum, Golgi or nuclei respectively. Indeed, efficient cellular 
uptake was obtained in live cells with stable fluorescent signal overtime. Future 
directions in this part of the thesis should concern investigations of the 
fluorescent properties of AAQs in a larger number of cell lines using time-lapse 
and confocal microscopy. It would also be desirable to track the specific AAQ 
location after cell mitosis and to investigate the effect on cell viability in a 
microscopy-based time course experiment.  
In light of these results, a second library of AAQ with different structural 
modifications could be synthesised and biologically tested. Specific objectives 
could involve (i) further explorations of chemical modification to the β-position 
located in proximity to the terminal acetal moiety and (ii) synthesis of other di-
substituted anthraquinones including 1,5 or 1,8 or 2,6-functionalised probes to 
further explore fluorescent properties and cellular localisations. 
Due to a relatively poor understanding of the ALDH expression and regulation, it 
was desirable to aid the current understanding of the genetic and epigenetic 
regulation of isoforms from the ALDH 1-3 family (ALDH1A1, 2 and 3A1). A 
“pilot” study was established with the aim of obtaining information in regard to 
the ALDH expression and regulation in four cell lines (MCF7, A549, HT29 and 
HeLa) derived from different cancer tissues. The data discussed in Chapter VI 
revealed that aberrant gene methylation was cell-type dependent for the three 
ALDH isoforms under investigation. Decitabine treatment led to enhanced 
protein expression for ALDH1A1 (A549), ALDH2 (MCF7) and ALDH3A1 (A549). 
In contrast, the protein level was reduced for ALDH1A1 in the HT29 colon 
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cancer cell line after decitabine treatment, suggesting the involvement of other 
mechanism than DNA methylation is responsible of gene silencing in this cell 
line. ALDH1A1, ALDH2 and ALDH3A1 were highly expressed in prostate cell 
lines, with expression linked to promoter methylation. In contrast, low levels of 
DNA methylation were found in primary prostate cancer cells and benign 
prostatic hyperplasia (Chapter VII). Interestingly, ALDH1A1, considered a SC 
marker, was found to be expressed at low levels in CD133+/α2β1
hi SC fraction 
and upregulated in CD133-/α2β1
lo differentiated prostate cancer cells.  
Considering the limited number of analysed primary prostate samples, the 
present study can only be considered a preliminary screening. However, future 
directions should take into account the tremendous difference between 
immortalised cancer cell lines and primary cultures and probably should focus 
more on detailed investigations on the latter. Furthermore, a larger number of 
prostatic primary samples should be included in order to apply statistical validity 
and significance to the preliminary data. Separate studies could also be carried 
out in other cancer tissues, which would possibly elucidate differential ALDH 
isoform expression and therefore validation of the potential of ALDHs as 
biomarkers. In addition, a number of ALDH isoforms (ALDH1A1, ALDH1A2, 
ALDH1A3 and ALDH8A1) have been shown to function in retinoic acid cell 
signalling via oxidation of all-trans-retinal and 9-cis-retinal (Marcato et al., 2011; 
Sladek, 2003). This function in particular has been linked to the “stemness” 
characteristics of CSCs (Ginestier et al., 2007; Gudas and Wagner, 2011), 
hence retinoid expression and possible regulation of ALDH activity could also 
be investigated. 
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In summary, the results in the presented thesis demonstrate the complexity and 
tumour type specificity of ALDH expression. This creates challenges for the 
development of selective probes for CSC isolation, such as the AAQs discussed 
in this study. Although inconclusive results were obtained in regard to AAQs 
and their potential in targeting ALDHs, selected AAQs were shown to reveal 
interesting biological properties, suggesting them as potential non-invasive 
cytometric probes for tracking molecular interactions in live cells. 
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Appendix I:  List of suppliers 
Abnova Peterborough, UK 
AGTC Bioproducts Hessle, UK 
ATCC      Manassas, VA, USA 
Beckmann Coulter Ltd High Wycombe, UK 
Becton-Dickinson Systems San Jose, CA, USA 
Bio-Rad                                   Hemel Hempstead, UK 
Biostatus Ltd Leicestershire, U.K. 
Calbiochem      Nottingham, UK 
Carl Zeiss Inc. Welwyn Garden City, UK 
Chroma Technology Corp Bellows Falls, VT, USA 
Coherent  Inc. Santa Clara, CA, USA 
COHU San Diego, CA, USA 
Corning          Loughborough, UK 
First Link                                 Birmingham, UK 
Fisher Scientific                      Loughborough, UK 
GE Healthcare                        Little Chalfont, UK 
Hamamatsu Photonics Welwyn Garden City, UK 
IKA Staufen, Germany 
Invitrogen Paisley, UK 
Kinetic Imaging Ltd Wirral, UK 
LGC Prochem                         Teddington, UK 
Lonza Biologics                       Cambridge, UK 
Martin Christ  Osterode, Germany 
Merck Dorset, UK 
Millipore     Watford, UK 
Miltenyi Biotec                         Gladbach, Germany 
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Molecular Devices Downingtown, PA, USA 
Nikon Amstelveen, The Netherlands 
PAA                      Sommerset, UK 
Perkin Elmer  Cambridge, UK 
Prior Scientific Cambridge, UK 
Promega   Southampton, UK 
QIAGEN        Valencia, CA, USA 
R&D Systems Abingdon, UK 
Roche Applied Biosystems     Burgess Hill, UK 
Sigma    Dorset, UK 
Solent Scientific Segensworth, UK 
Southern Biotech Birmingham, AL, USA 
StemCell Technologies Grenoble, France 
TCI                  Portland, OR, USA 
Thermo Fisher Scientific         Loughborough, UK 
Tree Star San Carlos, CA, USA 
Varian Agilent Tech. Stockport, UK 
VWR international Ltd             Lutterworth, UK 
Waters Ltd. Hertfordshire, UK 
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Appendix II: Composition of buffers, cell media and stock solutions 
DNA-binding assay buffers 
CT-DNA melting buffer 
CT-DNA melting buffer solutions used for the UV-melting experiments were 
prepared by making up a 1 L solution A of (10 mM NaH2PO4 and 1 mM 
Na2EDTA) and a separate 1 L solution B (10 mM Na2HPO4 and 1 mM 
Na2EDTA). Solution A was added to solution B, until pH 7.0 was achieved. 
Cell culture media 
Ham’s F-12 cell culture media was purchased from Lonza Biologics and Eagle’s 
Minimal essential media was obtained from LGC Prochem. Foetal Calf serum 
was purchased from PAA. Hank’s balanced salt solution was obtained from 
Sigma. All other reagents were purchased from Invitrogen unless otherwise 
stated. 
Hank’s balanced salt solution 
5.4 mM KCl, 0.3 mM Na2HPO4, 0.4 mM KH2PO4, 4.2 mM NaHCO3, 1.3 mM 
CaCl2, 0.5 mM MgCl2, 0.6 mM MgSO4, 137 mM NaCl, 5.6 mM D-glucose. 
Standard freezing media 
90% (v/v) complete mammalian cell line culture media, 10% (v/v) DMSO. 
D10 culture media 
Dulbecco’s modified Eagle’s media (DMEM) (Sigma), high glucose, 
supplemented with 10% (v/v) foetal calf serum and 2 mM L-glutamine. 
H7 culture media 
Ham’s F-12 media supplemented with 7% (v/v) foetal calf serum and 2 mM L-
glutamine. 
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K2 culture media 
KSFM (see below) supplemented with 2% (v/v) foetal calf serum.  
M10 culture media 
McCoy’s 5A Modified Media (Sigma) supplemented with 10% (v/v) foetal calf 
serum and 2 mM L-glutamine. 
R10 culture media 
RPMI 1640 media (Sigma) supplemented with 10% (v/v) foetal calf serum and 2 
mM L-glutamine. 
Keratinocyte serum-free media (KSFM) 
KSFM supplemented with bovine pituitary extract (BPE, 50 µg/mL), human 
recombinant epidermal growth factor (hEGF, 5 ng/mL) and 2 mM L-Glutamine 
(Sigma). 
Complete stem cell media 
KSFM, supplemented with leukaemia inhibitory factor (LIF, 2 ng/mL, Millipore), 
stem cell factor (SCF, 2 ng/mL, First Link), granulocyte macrophage colony-
stimulating factor (GM-CSF, 1 ng/mL, First Link) and 100 ng/mL cholera toxin 
(Sigma). 
BSA blocking buffer 
0.75 g of BSA (Sigma) were dissolved in 250 mL of PBS and heated for protein 
denaturation for 5 minutes at 80ºC then proceeded to filter sterilisation.  
MACS buffer 
PBS, pH 7.2, supplemented with 0.5% foetal calf serum and 2 mM EDTA. 
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Solutions for molecular biology  
All reagents were purchased from Sigma unless otherwise indicated. 
Western Blotting 
1x TAE buffer  
40 mM Tris-acetate, 1 mM EDTA, pH 8.0. 
RIPA Lysis buffer 
150 mM NaCl, 1.0% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS (GE 
Healthcare), 50 mM Tris, Aprotinin 8µg/mL, Leupeptin 10µg/mL, pH 8.0. 
5x sample loading buffer 
250mM Tris-HCl pH 6.8, 1% SDS (GE Healthcare), 30% glycerol (GE 
Healthcare), 0.02% bromophenol blue, 5% mercaptoethanol, made up to 10 mL 
with deionised water. 
Lower gel buffer 
1.2 M Tris in deionised pH adjusted to 8.8. 
Upper gel buffer 
545 mM Tris in deionised water, pH adjusted to 6.8. 
10% Resolving gel: 
Lower gel buffer 1.87 mL 
10% SDS (GE Healthcare) 0.1 mL 
Protogel (AGTC Bioproducts) 4.7 mL 
10% ammonium persulfate 0.04 mL 
TEMED 0.012 mL 
deionised water 39.7 mL  
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4% Stacking gel: 
 
Upper gel buffer 3.15 mL 
10% SDS (GE Healthcare) 0.5 mL 
Protogel (AGTC Bioproducts) 6.65 mL 
deionised water 39.7 mL  
 
Add 0.04 mL 10% ammonium persulfate, 0.012 mL TEMED to 10 mL of 4% 
stacking gel before use. 
5x TBS-Tween20 running buffer 
150mM NaCl, 50mM Tris-HCl pH 7.5, 0.01% Tween20 made up to 1 L with 
deionised water. 
Transfer buffer  
0.024 M Tris, 0.113 M glycine, 20% methanol in 1 L of deionised water. 
4% Blocking solution 
4% Blocking Reagent (GE Healthcare) in 1x TBS-Tween20. 
2% Blocking solution 
2% Blocking Reagent (GE Healthcare) in 1x TBS-Tween20. 
Appendix V                                                                                                      vii 
_______________________________________________________________________ 
 
 
Appendix V: Abstracts presented to attended conferences 
AACR Annual Meeting, April 2011, Orlando, FL 
Instability of ABCG2-associated side population expression in human A549 lung cancer 
cells and its contribution to drug resistance 
Laura Cosentino1 Marie Wiltshire2, Sally Chappell3, Phil Burns4, Laurence H Patterson1, Klaus 
Pors1, Rachel J Errington3 and Paul J Smith2 
1Institute of Cancer Therapeutics, University of Bradford, West Yorkshire BD7 1DP, UK, 
2Department of Pathology and 3Department of Medical Biochemistry and Immunology, School of 
Medicine, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK, 4Section of Pathology & 
Tumor Biology, Leeds Institute of Molecular Medicine, St James's University Hospital, Leeds, 
LS9 7TF, UK 
Keywords: ABCG2; side-population cells; drug resistance; A549 cells 
 
Dynamic changes in tumour subpopulations may contribute to post-therapeutic repopulation 
and treatment failure. Human tumours and established cell lines can maintain ‘side’ populations 
(SPs) - identified by a reduced accumulation of Hoechst dye 33342 attributable to ABCG2-
mediated efflux. Progenitors in SP fractions present a challenge for therapies that attempt to 
target active S phase if they also comprise agents subject to active cellular efflux. The current 
study addresses the impact of the SP phenotype on drug resistance characteristics with a focus 
on a predicted resistance to the S-phase targeting anticancer drug DNA topoisomerase I poison 
topotecan (TPT).  The human lung cancer A549 cell line system was used to isolate subclones 
that initially presented a range of SP expression (< 0.5 - >30 %) and a positive correlation was 
found between the size of the SP fraction and reduced TPT accumulation associated with 
ABCG2 expression. Representative clones were established with an initially low SP fraction 
(<1% SP; A549LowSP) or an initially high SP fraction (>30% SP; A549HighSP) compared with the 
A549parent (~7% SP). Using RT-PCR, cells were compared for the expression of drug resistance-
associated ATP binding cassette transporters (ABCG2, ABCB1). Increased ABCG2, but not 
ABCB1, expression, correlated with the degree of SP expression. A database survey of 59 
human tumor NCI60 panel cell lines suggested that expression of the cancer stem cell marker 
aldehyde dehydrogenase (ALDH1A1) may augment TPT resistance in cells with low-level 
expression of ABCG2. However, parental, A549LowSP and A549HighSP cells showed similar co-
expression patterns for ALDH genes (ALDH1A1, ALDH2, and ALDH3A1). A549LowSP increased 
its SP fraction during continued culture while A549HighSP maintained the SP fraction. The extent 
of the SP fraction reflected the degree of TPT efflux that was sensitive to the ABCG2-inhibitor 
Fumitremorgin C. To address whether innate SP expression provided an initial advantage for 
recovery from TPT exposure we studied the dynamic changes in the SP under in vitro selection 
of A549parent cells.  We found that human SPs have a selective advantage, with enrichment of 
>20-fold, in cell populations recovering from multiple rounds of TPT treatment. Clonal analysis 
of TPT recovering populations found no evidence of long-term enrichment of SP fraction 
suggesting innate instability in SP expression. 
The data suggest that A549 non-SP cell populations can re-create SP fractions indicating that 
they are likely to arise by variations that provide a proliferative advantage rather than a unique 
stem-like progenitor.  Innate SP fractions provide the tumor population with a short term 
selective advantage following TPT exposure related to their enhanced ABCG2 expression, and 
become enriched under dose fractionation.  
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AACR Annual Meeting, March 2012, Chicago, IL 
Cotreatment with Decitabine and Paclitaxel is Affected by the Re-expression of Drug-
Metabolising Enzymes  
 
Laura Cosentino1, Nahal Masrour2, Julie Burns3, Weishuo Fang4, Robert Brown2, Phil Burns3 
and Klaus Pors1 
1Institute of Cancer Therapeutics, University of Bradford, BD7 1DP, U.K., 2Imperial College 
London, Hammersmith Hospital Campus, London W12 0NN, U.K.,3Leeds Institute of Molecular 
Medicine, St James’s Hospital, Leeds LS9 7TF, U.K., 4Chemistry of Natural Products, Institute 
of Materia Medica, Beijing 100050, PR China 
 
The literature describes the role of DNA methylation in regulation of tumour suppressor genes, 
DNA repair genes, but not much attention has been paid to drug metabolising enzymes (DMEs). 
Some evidence has been reported and includes methylation of the promoter regions of CYP450 
and ABC transporters. Cotreatment with decitabine (DAC) and paclitaxel (PAC) has been 
reported in several studies, but few of these have reported in a focused manner on the effect on 
DMEs. As a consequence, the major DMEs involved in the detoxification of PAC (namely 
ABCB1, CYP2C8 and CYP3A4) were investigated. The aldehyde dehydrogenase enzymes 
(ALDH1A1, ALDH2 and ALDH3A1) were also explored, as they have recently been shown to 
play a chemo-protective role against taxanes. Analysis of the CpG island methylation level 
indicated that all the above-mentioned DMEs were densely methylated and that treatment of 
MCF-7 cells with DAC for 24 h resulted in a decrease in methylation within the gene promoter 
region. Furthermore, correlation of decrease in DNA methylation with increase in mRNA level of 
ABCB1, CYP3A4, ALDH2 and ALDH3A1 was observed, but not for CYP2C8 and ALDH1A1. 
However, only the ABCB1 protein level was shown to significantly increase. Chemosensitivity of 
DAC combined with PAC was tested in MCF-7 cells: treatment with DAC for 24 h was followed 
by PAC exposure on days 4, 6 or 8. Evaluation of the cotreatment on cell survival demonstrated 
that the cytotoxic potential of PAC was reduced proportionally to the exposure time to DAC 
before PAC treatment, suggesting that ABCB1 protein confers chemo-protection on the cells. 
To investigate whether this resistance was applicable to other taxanes with proven efficacy 
against MDR-resistant cells, the preclinical agent Lx2-32c (aziditaxel) was evaluated. Lx2-32c 
also lost potency similar to PAC, indicating that ABCB1 is responsible for loss of activity of these 
two taxanes. The same experiments were also carried out in HeLa cells as they were shown to 
contain low level of DNA methylation of the above-mentioned DME genes including the ABCB1 
gene. DAC treatment did not lead to significant reactivation at protein level and cotreatment of 
DAC and PAC produced a synergistic effect on cell killing. In conclusion, our data demonstrate 
that cotreatment of DAC and PAC can produce a synergistic effect, but that it is affected by the 
re-expression of DMEs. Our observations provide useful information for clinical evaluation of 
combination strategies comprising DAC and PAC, and chemotherapeutics in general that are 
affected by DMEs. 
 
 
 
 
